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A highly sensitive capture sandwich antibody assay was developed for the detection of
Herpes Simplex Virus alkaline nuclease in cerebrospinal fluid. Chemiluminescence,
using Isoluminol labelled antibody and p-Iodophenol enhanced Horse-Radish Peroxidase
catalysed Luminol, was compared with Horse-Radish Peroxidase colorimetric detection
in the assay. Luminol was superior to Isoluminol based chemiluminescence, but this was
no more sensitive than colorimetric detection. In vitro the final optimised colorimetric
assay had a sensitivity of 20 plaque forming units of Herpes Simplex Virus.
A method for dissociation of immune complexed alkaline nuclease, using Hydrochloric
acid as a chaotropic agent, was optimised for use with the assay.
The assay was applied to 12 cerebrospinal fluid samples from 9 cases of Herpes Simplex
Virus Encephalitis. All cases conformed to accepted criteria for the diagnosis of the
disease in the absence of a brain biopsy. All the tested samples were positive for
alkaline nuclease, which was present in either free or immune complexed foim or both.
The earliest positive sample was day 1 of the clinical illness, and samples were positive
up to day 56, which was the longest interval from onset of symptoms to lumbar puncture
in these patients. Free alkaline nuclease was present in the early stages of the disease,
being replaced by immune complexed alkaline nuclease after day 13, a time when
locally synthesised anti-HSVl IgG was also detected.
A total of 35 control patients were also studied. Five out of 6 patients with suspected
Herpes Simplex Virus Encephalitis or myelitis, and one case of definite herpes myelitis
were positive. Two of the the remaining 28 cases were positive: both of these were
patients with Subacute Sclerosing Panencephalitis. No demyelinating, inflammatory,
other infectious or non-neurological disorders were positive by the assay.
Page 2
ACKNOWLEDGEMENTS
My thanks go to Dr. Ed Thompson, who conceived the idea, supervised the work and
encouraged me throughout the project.
Also to Dr. Geoff Keir, and Mr. Richard Luxton without whose technical advice and
scientific support this work would have foundered early on.
To June Smalley, whose help with the manuscript and experience with word processing
was invaluable.
To Dr. Bob Hoeness, Dr. Sandy Buchan, Dr. Ken Powell and Dr. Dave Meredith who
generously gifted me antibodies and viral preparations, and also gave freely of advice on
technical matters.
Finally, and most especially, to my wife, who endured a newborn baby and my thesis
writing simultaneously without a murmur, and who has made all this effort worthwhile.
DECLARATION
The composition of this thesis, and the work described therein, was entirely the result of the






TABLE OF CONTENTS 4
LIST OF FIGURES 10
LIST OF TABLES 12
SECTION 1 : INTRODUCTION
CHAPTER 1 : Human Herpes Simplex Virus Encephalitis 16
1. Introduction and Historical Review 16
A. Introduction 16
B. Historical Review 17
2. The Clinical Picture 20
A. Epidemiology 20
B. Clinical Features 26
C. Morbidity and Mortality 34
3. Laboratory Findings in HSVE 38
A. CSF Abnormalities 38
B. Immunoglobulin changes 40
C. Cellular changes * 43
CHAPTER 2 : Diagnosis of Herpes Simplex Virus Encephalitis 44
1. Diagnosis Using Clinical Criteria 44
A. Clinical Diagnosis 44
B. Differential Diagnosis of Herpes Simplex Virus Encephalitis 47
2. Diagnosis by Detection of Specific Antibody to Herpes Simplex
Virus 50
A. Serological Diagnosis 50
Page 4
B. CSF Serology 53
C. Oligoclonal Bands 58
3. Diagnosis by Detection of Virus or Viral Antigens in CSF 60
A. Recovery of Virus 60
B. Detection of Viral Antigens in CSF 62
4. Diagnosis by EEG 70
5. Diagnosis by Neuroradiology 73
A. Angiography, Encephalography, Ventriculography and Isotope
Brain Scans 73
B. Computed Tomography and Magnetic Resonance Imaging 74
C. SPECT Scanning 77
6. Diagnosis by Brain Biopsy 78
CHAPTER 3 : Treatment of Herpes Simplex Vims Encephalitis and its outcome 81
1. Introduction 81





3. Morbidity after Therapy 90
CHAPTER 4 : Pathology, Aetiology and Pathogenesis 91





A. Latency in Humans 94
B. Latency in Animal Models 96
C. Genetics and Mechanisms of Latency and Reactivation 97
Page 5
3. Pathogenesis of Herpes Simplex Virus Encephalitis 99
A. Evidence from Human Studies 99
B. Evidence from Animal Models 102
C. Animal Models for Diagnosis and Therapy 108
4. Pathology of Herpes Simplex Encephalitis 109
CHAPTER 5: Chemiluminescence 112
1. Introduction 112




2. Luminol and Isoluminol based chemiluminescence 118
A. Labelling 118
B. The Chemical Reaction 119
C. Assay Systems 121
D. Sensitivity of Luminol and Isoluminol Chemiluminescence 123
E. Techniques for improving light output for isoluminol and
luminol 125
3. Detection Systems 126
SECTION 2 : MATERIALS, METHODS AND RESULTS
CHAPTER 6 : Assessment of Isoluminol and Luminol based
Chemiluminescence 128
1. Materials and Methods 128
A. Setting up reagents for Isoluminol Chemiluminescence 128
B. Assessment of commercial anti-HSVI IgG labelling 131
C. Assessment of immunological function of the Isoluminol
conjugated IgG 133
D. Setting up reagents for luminol chemiluminescence 136
Page 6
2. Results 139
A. Isoluminol based Chemiluminescence 139
B. Luminol based Chemiluminescence 144
3. Discussion 150
CHAPTER 7 : Isoluminol labelling of antibodies for use in an assay system 152
1. Materials and methods 152
A. Use of HSV Kos in affinity purification of labelled
commercial anti-HSVl IgG 152
B. Labelling and purification ofHyper-Immune rabbit antisera
alpha-T2 154
C. Labelling and purification of a commercial monoclonal
anti-HSVl IgG 155
D. Labelling and purification of human anti-HSVl IgG 156
2. Results 157
A. Use of HSV Kos in affinity purification of commercial
anti-HSVl IgG 157
B. Labelling and purification of Hyper-Immune rabbit antisera
alpha-T2 160
C. Labelling and purification of a commercial monoclonal
anti-HSVl IgG 162
D. Labelling and purification of human anti-HSVl IgG 164
3. Discussion 165
CHAPTER 8 : Choice of solid phase for the assay system 166
1. Materials and Methods 166
A. Sepharose 4B as solid phase 166
B. Polystyrene balls as solid phase 168
C. Microtitre (ELISA) plates as solid phase 174
2. Results 176
A. Sepharose 4B as solid phase 176
Page 7
B. Polystyrene balls as solid phase 177
C. Microtitre (ELISA) plates as solid phase 182
3. Discussion 184
CHAPTER 9 : Optimisation of the microtitre plate based capture assay 186
1. Materials and methods 186
A. Optimum captor-detector combination 186
B. Use of Immulon detachable wells 188
2. Results 189
A. Optimum captor-detector combination 189
B. Use of Immulon detachable wells 193
3. Discussion 195
CHAPTER 10 : Dissociation of antigen-antibody immune complexes 196
1. Materials and methods 196
A. Use of HC1 to dissociate antibody from bound antigen 196
B. Sandwich assay to detect antigen dissociated from immune
complexes 198
2. Results 199
A. Use ofHC1 to dissociate antibody from bound antigen 199
B. Sandwich assay of dissociated antigen 201
3. Discussion 202
CHAPTER 11 : CSF antigen assay from patients with HSVE 203
1. Materials and methods 203
A. Patients 203
B. Sandwich capture assay 205
C. Comparison of in-house assay with a commercial kit 207
2. Results 208
A. Sandwich capture assay 208
B. Comparison of the in-house with a commercial kit 215
3. Discussion 216
Page 8






1. Age distribution for cases of HSVE 24
2. Seasonal incidence of Herpes Simplex Virus Encephalitis 25
3. Chemical reaction of Luminol and Isoluminol chemiluminescence 120
4. Optimisation curve for Hematin catalysed luminescence 139
5. Calibration curve for Isoluminol labelled IgG 140
6. Calibration curve for Isoluminol light output 141
7. Iodophenol enhancement of Luminol chemiluminescence 144
8. Optimisation of Iodophenol concentration 145
9a. Optimisation of Hydrogen Peroxide concentration for luminescence 147
9b. Optimisation of Sodium Perborate concentration for luminescence 147
10. Calibration curve for iodophenol enhanced luminol luminescence 148
11. Kinetics of Chemiluminescence 151
12. Immunoblots of Isoluminol labelled antibody eluted from control and
HSV Kos sepharose 4B columns with NaSCN 159
13. Sensitivity of sepharose 4B Isoluminol based antigen capture assay 176
14. Effect of NaOH on the kinetics of p-Iodophenol enhanced luminol
chemiluminescence 178
15. Sensitivity of polystyrene ball Luminol based antigen capture assay 179
16. Comparison of colorimetric and chemiluminometric detection of HSV
using alpha-Tl captor, Q2 detector 183
17. HSV colorimetric sandwich assay with Q2 captor, 50/4 detector 190
18. HSV colorimetric sandwich assay using Q2 captor, and detectors
205/5, 220/3, 38/5 and human antisera 190
19. HSV colorimetric sandwich assay with R38/5 captor, Q2 and Human
antisera detector 191
Page 10
20. HSV colorimetric sandwich assay with human antiserum captor, 50/4,
220/3, R38/5, Q2, and 205/5 detector 191
21. HSV colorimetric sandwich assay with 205/5 or 220/3 captors, human
antiserum detector 192
22. Comparison of colorimetric assay using microtitre plates and
Immulon wells 194
23. Comparison of colorimetric and chemiluminometric detection
systems in HSV assay 194
24. Effect of 0.5 M HC1 on IgG bound to microtitre well 199
25. Dissociation of Ab from Ag bound to microtitre well using 0.5 M HC1
and retention of antigenicity 200
26. Dissociation of Ab from Ag dilutions bound to microtitre wells with
0.1 M HC1 and retention of antigenicity 200
27. Sandwich assay of 1:1000 HSV complexed with antibody dilutions
before and after dissociation with 0.1 M HC1 201
28. Calibration curve for HSV1 alkaline nuclease sandwich assay 208
29. Alkaline nuclease assay results for disease categories 212
30. Calibration curve for HSV1 using commercial Wellcozyme assay 215
Page 11
LIST OF TABLES
1. Annual cases of viral meningitis and encephalitis reported to the
Communicable Diseases Surveillance Centre 1978-1982
2. Annual reports of Herpes Simplex Virus associated encephalitis and
meningitis 1978-1982
3. Sex distribution of Herpes Simplex Virus Encephalitis in the largest
reported series over the previous 25 years
4. Literature review of clinical features of biopsy proven series' of
Herpes Simplex Encephalitis : a) Specific neurological features
b) General features
5. Outcome of untreated Herpes Simplex Virus Encephalitis
- literature review
6. Routine Cerebrospinal Fluid abnormalities reported in the major
studies in the literature
7. Accuracy of clinical diagnosis in major trials of therapy in Herpes
Simplex Virus Encephalitis
8. Differential diagnosis of Herpes Simplex Encephalitis 1972-1984
9. Literature review of results of attempted isolation of herpes simplex
virus from the cerebrospinal fluid of patients with herpes simplex virus
encephalitis.
10. Sensitivity and specificity of assays for antigen detection in the
cerebrospinal fluid of patients with Herpes Simplex Virus Encephalitis
11. Computed tomographic brain scan findings in patients with Herpes
Simplex Virus Encephalitis. Presence of a significant focal
abnormality and the earliest at which a lesion was visible
















13. Mortality and morbidity after treatment in patients with Herpes
Simplex virus encephalitis: a) Idoxuridine therapy 83
b) Cytarabine therapy 84
c) Vidarabine therapy 86
d) Acyclovir therapy 88
14. Site of detection for latent human herpes simplex virus 95
15. Possible routes of spread of herpes simplex virus into the human
central nervous system 100
16. Animal models of pathogenesis of spread of herpes simplex virus to
the central nervous system 103
17. Factors influencing the neurotropism and pathogenesis of herpes
simplex virus infections in animal models 105
18. Luminescent organisms 114
19. Resultant specific activity from varying isoluminol and IgG
conjugation proportions 141
20. Binding of labelled anti-HSVl IgG to an HSV1 coated sepharose 4B
column 143
21. Elution of Isoluminol labelled anti-HSVl IgG from antigen coated
sepharose 4B column using NaSCN 157
22. Elution of Isoluminol labelled anti-HSVl IgG from an antigen coated
sepharose 4B column using NaCl 158
23. Inhibition of chemiluminescence by NaSCN 158
24. Elution of Isoluminol labelled alpha-T2 from an antigen coated
sepharose 4B column using pH 160
25. Elution of Isoluminol labelled monoclonal anti-HSVl IgG from an
antigen coated sepharose 4B column using pH 162
26. Elution of Isoluminol labelled monoclonal anti-HSVl IgG from an
antigen coated sepharose 4B column using NaSCN 163
Page 13
27. Elution of Isoluminol labelled human anti-HSVl IgG from an antigen
coated sepharose 4B column using pH and NaSCN sequentially 164
28. Comparison of HSV1 assay sensitivities using different solid phases
and detector systems 185
29. Results of sandwich ELISA assay for HSV alkaline nuclease in
9 HSVE patients and 35 controls 210
30. Duration of clinical illness and result of CSF antigen detection in
patients with HSVE 211
31. Results of antigen index for HSV alkaline nuclease in 3 patients with





CHAPTER 1: HUMAN HERPES SIMPLEX VIRUS ENCEPHALITIS
1. Introduction and Historical Review
A. Introduction
Herpes Simplex Virus Encephalitis (HSVE) is a rare complication of an infection with
an extremely common vims. Despite its rarity, establishing the diagnosis has become
increasingly important for two reasons. Firstly HSVE is the commonest fatal sporadic
encephalitis in the developed western countries, survivors of the encephalitis having an
exceptionally high morbidity. Secondly, there is a specific anti-viral agent available,
Acyclovir, which is extremely efficient and successful at preventing viral replication.
Thus of all the encephalitides of viral aetiology, those due to Herpes viruses, being the
only potentially treatable disorders, become the most important in establishing a firm
diagnosis.
As will become apparent in this review, the major problem in the diagnosis of HSVE is
establishing the cause at the earliest possible stage in the disease to allow institution of
effective anti-viral therapy. The criteria for establishing a diagnosis however, are the
subject of continual debate, with views polarised between the USA and Europe, the
former demanding brain biopsy and the latter advocating indirect methods of diagnosis.
In this country, brain biopsy is generally not considered now to be an ethical procedure
for diagnostic purposes in HSVE, therefore reliance on indirect methods, combined with
clinical suspicions, are the main-stay of diagnosis. It was the need, therefore, for a
reliable method of non-invasive and rapid diagnosis, that prompted the development of
an assay for Herpes Simplex antigens in the cerebrospinal fluid (CSF) of encephalitis
patients, which forms the basis of this research project.
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Neonatal HSVE has not been specifically included within this review for two reasons.
Firstly it presents as a separate clinical problem, with, in the main, a different Herpes
Simplex virus to adult encephalitis, and a distinct pathogenesis and clinical picture.
Secondly, the patients studied in this work were all adults with Herpes Simplex Type 1
Encephalitis. So saying, there will undoubtedly be included material from, and reference
to, work performed using neonatal material, but this will not be specifically alluded to
unless it is considered important to make a distinction.
B. Historical Review
The results of human infections with Herpes Simplex viruses affecting the skin have
been reported for almost 2,000 years [256], Hippocrates was familiar with herpes
febrilis and shingles, but called only shingles by the term herpes. Herpes meant 'to
creep', and was applied by the Greeks to diseases such as cancer, infections, ringworm
and eczema. Herpes febrilis was known by a different name. The first English reference
to herpes came in 1676, where Cooke commented
'In herpes there's little Pustules like to millet-seeds, Heat Itching,
after rubbing a little moistness and little ulcers...' [46].
Probably the first notion of the modern concept of herpes was made by Bateman in 1814
in his book on cutaneous diseases, but he did not consider it infectious, and still included
ringworm and erythema multiforme within the terminology [19]. Vidal, in 1873, first
showed herpes to be infectious by human inoculation [265], and Gruber in 1920
demonstrated that herpes could be transmitted from animals to man, by the transfer of
herpes from an infected rabbit to the cornea of a blind man [96]. The identification of
the causative agents of cutaneous herpes, including cold sores and genital herpes rapidly
followed, and it was not long after this that the first reports of a possible association with
acute encephalitis were published by the Matheson Commission, in 1929 [165]. In this
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survey, a literature review yielded 9 cases of epidemic encephalitis from which a herpes
simplex virus was identified. Later work again suggested an association [88]. However,
proof of the presence of herpes virus in brain tissue from patients with encephalitis
remained elusive until 1941, when a report was published of a one month old child
which died of a rapidly progressive diffuse encephalitis and intranuclear inclusions were
identified in brain tissue and herpes simplex virus was isolated [236]. Once doubt about
the association between herpes virus isolation and acute encephalitis had been removed,
there ensued a rapid increase in literature reports and a realisation that other variously
named acute encephalidites, such as acute haemorrhagic leukoencephalitis of Hurst
[164], acute necrotising haemorrhagic encephalitis [37], acute necrotising encephalitis,
acute inclusion encephalitis, acute necrotising encephalitis with inclusions, acute
inclusion encephalitis of the herpes simplex type, acute inclusion body encephalitis, were
all likely due to herpes simplex [21, 65, 3, 4]. Subsequently there was harmonisation of
all these descriptions to a single diagnosis of Herpes Simplex Virus Encephalitis. In
1971, a literature review demonstrated that of 39 cases of acute necrotising encephalitis
where electron microscopy was performed, 36 showed herpes simplex particles [207].
This finally confirmed that acute necrotising encephalitis and HSVE were synonymous.
Once the characteristic pathology of temporal lobe involvement was highlighted in the
1940's and 1950's [103], it was not long before attempts at diagnostic biopsy in life were
made. Although the first biopsy report in 1956 did not confirm herpes simplex as the
particular viral cause [63], in 1964 the first cases were confirmed by viral isolation [162],
Thus, the clinical spectrum of neurological disease caused by herpes simplex virus could
be more widely identified to include not only those whose condition was fatal but also
those who survived. Over the past 25 years, the clinical characteristics of the disorder
have become well documented (for reviews see Illis et al [107], Whitley et al [278]),
diagnostic criteria set down [80], and then specific treatment become available [206,
191, 113], such that now HSVE is the most important non-epidemic acute viral
encephalitis affecting man.
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In recent years, with the rapid increase in patients infected with the Human
Immunodeficiency Virus 1 (HIV1) virus, opportunistic infection with herpes simplex
viruses have presented a great diagnostic problem. It is, as yet, still too early to compare
the disease with non-immunocompromised patients, and insufficient data is available to
comment specifically on this group in great detail, but there is no doubt that in the future
the recognised spectrum of HSVE may well change.
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2. The Clinical Picture
A. Epidemiology
i) Incidence
Infection with herpes simplex virus type 1 (HSV1) is ubiquitous. By the age of 15, 50%
of the population has antibodies to HSV1, and 90% by adult life [113]. Herpes simplex
virus encephalitis (HSVE), by comparison, is relatively rare. In the United States
1,000-2,000 cases are estimated to occur each year [113], which accounts for 5%-10% of
all annual reported encephalitis cases [101, 83], or an incidence of 1:250,000 to
1:500,000 persons per year [273]. In Sweden, the reported incidence is similar, at 2.3
cases permillion inhabitants per year [233].
Neonatal HSV infection, usually HSV II type and acquired from infected maternal
genital secretions at birth, occurs in about 1:2,500 to 1:5,000 deliveries per year in the
United States and 50% of neonates so infected will have brain involvement [273].
In the United States, encephalitis in childhood is far more frequent than encephalitis in
adults, with a peak incidence of about 30 per 100,000 of the population versus 5 per
100,000 [22], although herpes simplex virus is a commoner cause of encephalitis in
adults than in children. This whole population based study found that in only a minority
of cases could an aetiological agent be identified, but in those where a firm diagnosis
was possible, 14% of those due to viral agents resulted from HSV infections. Hospital
based studies of encephalitis give a similar picture. Even though the majority of patients
with encephalitis have a causative agent identified (72%), the proportion found due to
HSV remains the same at 13% of diagnosed cases [176]. HSV is also a cause of aseptic
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meningitis, but is much less prevalent, accounting for only 2% of hospital cases where
causal agents are identified. Combining aseptic meningitis and encephalitis, HSV
accounted for 4.7% of all hospital diagnosed cases.
In Finland the reported annual incidence of hospital based encephalitis in children aged
1 month to 16 years has changed from 11.4 per 100,000 in 1968 to 3.4 per 100,000 in
1987, with an overall mean annual incidence of 8.3 per 100,000, of which 6.4% were due
to HSV [138]. This dramatic reduction in encephalitis has been due to the introduction
of successful vaccination programs against mumps, measles and rubella, and although
the absolute incidence of HSVE has remained stable, the relative proportion has
consequently increased.
In the United Kingdom data on the annual incidence of encephalitis, and particular
specific encephalitides, is far more difficult to ascertain, because of the relative
inefficiency of reporting and collection of data. One hospital based study over a 15 year
period, found only 12 out of 60 patients with encephalitis had a confirmed diagnosis
made, of which 6 were HSV. Of all cases of acute viral encephalitis admitted to the
hospital during this time HSVE accounted for 10%. The problem of reporting of HSVE
was confirmed in the USA in a full population based study from Minnesota [22], where
the incidence of encephalitis was found to be 12 times that reported to the Centre for
Diseases Control.
Table 1 shows the annual reported cases of all viral encephalitis and meningitis in the
UK from 1978 to 1982, from all age groups. The figures suggest an annual incidence of
between 1.7 and 3.3 per 100,000 population, of which HSV infections comprise between
6% and 11.4% (average 8.5%). When only those cases of HSV infections where there
was unequivocal evidence of causal association between the virus and the encephalitis
(i.e. viral isolation from brain, CSF, or raised antibody titres in CSF and/or serum) are
used however, and cases ofmeningitis are excluded, the proportion drops to between
Page 21
1978 1979 1980 1981 1982 TOTAL
Echoviruses 680 308 778 386 298 2450
Mumps 479 260 182 240 108 1269
Herpes Simplex 103 98 107 109 95 512
Coxsackie B 136 69 74 171 51 501
Coxsackie A 25 56 30 33 71 215
Adenovirus 46 32 52 35 39 204
Measles 44 32 46 30 23 175
Varicella Zoster 43 25 39 30 32 169
Influenza B 1 23 - 3 30 57
Influenza A 13 8 15 6 8 50
Others 96 118 89 74 77 454
TOTAL 1666 1029 1412 1117 832 6056
TABLE 1 : Annual cases of viral meningitis and encephalitis reported
to the Communicable Diseases Surveillance Centre 1978-1982195 .
2.2% and 5.8% (average 3.7%), as shown in Table 2. Although the figures for incidence
of encephalitis/meningitis are much lower than reported elsewhere, the proportion
attributed to herpes simplex virus appears to be similar to the other studies. Thus in the
UK one should expect to see from the official figures from the USA, Sweden and






1978 103 (6.0) 45 (2.7) 37 (2.2)
1979 98 (9.5) 47 (4.6) 40 (3.9)
1980 107 (7.5) 61 (4.3) 52 (3.7)
1981 109 (9.8) 59 (5.2) 47 (4.2)
1982 95 (11.4) 55 (6.6) 48 (5.8)
TOTAL 512 (8.5) 267 (4.4) 224 (3.7)
TABLE 2 : Annual reports of Herpes Simplex Virus




From 805 cases in the literature where sex was reported, 443 (55%) were male 362
(45%) were female, a ratio of 1.22:1 male to female. This ratio has remained relatively
constant over the last 20 years (Table 3), with only slight male to female preponderance
throughout.
Male Female M/F Ratio Refs
1965 33 19 1.74 154
1972 107 81 1. 32 107
1973 10 11 0.91 215
1982 61 52 1. 17 278
1984 27 26 1. 04 233
1985a 140 125 1. 12 195
1986 43 26 1. 04 274
1988 10 14 0.71 125
1989b 12 8 1.50 132
TOTAL 443 362 1.22
a - includes some meningitis cases
b - under 16 years old only
TABLE 3 : Sex distribution of Herpes Simplex Virus
Encephalitis in the largest reported series over the
previous 25 years.
iii) Age distribution
A summary of the 8 major reports on HSVE shows that age distribution tends to bias
towards the young and the old, but is not so striking as has been described by some
(Figure 1). Two studies excluded patients under 6 months old, so that neonatal
encephalitis, usually due to HSV2 and presenting with a different clinical pattern, were
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Months
Figure 2 : Seasonal incidence of
Herpes Simplex Virus Encephalitis
iv) Seasonal variation
Few studies have recorded any seasonal figures, and when known there appears to be no
obvious seasonal association [154, 278, 107, 176, 193] (Figure 2).
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B. Clinical Features
With the wealth of literature documenting the clinical course of both treated and
untreated HSVE, a basic pattern of evolution is apparent which applies to most patients
[80], but the variation in temporal aspects, severity and the occasional unusual and
misleading presentations, make the spectrum of clinical features fairly wide.
There is usually a prodrome that can last for several weeks, often taking the form of a
'flu-like illness, but this can be absent in some with fulminant onset [125, 3]. In almost
all patients, headache and fever and meningism are the earliest features of imminent
neurological deterioration. Table 4 shows a summary of the clinical features from 442
cases, of whom 374 were biopsy proven, reported in the literature since 1965; before this
time biopsy proof was often not available.
The majority had fever and headache on presentation (85% and 70% respectively), rising
to 95% with fever during the illness. Meningism, including vomiting, occurred in about
40% of the patients. Copsdousness was frequently altered at admission, with 68%
drowsy, confused or disorientated, and 33% in coma. The state of consciousness related
to timing of admission, and invariably worsened during admission with 40% in coma at
some time. Personality change was frequent at presentation, occurring in 73% of
patients rising to 88% after admission, and was often bizarre, with behavioural
abnormalities mistaken for acute psychoses. Amnesia was reported in 22% of patients.
Clinically evident epilepsy was not as frequent as would be expected considering the
degree of electroencephalography (EEG) abnormalities reported (see Chapter 2). 56%
presented with epilepsy, with 70% having epilepsy at some stage in the illness. When
recorded, focal epilepsy was the usual manifestation, and presented in 44% of patients,
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Only 19% of patients had generalised epilepsy alone, and 9% experienced both forms.
In some patients, the seizures were manifested early in the disease by olfactory
phenomena [94], or gustatory and gastrointestinal symptoms, highlighting the temporal
lobe nature of the pathology.
Focal neurological signs of an unspecified nature were reported in 68% of patients on
presentation rising to 100% during admission. When itemised, hemiparesis was present
in 41% of patients on presentation increasing to 52% during admission, and speech
disturbances, such as dysphasia and aphasia presented in 46%. In some patients, the
aphasia was so severe as to mimic an akinetic-mute syndrome [3]. Cranial nerve deficits
were found in 32% of patients, and visual field losses in 15%.
Other major features included autonomic dysfunction in 64% of patients, and ataxia in
45% of patients, both presumably related to brain stem involvement. Raised intracranial
pressure, as manifested by papilledema, was found overall in 24% of patients upon
presentation, although in 1 study 55% showed raised intercranial pressure, a figure
achieved in another small study only some time after admission to hospital.
In a typical patient, the illness falls into 3 phases [80]. During the first phase, meningitic
symptoms predominate for the first 2-4 days, and is characterised by headache, fever and
vomiting. This is followed by the second or local encephalitis phase from about days
3-7, where the temporal lobe features encountered above predominate, accounting for the
seizures, speech and behavioral disturbance, and visual symptoms. As the pathology
extends, the third or generalised phase with cerebral oedma takes over from about days
7-12. During this time the hemiparetic features, papilledema, autonomic dysfunction,
ataxia, and disordered conciousness predominate, ultimately in some resulting in death.
Those who do not die usually show signs of slow recovery from about 2 weeks onwards.
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The literature abounds with cases of atypical presentation of HSVE, although few
substantiate the diagnosis with viral isolation. Only some of the more important and
interesting variations will be considered in detail here.
The cases presenting with behavioral disturbances were highlighted by the papers of
Drachman and Adams [66] who described 1 patient who:
"during the next night, he arose, dressed, shaved, awakened his
wife, and declared that he was going to a funeral".
Subsequently, his illness resembled delirium tremens with
"conversations with imaginary people , reachedfor imaginary
objects, andpicked at the bedclothes. A fine tremor of the
outstretched hands and lips was present".
Psychotic symptoms could be so florid that patients were admitted to mental hospitals
before the diagnosis became apparent [4],
Brain stem involvement was first reported by Dyanne et al 1972; [58], with 2 cases, 1
biopsy proven, which was not confined to the brain stem. Other cases have been
reported since; 1 biopsy proven with a lateral medullary syndrome only [213], another 3
without biopsy evidence, 2 with focal brain stem signs, 1 of which presented with sudden
respiratory arrest [82, 127] (also a feature of the case of lateral medullary syndrome
above), and after recovering required sleep ventilation, simulating the syndrome known
as "Ondine's Curse". Brain stem involvement has also been reported presenting as an
isolated III nerve palsy [227], oculogyric crisis, trismus, masticatory and facial spasms
[167, 82] and "locked-in" syndrome [167, 150, 143], but despite the severity of
symptoms some patients have recovered completely [167].
A chronic encephalopathy, lasting more than 5 months has been reported in 2 patients,
both positive for HSV isolation [217]. In one the patient had been treated for multiple
sclerosis (MS), when at the age of 26, she developed a monoparesis, headache and
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malaise, and had delayed visual evoked potentials (VEP's). However, chronic
progression led to a revision of the diagnosis, but it was only the EEG showing
bitemporal foci that led to a brain biopsy confirming HSVE. In the second, a 76 year old
woman became forgetful and confused 3 months before admission. EEG and computed
tomographic scanning (CT) were unhelpful, suggesting only encephalopathy, but
serology suggested HSVE and the CSF cultured HSV isolates.
Not all forms of HSVE present with severe symptoms and signs. There has now been a
report of 3 cases, 2 biopsy proven, where the clinical course was mild [128]. One patient
developed only headache and confusion, 1 meningism, drowsiness and memory loss, and
the third beginning with focal signs progressing to coma improved and then subsequently
relapsed with meningism and coma. All 3 recovered without specific antiviral therapy,
and only 1 patient was left with any sequelae, taking the form of grand mal epilepsy,
although this latter patient had undergone brain biopsy. The suggestion was made that
many more patients with mild forms of encephalitis may have HSVE, and that the
incidence is thus underestimated, but more importantly, appropriate treatment may be
withheld.
There have been reports of relapsing forms of HSVE. Ross and Stevenson [214]
reported a 14 month old boy who, after an initial classical presentation, recovered
completely only to relapse 30 days later with acute hemiparesis, hemianopia and
chorieform movements. Recovery followed, but was not complete the second time.
Shearer et al [229] reported a 9 year old boy whose recurrent herpes labialis (culture
proven) were followed within 2-9 days by severe psychotic episodes on 17 separate
occasions, with occasional focal neurological signs. With each episode, mental function
slowly became progressively impaired. At the time of the reports there was great debate
as to whether these were genuine relapses, with the first being termed by some critics a
biphasic illness, and the second had no virological proof that the encephalitis was due to
HSV invasion. Since this time however, undoubted relapses of HSVE have become well
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documented. In several cases, relapse has occurred within days of discontinuation of
specific anti-viral therapy which had resulted in complete recovery [260, 216], but in
most the delay after successful treatment and relapse was longer at between 10 days and
1 month [233, 62, 56, 16], without any clinical doubt the relapse was virally caused.
Relapse has been reported after treatment in other studies [97, 232, 133] but without
pathological confirmation and with response to further therapy. In one study, relapses 14
months apart without specific treatment were confirmed by raised titres in serum to HSV
and abnormal brain biopsy but without viral isolation [179]. Apart from the single case
of Shearer reported above, there has been no documented case ofmore than one
clinically defined relapse in the literature, so cases of chronic relapsing encephalitis or
encephalomyelitis are unlikely to be due to HSV.
One extremely unusual complication ofHSVE has been reported by 2 groups:
Post HSVE encephalomyelitis or leukoencephalomyelitis. One case followed a classical
"locked-in" brain stem syndrome, and at post-mortem, extensive demyelination of
hemispheres and cerebellum were found, with HSV1 in the brain stem, especially the
trigeminal area [143]. The second followed successful treatment of biopsy proven
HSVE with adenine arabinoside (ara-A), and after what was thought to be a relapse, a
further biopsy showed extensive demyelination with no evidence of viral reactivation.
This raises the possibility that some cases labelled as relapses without biopsy evidence
could be post infectious demyelination and this complication can certainly confuse the
clinical picture. In the early studies of acute hemorrhagic leukoencephalitis,
demyelination was in the context of massive necrosis, and was accompanied by Cowdry
A inclusions, suggesting primary herpetic infection [164] rather than some form of
autoimmune phenomenon, which the first 2 cases presumably represent.
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Finally, the clinical spectrum ofHSVE will be further complicated as the incidence of
cases amongst HIV1 infected patients increases. The presentation is often in the context
ofmultiple other pathologies, and making a clinical diagnosis can be difficult [149].
Thus in the future, the importance of non-clinically based diagnosis will be paramount.
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C. Morbidity and Mortality
The advent of specific anti-viral therapy has altered the outcome for HSVE considerably.
In this section, the course of the disease untreated with specific anti-viral therapy will be
considered, although the number of series concerned is small, and not surprisingly the
early literature paints a gloomy picture and generally does not dwell on the subject. The
course of treated patients, and the comparison with untreated, will be dealt with in
Chapter 3.
The problems of establishing a clinical diagnosis have resulted in many of the early
studies focussing on fulminant cases, reporting post-mortem findings only, before biopsy
in life was successful in 1963 [162]. Even after this time, case reports contained few
numbers, so establishing the typical outcome was difficult.
Early reviewers ofmorbidity and mortality not only referred to each other, but also
duplicated each others data and referred to common data [107, 250], so the morbidity
and mortality figures are difficult to ascertain. Many early studies were flawed by lack
of consistent diagnostic criteria, with some requiring brain biopsy results [193] and some
relying solely on raised serum titres [214]. Consequently (and not surprisingly) those
requiring brain biopsy had higher mortalities and morbidities than those whose diagnosis
rested on serum titres alone. For example Rawls in 1966 [208] had 100% mortality in
biopsy defined cases but Ross in 1961 [214] had only 13% mortality with 50% complete
recovery in cases diagnosed on serological ground only.
With the diagnosis and reporting of encephalitis improving, the full impact of the
severity of untreated HSYE became apparent. The pioneering epidemiological study of
all encephalitides and aseptic meningitis referred to the Veterans Administrations
Hospitals over 5 year by Meyer et al in 1960 [176] found that although HSVE was not
the commonest encephalitis, accounting for only 13% of all proven cases, with mumps
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and lymphocytic choriomeningitis (LCM) being more frequent, the mortality untreated
was by far the highest, with 5/13 cases dead (38%), 6 with severe sequelae (46%) and
only 2 recovering to a "normal" state.
This finding was paralleled by the Communicable Diseases Surveillance Centre reports
of encephalitis/meningitis in the United Kingdom from 1978-1982 (some 20 years later)
where, although presumably most cases were treated with anti-viral agents, HSVE still
had the highest mortality, with 60 deaths in 267 cases (22%), even though echovirus,
mumps and coxsackie virus infections were all more frequently reported than HSV.
Even though these statistics can be criticised, a review of all cases of encephalitis from a
single hospital in London in 1981 [124] found that of 60 cases, in only 12 could an
identifiable agent be found, 6 of which were HSVE (50%) and in which mortality was
the highest at 4/6 (67%).
In the latest review of encephalitis from Finland in 1989 [132] HSVE had the highest
mortality at 10%, and morbidity at 40% of all encephalitides caused by a single viral
agent. Most, if not all, of these cases would have been treated with anti-viral agents.
Since the early reviews, most studies have concentrated on comparisons of therapies,
initially with placebo, but then when that was deemed unethical, with other anti-viral
agents. Therefore, most recent figures are culled from these patients, and added to the
early non-treated summaries. A review of the literature reports of mortality and
morbidity in untreated patients, where the diagnosis was made by brain biopsy or
unequivocal serum and/or CSF antibody changes, is summarised in Table 5.
Of 160 patients, 94 (59%) died. Of the survivors, 17 (11%) suffered severe sequelae, 7





Dead Sequelae in survivors Ref.
Severe Moderate Mild None
1960 13 5 6 2 176
1961 8 1 2 1 4 214
1965 13 3 4 2 4 154
1966 20 10 * * * * 177
1966 5 5 208
1967 36a 25 5 3 193
1973 1 1 156
1973 8 7 1 3
1973 10 7 1 2 194
1975 1 1 30
1975 4 4 727
1977 10 7 1 1 1 276
1978 2 * * * * 73
1980 1 1 133
1981 4 2 2 124
1982 10 6 3 1 69
1984 3 1 2 128
1988 11 9 * * * * 125
TOTAL 160 94 17 7 7 15
* - individual figures not given. Total 14 patients,
a - includes 3 survivors not followed up.
TABLE 5: Outcome of untreated Herpes Simplex Virus Encephalitis -
literature review.
Thus only 15% of patients returned to a near normal state. The definition of mild or
normal in some papers left a lot to be desired. In one review, 12 patients were said to be
normal and then identified as containing 7 dysphasic patients. Many others claim a
return to home and work as normality, but there is no doubt that psychological testing
reveals subtle intellectual changes, and in some marked personality changes.
Mortality figures can be underestimated if follow up is for short periods of time. The
majority of cases who succumb do so in the first 3 weeks after admission. Illis [107]
gives figures of 94% of 99 fatal cases dying in the first 3 weeks with the remainder dying
by the 6th week. However, later reports show patients dying up to 4 years after the
encephalitis, of what was considered direct sequelae of the disease [194, 276].
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Because of the numbers of survivors in the untreated patients was relatively small, few
generalisations can be made, and most studies did not differentiate between treated and
untreated survivors. Oxbury et al [194] did detail the outcome in untreated patients. All
severe sequelae survivors had varying degrees of dementia, from mild to severe with
behavioral problems. Dysphasia was common especially of the jargon variety. One
patient had a severe amnesic syndrome, of the type typically associated with bilateral
hippocampal lesions, and 2 patients displayed signs similar to Kluver-Bucy syndrome
with unrestrained eating, disinhibition, and marked oralisation. Half of the severely
affected patients were tetraparetic, and also complicated by epilepsy. Of untreated mild
sequelae survivors, mild dysphasia, personality change, memory and learning deficits
predominated.
Some untreated survivors did return completely to normal, and in some, coma was
present at some stage in the illness [128], but usually only mild cases recovered so well.
Signs and symptoms could continue to improve for months to years after the illness,
sometimes even after a delay ofmonths. Age at presentation did not have any influence
on mortality, except in under 2 months group, which in one review had 100% mortality
against 50% - 83% for each other decade of life [107]. Later studies however, suggested
that the very old and the very young did consistently worse than middle years, though
these were tied in with therapeutic trials with anti-viral agents, and so will be considered
later. Other prognostic features will also be considered later under their individual
headings.
Page 37
3. Laboratory Findings in HSVE
A. CSF Abnormalities
CSF changes reflect the viral aetiology of the process, and the necrotic nature of the
pathology. Since the disease undergoes a rapid evolution, CSF changes also evolve, and
this variability results in the conflicting comments made by investigators, who were not
necessarily comparing patients at the same stage of disease. Table 6 shows the main
CSF findings reported in the major series'.
The majority of patients show an elevated total protein, up to 7.88 g/1, with white cell
counts of up to 1,400/mm3, which are predominately lymphocytes. Although
polymorphonuclear leucocytes can be present at some stages, this is usually a minor
component even though one author reports them at up to 90% of the total WBC count
[193]. The presence of red blood cells (RBC) has caused most confusion, since small
numbers of cells may reflect traumatic taps rather than true haemorrhage, and one report
emphasises that absence of xanthochromia in patients [97]. Most studies confirm the
presence of RBC's, up to 7,000/mm3, but usually below 500/mm3. The CSF glucose is
usually normal, although a few patients have a CSF:serum ratio below 50%.
(Occasionally elevated values are given, without mention of the serum values).
When intracranial pressure measurements have been recorded, an increase is reported in
28 of the 64 cases (44%). In one series, sequential measurements showed a progressive
rise in intracranial pressure, peaking around 2 weeks after the disease onset, and those
patients with higher pressures initially were more likely to die [15].
The CSF may be initially entirely normal, and may remain normal throughout [97], but
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In those studies where sequential punctures have been performed, the initial profile
earliest in the disease may be normal, with the total protein most often elevated early
[133], gradually rising to a maximum within 2 months, then slowly declining. Cells
become apparent within the first 4 days [245], again peaking within the first few months,
then declining. The initial profile often shows some polymorphonuclear leucocytes and
macrophages, but this soon shifts to almost entirely lymphoid populations [133, 245,
193], which are invariably pathologically enlarged stimulated cells after day 12 [245].
This profile is by no means diagnostic of HSVE [225], with non HSVE diseases having
similar abnormalities. In a comparative study of brain biopsy positive and negative
patients, only the elevated WBC count showed a statistically significant difference in the
HSVE patients [278].
A few other proteins have been studied in the CSF in HSVE. Ferritin and S100 levels,
markers of haemorrhage and astrocyte damage respectively, have been found to be
elevated in the CSF from the 3rd day, persisting to at least 40 days [231], and not in
other encephalitides, TB meningitis or neurosyphilis. These proteins are not specific for
HSVE, occurring in other traumatic and haemorrhagic disorders.
B, Immunoglobulin changes
Before the advent of sensitive assays, immunoglobulin studies were limited to the
examination of changes in serum only. Neutralisation and complement fixation tests for
specific IgG showed that accompanying the neurological disease there was an elevation
of the serum titres up to very high levels, although there was rarely any detectable
response before day 5, and not all patients showed an increase [215].
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30% patients are seronegative at the onset of the clinical disease, seroconverting during
the course of the illness, indicating that the infection is primary. 70% of patients have
detectable titres at onset, showing a rise during the illness, indicating secondary
reactivation or reinfection. Up to 7% of patients, however, fail to demonstrate any
significant increase in serum titres [188].
Current serological testing has provided much greater sensitivity, and changes in serum
and CSF antibody levels, both total and HSV specific, are now well documented. Total
IgG, and locally synthesised IgG as measured by the IgG index, have been demonstrated
to be elevated in the CSF from day 10 onwards, and to remain elevated for over a year in
some patients [133, 134, 245], In the same patients, serum and CSF HSV specific titres
are elevated, with ratios of serum to CSF of 32:1 to 1:1, indicating local synthesis.
Elevated CSF titres have sometimes been found as early as day 4 [188], but usually not
before day 8, but they may remain elevated for over a year [133, 111] and up to 29
months [134, 245].
The most sensitive techniques, measuring quantitatively specific IgG responses, confirm
that the serum response is usually only detectable around day 10, but with a rapid
increase over a few days to a high level, falling slowly thereafter over months. In some
patients the rise is much slower and the levels achieved less dramatic. CSF changes
parallel the serum changes, and the levels as a proportion of the total IgG are always in
excess of the serum proportions [81].
Studies of specific IgM responses are much less common, as sensitive assays only
became available in the 1980's. Serum specific IgM titres have been reported as early as
day 2 and 3 [34, 126], and elevated CSF titres with local synthesis by days 5-6 [34, 245,
231], remaining elevated for about a month before declining thereafter [231].
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Total IgA has been found to be locally synthesised in CSF after day 5 [231, 245, 263],
remaining elevated for about a month, as with IgM, and then declining after [231].
Animal models have also confirmed this finding [148]. Specific IgA responses have
only been reported in one paper, and although it was found in serum and CSF from day
2, the poor presentation of the data meant that local synthesis of specific IgA could only
be shown from day 16.
Anti HSV1 specific IgG subclass reactivity has been studied in serum and CSF in two
studies [111, 166]. Both found IgGl predomonating, with IgG3 and IgG4 less common
and IgG2 least often found. One group found the serum and CSF distribution to be
identical [111]; the other group reported local synthesis of all subgroups, particularly
IgGl which was usually the earliest response, although in some patients the development
of IgG3 and IgG4 local synthesis could precede IgGl.
There have been no reported studies of the specificity of the response in HSVE in
humans to particular viral epitopes. Animal models appear to show a difference in the
specificity of the IgG response to primary and secondary infection, noting that in primary
infection the anti-glycoprotein activity is too late to contribute to viral clearance [172,
174], The IgM response also differs in epitope specificity to IgG and in primary and
secondary infection [140]. A mouse model of HSVE has also demonstrated the presence
of anti-myelin basic protein antibodies, but the relevance of such antibodies to the
pathological changes is uncertain [25].
The role of the immunoglobulin responses to HSV infection in the diagnosis of HSVE is
considered in more detail in Chapter 2, where the qualitative aspects of the intrathecal




As indicated in section A, the cellular response is predominantly lymphoid, and precedes
the antibody response [81]. The pleocytosis usually appears from day 4, peaking within
1-2 months, then declining, but may persist for up to 16 months. The neutrophil and
plasma cell response is usually early, but the lymphoid response takes over, and the cells
that display reactive features predominate from day 12 [245].
One study has examined lymphocyte sub-types in a case of HSVE. The lymphocytic cell
surface markers show that whilst pan B cells predominate early, they decline to be
replaced by cells with pan T markers. In addition, the T4:T8 ratio in the CSF parallels
blood until about day 20 when the ratio increases only in CSF, declining to blood levels
by 50 days, indicating compartmentalisation of the response [10]. Animal models have
demonstrated high concentrations of T4 and T8 lymphocytes adjacent to HSV infected
cells in areas ofmyelin loss, indicating that in animals, and perhaps in man, lymphocytic
responses may be responsible for as much of the pathology as the virus itself [39].
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CHAPTER 2: DIAGNOSIS OF HERPES SIMPLEX VIRUS ENCEPHALITIS
1. Diagnosis Using Clinical Criteria
A. Clinical Diagnosis
From the review of clinical features in Chapter 1, it can be seen that in the early stages,
symptoms are non-specific, consisting of vague malaise, 'flu-like symptoms, headache,
fever, mild meningitic or encephalitic symptoms, so clinical diagnosis is almost
impossible at this stage. In only a minority of patients, about 20%, is there a history of
recurrent or recent herpetic infection (see Table 4b), which, given the prevalence of HSV
gingivo-stomatitis in the community, does not aid particularly in the diagnosis. In one
comparative study, the incidence of recurrent HSV lesions was 24/108 in HSVE
sufferers and 18/81 controls or 22% in both [278]. It is only when signs of focal
temporal lobe involvement become apparent that the suspicion of HSV pathology
becomes raised. Thus, any febrile patient with signs of disturbed consciousness or
behavior, and focal neurological symptoms and signs, especially focal epilepsy,
Wernicke's dysphasia or hemiparesis, should be considered to have HSVE. Even better
if temporal lobe symptoms predominate, such as olfactory or visual hallucinations, or
amnesia.
HSVE, however, is only one of several conditions that can cause fever, confusion, focal
neurological signs and temporal lobe involvement. The difficulty in correctly identifying
HSVE from clinical criteria, even when some supplementary investigations have been
instituted, is illustrated by the results of the major trials into therapy for HSVE. In the
Boston Inter Hospital (BIH) idoxuridine study in 1975 [30] 12 patients with clinical
features indicative of focal encephalitis were recruited, space occupying lesions were
excluded and other fungi and bacteria were not cultured from CSF, yet 3 did not have
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HSYE on biopsy. In the 1981 National Institute for Allergies and Infectious Diseases
(NIAID) collaborative study on vidarabine [277], which included for statistical purposes
the 1977 study results [276], 182 patients were enrolled with a clinical diagnosis of
HSVE, of which 76 (42%) did not have HSVE on biopsy. One could argue that biopsy
was falsely negative, but in 35 (19%) of the 76 cases an alternative diagnosis became
apparent, and in 37 of the remaining 41 cases brain histology suggested viral
meningo-encephalitis due to agents other than HSVE. The remaining 4 had serological
changes suggestive of HSVE. In the NIAID study of 1982 [278], which updated 1981
work, of 202 patients recruited, 113 were positive for HSVE and 89 (44%) were not
HSVE on biopsy with 35 having alternative diagnosis, and in 50 other viruses likely.
The collaborative Swedish Herpes Encephalitis Study Group in 1984 [233, 232] enrolled
127 cases with clinically suspected HSVE, of which 74 (58%) were considered finally
not to have the disease, although not all were brain biopsied. 22 of these latter patients
were found to have another cause for their disorder. Finally, in NIAID study of 1986
[274], of 208 enrolled patients undergoing brain biopsy, all again clinically diagnosed as
suspected HSVE, 139 (67%) did not have HSVE on biopsy. Only 3 (2%) of these latter
patients had serological changes compatible with HSVE.
Table 7 summarises the clinical diagnostic accuracy of these 5 major studies over 10
years, during a time when experience of clinicians in these centres should have improved
the accuracy. As one can see however, the accuracy steadily declines from 75% in 1975,
to 33% in 1986. This was partly attributed to the realisation of the larger spectrum of
disease that existed, with the inclusion of milder cases, the lowered threshold for
diagnosis, given that by 1986 acyclovir was in use, and the early referral of patients in an
attempt to have therapy instituted, given the associated between conscious state and
timing of therapy with outcome. Overall, clinical diagnosis was correct in 45% of
patients, or less than half. This does not necessarily mean that clinical diagnosis
correctly identifies all those patients who have HSVE; mild cases may survive
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unrecognised, and in others the diagnosis may only be apparent post mortem, but aside







BIH 1975 12 9 (75) 3 (25) 30
NIAID 1982 202 113 (58) 76 (42) 278
SMS 1984 127 53 (42) 74 (58) 233
NIAID 1986 208 69 (33) 139 (67) 274
TOTAL 549 244 (44) 305 (56)
BIH - Boston Inter Hospital study
NIAID - National Institute for Allergic and Infectious
Diseases Collaborative study
SMS - Swedish Multicentre Study of Skoldenberg et al
TABLE 7 : Accuracy of clinical diagnosis in major trials
of therapy in Herpes Simplex Virus Encephalitis.
It would be unreasonable to suggest that many serious cases escape diagnosis in
neurological centres, given the other means of aiding in diagnosis, but it would be
interesting to see how many clinical diagnoses without investigative aids are revised.
Whitley et al [278] estimated that in only 83% of patients had HSVE been clinically
suspected (and this included the use of CT, EEG, but excluded biopsy and serology).
The importance of accuracy in diagnosis is therefore not only to identify HSVE for
antiviral therapy, but also to treat appropriately those conditions mimicking HSVE
which may be eminently treatable.
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B. Differential Diagnosis of Herpes Simplex Virus Encephalitis
Before considering the differential diagnosis of a clinically defined case, it should be
pointed out that in practice many investigations now exist to exclude many of the
alternative diagnoses, and with brain biopsy, the diagnosis of a positive, and one would
hope a negative case should not be in doubt. But, as illustrated already, the early
features of HSVE may be non-specific, and the first focal features suggestive of temporal
lobe problems may arise with any temporal lobe pathology.
In the 1960's, it was apparent that "acute necrotising encephalitis" caused by HSV1,
could present as an expanding space occupying lesion, with angiograms and air
ventriculograms demonstrating shift of vessels [37, 4], It was important to exclude
tuberculous meningitis and meningo-encephalitis, or cerebral abscess, both treatable with
specific therapy, and cerebral tumours, the symptoms of which could be relieved by
decompression. In the monograph by Illis and Gostling on HSVE in 1972 [107], their
table of differential diagnosis does not differ greatly from the diseases found to be
clinically diagnosed as HSVE in recent studies (Table 8). Commonest confusing
diagnoses were other viral meningitides which presented like HSVE, but tumours,
tuberculosis and abscesses are still being misdiagnosed. Of the 35 patients (of 76 total)
misdiagnosed in Whitley's study, 11 could potentially have been treated in some way,
and in particular 7 would have required specific therapy, which would not have been
instituted as soon as was done when brain biopsy was performed. In the Swedish study
of Skoldenberg [233], 22/74 non HSVE patients were given an alternative diagnosis, of
which 9 were potentially treatable and required specific therapy. There is obviously no
confusion in some diagnostic categories now - multiple sclerosis is unlikely ever to be
confused with HSVE.
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111Is 1972107 Whitley 1981277 Skoldenberg 19842^
Viral Post infectious Post influenza Post influenza
Arthropod-borne St. Louis encephalitis Tick-borne
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TABLE 8 : Differential diagnosis of Herpes Simplex Encephalitis. 1972 - 1984.
More recent studies have focussed on individual cases presently like HSVE, but having
other confirmed diagnoses. There have been 2 case reports of isolated small vessel
angiitis of the brain, presenting in an identical fashion to HSVE. In the first [184] a 15
year old girl developed malaise, headache, confusion, followed by a generalised seizure
and in 12 hours had a right hemiparesis, dysphasia and was drowsy. A CT brain scan
showed a left parietal hypodense mass. A brain biopsy showed necrosis only and at post
mortem only necrotising vasculitis was seen. In the second case [261], the signs and
symptoms more closely mimiced the typical course of HSVE, with a 10 day prodrome of
'flu-like symptoms, then decreasing conscious state and left hemiparesis with dysphasia.
Vidarabine was commenced before a biopsy showed angiitic changes with little or no
parenchymal changes.
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A review of cases of eastern equine encephalitis (EEE) from Massachusetts over 14
years [204] described the clinical similarity of the condition with HSVE. There was in
general a similar vague prodromal period, most patients developed focal signs, such as
cranial nerve palsies or hemiparesis, many were confused and drowsy, and many were
treated as HSVE with appropriate antiviral agents. However, the EEG (non-specific
background changes) and CT (generalised oedema in EEE) were found to be
distinguishing features once the diagnosis was confirmed serologically. Until serological
results were available, CT or EEG could not be used to unequivocally exclude HSVE.
A retrospective study of 25 acute viral encephalitis cases not caused by HSVE was used
to examine what features, if any, could be used to exclude HSVE in early phase [225].
Using clinical, laboratory, radiological and electrophysiological features, the authors
decided none were able to reliably exclude HSVE and 9 of these cases had other
aetiological agents identifiable: 3 epstein-barr virus, 3 measles, 2 varicella, and 1
rubella. Five of these did however, have preceding exanthem which would have led to
the correct diagnosis. In particular focal signs were appropriate to the tempero-parietal
area clinically in 7, and on EEG in 13. Twelve patients were so clinically similar to
HSVE that antiviral therapy was instituted. One major caveat was the lack of biopsy
evidence to exclude HSVE, and the exclusion made on serological grounds. The authors
admitted that
"... our series might contain patients with serologically negative HSVE".
The importance of being aware of potentially treatable other conditions when one does
not use viral antigen detection as a means of diagnosis cannot be underestimated.
Apparent response to therapy should not be taken as evidence of correct diagnosis, and
failure to respond should prompt a re-evaluation of the diagnosis along the lines
illustrated. One must also remember the unusual presentations of definite HSVE,
illustrated in Chapter 1, which may initially suggest another diagnosis.
Page 49
2. Diagnosis by Detection of Specific Antibody to Herpes Simplex Virus
A. Serological Diagnosis
By convention, proof of primary infection with an organism by serological means
requires evidence of an increase in specific antibody production by a factor of at least
4-fold. To detect such a change, 7-10 days usually has to elapse between samples. In a
disease of such rapid progression therefore, serological diagnosis is usually of little or no
help in the acute management of the patient, and offers only retrospective diagnosis. So
saying, in the time before brain biopsy in life was shown to be feasible, and in those
countries which still do not accept brain biopsy as an ethically justifiable procedure
(such as the United Kingdom), serological evidence is often the only laboratory
supportive means of diagnosis.
Complement fixation tests (CFT) are the usual methods applied to HSVE, although
neutralisation antibodies can be assayed to discriminated between HSV1 and 2 [207]. In
early studies a 4-fold rise in serology was taken as definite evidence of HSVE, so many
studies did not compare serology with brain biopsy in the same patients. In addition,
brain biopsy was often a post mortem biopsy, and death occurred before a second serum
sample was taken, so comparisons were often impossible.
In the first non fatal case undergoing brain biopsy in 1956 [63], the serology taken after
day 15 showed a 4-fold decrease in CFT to HSV, taken as evidence of the aetiology. It
wasn't until 1964 and the first 2 biopsy cases in life were reported, that both were shown
to have greater than 4-fold rises in CFT [162]. Miller et al in 1966 [177] reported 20
cases, of which 10 were biopsy positive. Although 14 patients showed greater than a
4-fold rise by CFT, of the 10 patients who died only 4 had rising titres, with all having
paired sera analysed. No patient exhibited a response to other viral agents, but they
demonstrated that any primary infection i.e. focal herpes labialis or genitalis could result
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in greater than 4-fold rises to high titres, and during quiescence titres were always below
64. Thus careful search for intercurrent mucocutaneous herpes was indicated in case the
serological response was consequent upon this and not the encephalitis. Leider reported
15 encephalitis cases of which only 2 were virus positive. In one, considered HSVE on
serological grounds, there was a similar 4-fold rise in influenza titres, so that accuracy of
this diagnosis remains in doubt [154].Asimilarly disappointing association was found in
the study of Olson et al (1967) [193], who reported 15 cases of serologically diagnosed
HSVE in whom 4 biopsy was attempted and were all negative.
Ross et al in 1973 [215] reported 20 cases, of whom 15 had virus identified. Eleven had
>4-fold elevation in CFT titres, some from <8 to>1024, with 3 showing high static
levels, and 5 dying before a second sample could be taken. Two biopsy negative patients
were serologically positive. Four patients showed a significant elevation to herpes zoster
by complement CFT, but this was not thought to be a problem as neutralisation tests
could be used to differentiate.
Illis et al [107] suggest that in mucocutaneous herpes, serum titres never achieved the
level seen in encephalitis. They reported 9 cases ofmucocutaneous herpes with a
highest CFT titre of 320, and the mean 93. For 6 encephalitis cases the highest titre was
2,560 and the mean 640. Neutralisation titres were only done in 3 cases of HSVE, but
paralleled the CFT findings.
Rappel in 1970 [207] noted that the appearance of CFT antibodies in serum alone could
not be taken as evidence ofHSVE, as other diseases could reactivate CFT antibodies.
Johnson [116] noted non-specific rises with other intercurrent infections such as
pneumonia and hepatitis.
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Because not all cases of biopsy proven HSVE have rising antibody titres in serum to
HSV, and not all cases of rising antibody titres were associated with positive biopsy
results, and in some patients there were simultaneous rises to more than one agent,
reliance on serology alone has fallen from favour, until now in many centres it is not
considered sufficient evidence to establish the diagnosis. Despite this, reports still
appear of HSVE "proven" on serum antibody changes alone, and indeed the majority of
cases in the United Kingdom of HSVE are still "confirmed" by serum antibody rises
alone (168/267 reported to the PHLS) [195].
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B. CSF Serology
Since Kabat first identified abnormalities of CSF immunoglobulins in neurological
diseases in 1942 [117], it became apparent that specific encephalitides were associated
with intrathecal production of specific antibody to the aetiological agent. Early studies
produced initial poor results, with CSF neutralising and CFT antibodies not being
detectable before day 9 at the earliest and usually not until after day 14 if at all [161,
113]. As assay sensitivities improved, it became apparent that antibody detection was
feasible consistently in the CSF, but interpretation of the findings was sometimes
mistaken because of the failure to appreciate that CSF immunoglobulins are also derived
from serum by passive transfer.
In 1978 Levine et al [155] were the first to identify local synthesis of specific antibody
within the CNS in biopsy proven cases by using both passive haemagglutination, and a
more sensitive immune adherence haemagglutination assay on CSF and simultaneous
serum samples, and using the ratio to establish evidence of local synthesis. They were
aware that passive transfer of serum immunoglobulins to CSF would give positive CSF
results if serum titres were high enough, so included a cut-off value of serum:CSF < 20
before considering a result to indicate local synthesis. By these criteria, they established
local synthesis in all 8 patients studied, 3 of which gave a positive result before brain
biopsy was performed, the earliest at day 4 of the illness and in 4 patients by the 10th
day of the illness. However, 4/28 controls were also positive: 1 HSV2 meningitis, 2
varicella zoster infections and 1 multiple sclerosis. The first 3 were readily explained by
cross-reactivity, but the MS patient required invoking non-specific activation of CSF
antibody. A more likely explanation was the failure in their analysis to correct for blood
brain barrier damage, which could reduce the serum:CSF ratios in the absence of true
local synthesis. Radioimmunoassay for specific IgG was initially reported in 1981 by 2
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groups. Both used solid phases coated with antigen to capture specific antibody.
Klapper et al [129] calculated an antibody index to correct for blood brain barrier
damage:
CSF HSV antibody Serum Albumin
x
Serum HSV antibody CSF albumin
Forty seven control patients with back pain were used to establish a cut off value of 1.91.
They studied 26 patients with HSVE (14 biopsy or necropsy diagnosed), and found local
synthesis of specific antibody in 24. Five of 10 patients studied before day 10 were
positive, 3 of the initial negatives becoming positive after day 10. The earliest positive
result was on day 3. However, no disease positive controls were included in the study,
so the specificity of the assay could not be verified.
The second study by Skoldenberg et al [234] used polystyrene balls as solid phase, and
studied 16 patients with HSVE, 4 of which had viral isolation from CSF, brain biopsy or
necropsy. They similarly corrected for blood brain barrier damage by using albumin or a
non-neurotrophic control virus (respiratory syncitial virus). They demonstrated local
synthesis of IgA, IgG or IgM in 1/4 patients 3-4 days after disease onset, 5/9 patients 6-8
days after disease onset and in all patients after day 10. For controls, HSV2 meningitis
were used, 4/5 showing IgM local synthesis, and 42 non-neurological patients, none of
which where positive. In the HSVE patients, long term follow up showed local synthesis
of IgM declining after 2-3 months, but in 2 patients persistence for 4 and 15 months was
demonstrated. IgA findings paralleled IgM, with persistence in 4 patients beyond 7 and
up to 32 months. Persistent IgG production was evident in all patients up to 43 months,
maximal by 4 months, with slow decline thereafter.
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Thus both RIA methods using single paired CSF and serum samples could detect locally
synthesised antibody in all patients beyond the 10th day, but before day 10 were far less
successful. Both studies omitted positive controls with non-herpetic neurological
illnesses. Thus the crucial problem of early diagnosis to institute appropriate therapy
still had not been resolved, and the specificity of the systems properly assessed.
Felgenhauer et al in 1982 [81] used a wide variety of positive controls, and a sepharose
4B solid phase colorimetric ELISA assay, to demonstrate local synthesis in all 25 cases
ofHSVE (12 biopsy proven) but only recorded 1 positive result before day 10 and did
not correct for barrier damage. Koskiniemi et al [134] looked at 11 patients (6 biopsy
proven) by CFT to a number of viruses, and calculated an IgG index to determine local
synthesis of total IgG, but not specific IgG. All patients after day 10 demonstrated local
synthesis of herpes specific IgG but only 7 had an elevated IgG index indicating locally
synthesised antibody and absence of relevant data for the other 4 patients means local
synthesis could not be verified in these. Only 2 patients had detectable CSF antibodies
to any other virus, both varicella zoster. Forty-four control patients, including other
encephalitides did not produce HSV specific locally synthesised antibody. Local
synthesis of specific IgG in the HSVE patients was prolonged, up to 29 months, as found
by Skoldenberg et al [234], Nahmias et al (1982) [188] in their NIAID study, used the
serum:CSF ratio of specific IgG and found 90% of 113 biopsy positive patients had local
synthesis as defined by a value of < 20, but also 19% of 93 biopsy negative cases,
although barrier damage was not corrected for. The majority however, did not show
local synthesis until after day 10. In the 1984 Swedish multi-centre study [233],
Skoldenberg et al reported 25/26 biopsy proven HSVE patients to have locally
synthesised anti-HSV IgG with barrier damage corrected for, but noted that in many
cases the response only occurred after day 12 of the illness. Tests for simultaneous rises
to measles and varicella zoster, showed only a few patients demonstrated the latter and
the rise was small. They found the test specific, with 24 patients with non-HSV or VZV
infections, both bacterial and viral, not showing any response. However, some reports
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have doubted this apparent specificity of response, with one report ofmumps meningitis
showing apparent local synthesis of anti-HSV IgG [262], and another presumed TB
meningitis having local synthesis of anti-HSV IgG [44], although in this latter case there
was no good evidence that HSVE could not have occurred since no tubercle bacilli were
ever isolated.
Since these studies, other attempts have been made to improve the serological studies
and their sensitivities. Jeansson et al (1983) [109] developed and in-house ELISA kit
based on solubilised HSVE infected cell membranes containing all the major HSV
glycoproteins and demonstrated intrathecal synthesis of specific IgG in 3 patients
(without barrier correction but with measles virus as a control). The earliest response
was day 10, but levels rose approaching serum levels for up to 7 years in one patient.
Sugimoto et al [242] studied 3 children using a commercial ELISA kit and demonstrated
specific IgG from day 3-4 in the CSF when conventional CFT and neutralisation tests
were negative, and Keunen et al [126] used an ELISA to show local synthesis from day
16 of specific IgA in 2/5 patients, but neither studies used adequate correction for blood
brain barrier function. Johansson et al [111] corrected for BBB damage in 10 patients (3
biopsy positive), found local synthesis in 9/10 but only 1/5 before day 10.
Using purified glycoprotein B as a captor antigen, Kahlon et al (in 1987) [118]
demonstrated with a radioimmunoassay that 35/36 biopsy proven HSVE CSF samples
contained specific antibody, but also 6/22 controls. They did not correct for BBB
damage in any quantitative fashion, but used the presence of CSF antibodies to
adenovirus as an indicator of damage. By this criteria the 6 controls could be excluded,
but no mention was made of how many biopsy proven cases would have to be excluded.
The earliest recorded day for a positive result was not given, but day 5 mentioned as the
time after which most became positive.
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Finally, intrathecal synthesis of IgG subclasses has been examined [111, 166], with IgG3
and IgG4 being the earliest intrathecally synthesised subclasses in some patients,
although IgGl was the commonest intrathecally synthesised antibody, with most
producing at least 2-3 subclass types. No researchers were detecting antibody much
earlier than day 10.
Thus intrathecal synthesis of specific antibody is sensitive (up to 96% of biopsy proven
cases), in most studies is specific (although isolated case reports suggest occasional
increases in other diseases), is non-invasive, but is virtually useless before day 10 of the
illness, by which time the pathological damage has reached its peak and many patients
are in coma. As a diagnostic tool, it is reserved therefore for making a retrospective
diagnosis, although when positive before day 10, and as early as day 3, the results can be
taken as confirming HSVE.
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C. Oligoclonal Bands
Oligoclonal IgG, locally synthesised within the CNS, has been associated with CNS
infections, including HSVE, since the phenomenon was first identified. In
Skoldenberg's study of 11 patients [234] 4 of which were biopsy proven, locally
synthesised oligoclonal IgG was not detected before day 10 in the 6 patients where it was
sought, but was found in all after 10 days, and in every sample analysed during follow
up, for up to 1,103 days. The specificity of the oligoclonal bands was investigated by
Vandvik et al in 1982 [263] in 7 cases of HSVE, using imprint immunofixation of
agarose electrophoresed or electrofocused IgG and autoradiography. All 7 patients had
local synthesis of oligoclonal total IgG, but not before day 9, and all showed
HSV-specific oligoclonal IgG, in 1 case on day 5 despite the total IgG being negative.
HSV-specific oligoclonal IgG was visible up to day 390. Oligoclonal HSV-specific IgM
was only found in 3/6 patients, between days 15 and 37, but HSV-specific IgA was
found in all 6 patients tested, from day 8 up to day 390. The results were specific, in that
normal patients, and patients with other neurological diseases, did not show any response
to HSV. However, 1 HSVE case did show a transient small oligoclonal response to
measles, suggestive of non-specific activation. The oligoclonal HSV-specific IgG was
estimated to account for about 50% of the total CSF IgG in 1 case where elution was
attempted.
Further refinements to the technique have confirmed the sensitivity and specificity of the
method using, using isoelectric focusing antigen immunoblotting and HRP catalysed
staining [182, 64], but further studies using antigen radioimmunoblots on purified
glycoprotein B were flawed technically and results reported showing local synthesis in
some patients were not convincing because of the excessive artefactual banding visible on
the illustrations, and the interpretation of these were open to question [95].
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Thus, like quantitative studies, qualitative studies were generally not positive until after
day 9-10, and even though specific immunoblotting could detect HSV-specific IgG
earlier than total oligoclonal IgG, the use of this technique for diagnosis was recognised
as limited.
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3. Diagnosis by Detection of Virus or Viral Antigens in CSF
A. Recovery of Virus
Without exception, the rate of recovery of HSV from the CSF is disappointingly low,
and is thus one of the least useful means of establishing a diagnosis. There have been
several individual case reports of HSVE with viral isolation from the CSF, the first being
Armstrong et al in 1943 [7], who isolated the vims from a case initially suspected of
having lymphocytic choriomeningitis (LCM), and over the years occasionally others
have been reported, none of whom had brain biopsy proven disease [128, 150, 217].
Table 9 summarised the major studies where positive attempts have been made to
isolated the vims from CSF, and the results given when mentioned.
Year Patient Isolation Isolation Ref.
Number attempted positive
1961 5 (0) 5 0 214
1965 6 (6) 6 1* 37
1966 22 (22) 10 0 208**
1966 20 (10) 20 0 177
1967 36 (21) 7 1 193
1973 20 (14) 9 0 215
1973 17 (?) 17 1 251
1975 9 (9) 9 1 30
1977 28 (28) 28 1 276
1980 6 (3) 6 0 133
1982 113(113) 45 2 188
1985 267 (63) (?) 10 195
TOTAL 162a 7a
( ) - numbers within are biopsy positive cases
* - probably ventricular fluid
** - review paper
a - excluding 1985 paper
TABLE 9 : Literature review of results of attempted
isolation of herpes simplex virus from the
cerebrospinal fluid of patients with herpes simplex
virus encephalitis.
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Rawls study of 1966 [208] was a complete literature review of all cases from 1941-1966
where brain biopsy was positive, and there weieno cases in 10 attempts where HSV was
successfully isolated. Subsequent reports refer to therapeutic trials, or reviews of
personal experience, so there was no doubt as to the attempts being made to culture the
virus. Excluding the 1985 PHLS report, where the number of cases where attempts to
culture were performed was not stated, of 162 attempts, most of which were biopsy
positive, only 7 cases were successful. In one of these, the CSF was obtained after death
and so was likely to be ventricular [37], which was also the source in a case of Klapper
et al (not included in the table), when CSF was taken at biopsy [128]. Indeed Flewitt in
1973, who studied 12 biopsy proven patients states:
"we have never isolated herpes febrilis virus from lumbar CSF. Virus
is usually present in ventricular CSF, though CSF often takes 1 -2 days
longer than brain suspensions...." [84],
In no cases has virus been isolated from lumbar CSF and not from brain tissue if biopsy
has been performed.
Thus, even if one includes the PHLS study and assumes all had CSF culture attempted,
only 4% of CSF will yield a positive result. This probably represents the highest figure,
as innumerable studies don't even mention results of CSF viral culture presumably
because of negative results.
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B. Detection of Viral Antigens in CSF
Recovery of whole virions from CSF that are viable, can be cultured and then
reidentified, is disappointing, but whether poor results are related to absence of virus, or
that virus is present but either inactivated or modified or in insufficient quantities to be
adequately cultured remains uncertain. Given the degree of brain necrosis in some
patients, it would be surprising if virus was absent from CSF, so it is likely that it is
either present in small quantities or modified or inactivated in some way.
Sommerville in 1966 first reported identification of HSV by immunofluorescence in
cells from patients with herpes meningitis^llut no one was able to substantiate this
finding [158]. Dayan in 1973 reported an immunofluorescent method for examination of
the cells in CSF of patients with encephalitis for presence of viral antigens [59].
Ninety-five patients were examined, 33 with a variety of proven encephalitides, of which
87 they correctly identified as encephalitis or not encephalitis. Three patients were
incorrectly identified as not encephalitis. Of 12 cases of HSVE (the diagnostic basis for
this was not specified), 11 were positive for cells containing HSV antigens. In 2 cases of
clinically progressive HSVE for 3 weeks, antigen containing cells were present for as
long as the signs progressed. In 1 case, cells recovered within 24 hours of onset of
symptoms were negative, but a second sample 30 hours later was positive. Numbers of
positive cells was given as a percentage and was 10%-25% at best, but since absolute
numbers of cells in each specimen was not given and the methods were incompletely
reported, the significance of this finding was disputed [251, 159]. Indeed Longson and
colleagues pointed out that in cases of positive culture from CSF, cells cannot be
demonstrated containing viral antigen [159], and Nahmias et al found only 2/47 biopsy
proven cases had immunofluorescent detection of antigen in CSF cells [188]. Since
Dayan's report, no one has published confirmation of these findings, and when
specifically looked for, no positive results have ever been found [133]. Since CSF cells
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have thus proved an unreliable source, investigators have redirected their efforts to the
detection of free viral antigen in CSF, although there have been comparatively few
reports in the literature.
Chen et al in 1978 [41], purified and radio-iodinated a glycoprotein from HSV infected
rabbit kidney cells, which although not fully characterised, appeared to be a structural
non-envelope glycoprotein. Using a competitive assay, CSF's from 6 biopsy proven
cases of HSVE were examined and all were found to block precipitation by between
15%-66% with no negative controls showing blocking (3 seizures, 1 mumps
encephalitis). Although the authors mention that antigens were detectable early in the
course of disease in CSF, no data was given. They also confirmed the problem of using
a competitive assay when CSF samples would also contain specific antibody which
could interfere. The rational for use of an excreted glycoprotein was that in patients this
was more likely to be present in extracellular fluid at an earlier stage than whole virions.
Coleman et al in 1983, developed a competitive inhibition ELISA for HSV antigens in
CSF [45]. By coating a plate with HSV, incubating the CSF with a known amount of
polyclonal rabbit anti-HSV globulin, and measuring the reduction in binding to the plate
versus controls consisting of uninfected cells supematants, they examined CSF's from
neonates and adult HSVE patients, all biopsy proven. They found 61% of neonatal
CSF's showed significant reduction and 15/23 (65%) of adults who were brain biopsy
positive, but also 4/29 (14%) of brain biopsy negative controls were positive. They
found no association between presence of HSV specific antibody in the CSF and the
result, and fewer patients were positive early in the disease than later. (10/21 <10 days,
11/14 11-20 days, and 5/6 >20 days). They were unable to determine what epitopes the
polyclonal antibody were directed against, but showed they were common to both HSV 1
and 2.
Page 63
Bos et al in 1987 developed an ELISA capture technique based on a sandwich assay
principal [29]. Using microtitre plates as solid phase, CSF antigen was captured by
polyclonal goat anti-HSVl IgG and probed by polyclonal rabbit anti-HSVl IgG, with a
final amplifier of sheep anti-rabbit peroxidase conjugate and OPD substrate. The
method was made more elaborate by the running in parallel of a control plate of
preimmune goat IgG, so that an index could be calculated. By running HSV infected
vero cell extracts and vero cell controls, they established a cut-off ratio of 1.5, modified
to 1.93 when it was found there was some cross-reactivity of rabbit antisera with goat
hyperimmune but not preimmune antisera. Eighteen patients with HSVE were
examined, of which 5 were biopsy positive and 3 had CSF isolation of virus. Twelve
controls consisted of non-infectious neurological disorders and 21 non-HSV encephalitis
cases. The results were disappointing. Of 38 CSF's studied from the 18 patients^only 8
were positive, representing 6 patients (33%). Only 1 of the 3 patients with virus isolated
from CSF produced a positive result. One of the 33 controls was positive, a case of
encephalitis of unknown origin. In all 6 positive patients, the first CSF taken was
positive, and in 1 case with 3 serial punctures the CSF remained positive from day 15 to
day 19. When serial samples were followed, decreasing antigen ratios were sometimes
accompanied by increasing levels of intrathecal synthesis of specific IgG, suggesting the
possibility of immune complex formation binding antigen, but only 2 cases of positive
antigen ratios had serial samples, neither of which supported this contention. The
earliest day recorded for a positive result was day 5, and the latest day 19, but for 4 of
the positive patients no dates of samples were given. The negative samples dated from
day 2 to day 37. Although the sensitivity with this assay was poor at 33% and worse
than intrathecal antibody detection, the specificity was good at 97% and antigen could be
detected from day 5.
Agut et al in 1988, employed a commercial HSV1 antigen detection ELISA kit
(Wellcome), which was developed for the diagnosis of genital herpes [6]. This simple
capture ELISA probed by an NADPH linked monoclonal antibody was adapted by
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prolonging the incubation of antigen to 20 hours. Twenty-one cases of HSVE and 24
non-herpetic infections were analysed and straight optical density results plotted. Nine
of the twenty-one (43%) HSVE CSF's studies were above 3 standard deviations of the
mean of the non-herpetic controls and also exceeded the highest value for the
non-herpetic group. The highest OD values were obtained in those patients within one
week of onset of clinical signs, and who had not yet any recorded anti-HSV 1 IgG. The
lowest OD's were recorded from those whose CSF's were taken after one week and with
the presence of anti-HSVl IgG. Overall 7/9 patients without specific IgG were positive
for antigen and only 2/8 patients with antibody were positive. The sensitivity of the test,
thus was only 43% but the specificity 100%. The results also suggested that immune
complexing was occurring after the development of the antibody response, thus
preventing antigen detection. The earliest time for a positive result however, was not
given.
Lakeman et al in 1987 employed a pool of monoclonal antibodies to glycoproteins B, C,
D and E to probe CSF's which had been dried onto nitrocellulose membranes [147], The
final antibody was anti-mouse, either radio-iodinated or biotinylated. Twenty-six biopsy
positive and 17 biopsy negative patients were studies, using 40 and 25 CSF's
respectively. Radiolabelled antibody give identical results to the streptavidin-biotin
systems. Thirty-five out of forty biopsy positive specimens gave a positive result (88%
specificity) and all 5 negatives being part of the 13 CSF's taken within 7 days of onset of
the illness. Thereafter, all specimens were positive, including 3 from patients initially
negative. Three of twenty-five biopsy-negative specimens gave positive results (88%
specificity). Antigen could be detected up to one month after onset and as early as 3
days. Taking patients individually, the sensitivity was 92% (24/26) and the specificity
82% (14/17). Specimens taken within one week of onset of disease were only 64%
sensitive, after this time rising to 100% sensitivity. This method was by far the most
sensitive antigen detection method reported, but the results contrasted dramatically with
those of Agut et al, who could not find antigen after day 7. The monoclonal probe used
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by the commercial kit, is believed to be against glycoproteins B or C, so the result should
have been similar. In this study the effect of native CSF IgG was found to be negligible.
Perhaps the differential antibody response in CSF to glycoproteins may explain the
results. Lakeman et al commented that the use of glycoprotein B monoclonal antibody
alone gave poor results.
Viral DNA has been sought in CSF, using dot blot hybridisation techniques. Sdiuster et
al in 1986, using in vitro synthesised radiolabeled RNA transcripts, examined CSF
samples from 2 patients which had been both SDS and proteinase K treated before DNA
extraction and spotting and drying onto nitrocellulose filters [226]. Both samples were
positive for DNA: 1 patient had also HSV DNA detectable from post-mortem temporal
lobe and the other was diagnosed on the basis of intrathecally synthesised IgG and IgA.
Neither CSF's were culture positive. No negative controls were run, but the probe was
demonstrated not to react with CMV or varicella zoster DNA and to only a small degree
with HSV2 DNA. The assay sensitivity was 3 pg of plasmid DNA (1.5 X 105 genomes).
Boe rman et al in 1987 used radiolabelled nick-translated DNA fragments for
hybridisation to DNA extracted from CSF's from a single patient and dried onto
nitrocellulose filters [28]. The diagnosis of HSVE was made on the basis of a 4-fold rise
in CSF specific IgG titres, without reference to serum values. CSF culture again was
negative. CSF's taken on day 12 and day 23 were both positive for specific DNA, the
latter more so. The assay sensitivity was 1 pg of human HSV1 DNA (0.5 X 105 genomes).
Both these assays took under 48 hours, but the procedure was elaborate, reagents not
readily available to most departments, and only 3 patients in total were reported,with no
patient controls with other neurological disease. However results do show that DNA is
present and for some considerable time in the CSF. Antibody complexing prevents viral
detection in vitro but the detection of DNA is not affected.
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Further evidence for the role of immune complexes has come from 2 studies using
particle counting immunoassays demonstrating immune complexes in the CSF of
patients with HSVE increasing from day 12 of the disease in parallel with intrathecal
specific antibody production [230, 231]. Immune complexes persisted for 3-4 weeks
then decreased, but specific antibody production was maintained thereafter.
Finally there has been one previous single attempt at applying chemiluminescence to
herpes antigen detection. Pronovost et al in 1981 [203], developed a chemiluminescent
immunoassay (CELIA) to HSV antigens based on a double antibody sandwich with
rabbit polyclonal anti-HSVl as captor and human anti-HSVl as detector. The assay
compared absorptiometry with luminescence in detection, with CELIA detecting 40
plaque forming units (PFU) versus absorptiometry 2,500 PFU. When clinical samples
were ran, the CELIA was successful in detecting HSV1 from 15/18 mucocutaneous
lesions of both HSV1 and HSV2 sera types but was unable to detect any antigen from 6
CSF specimens which were also culture negative. No specific details were given of the
CSF specimens so little further comment can be made except that the assay in these
circumstances was completely unsuccessful.
Table 10 summarises all these studies, comparing their specificity and sensitivity. The
detection of antigen in the CSF has been shown to be feasible in at least 7 separate
studies (excluding Dayan's disputed work): 2 for generalised HSV1 antigens, 2 for DNA
and 3 for envelope and non-enveloped glycoproteins. Radiolabelling and enzyme
catalysed substrate reactions were both successful in either competitive or non
competitive assays. However, the sensitivity varied considerably, from 33%-100%, and
in some depended on the timing of the assay, with some evidence suggesting immune
complexes may play an important role. Antigen was detected as early as day 3 of the
illness, which is as early as the most optimistic of the antibody based diagnostic tests.
The chemiluminescent assay however, was unsuccessful in CSF testing, despite the
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The principle of viral antigen detection has thus been established, but is not so successful
that it can be considered an alternative to other methods. There is clear evidence that
antigens may be present early enough in the CSF to warrant the pursuit of this avenue of
research, which was the main aim of this study.
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4. Diagnosis by EEG
The EEG tended to be ignored as a diagnostic aid in the earlier reports of HSVE.
Drachman and Adams in 1962 for example, only gave brief mention to the EEG in their
6 cases, reporting that although all were abnormal, none was distinctive, and only 1
showed focal features with sharp waves, the rest being diffuse slow wave activity
predominantly lateralised [66]. The first detailed report to show significant changes in a
series of HSVE cases came from Rawls et al in 1966, when in reporting 5 cases all
postmortem proven, 4 of the EEG's all taken within the first 8 days of the neurological
illness were markedly abnormal, with 3 showing localised sharp waves or spike and
wave complexes at regular intervals which sometimes developed into focal seizures
[203]. These had been traditionally associated with cerebral infarction and tuberculous
meningitis, where the term "periodic lateralised epileptiform discharges" was applied.
Until this paper, the association between these focal discharges and encephalitis had not
been recognised, and was concluded to be a reflection of the localisation of the severe
pathological changes. Thereafter, despite the occasional report to the contrary [4], the
value of the EEG in HSVE in demonstrating localised abnormalities and correlating with
the pathological changes became increasingly recognised [193, 156]. Upton and
Gumpert reviewing their own cases and some from the literature, summarised the typical
findings in HSVE as being a diffuse slow wave background, periodic complexes from
day 2-15 after the onset of the illness at about 0.5-1.0 Hz, which disappear thereafter,
rapid onset of the complexes and disappearance irrespective of clinical state, and
abnormal activity in frontotemporal regions, mainly periodic complexes and sharp and
slow waves [257]. These, they felt were pathognomonic features. Illis and Taylor in
1972 in their review of the literature and their own 20 cases, reported similar findings,
though were less stringent in their limitations, finding about half the patients had focal
temporal lobe abnormalities with persistence of periodic complexes up to several weeks,
and the degree and type of abnormality correlating more closely with the severity of the
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illness and with timing [108]. They suggested their findings indicated localisation of
pathology rather than any specific type of pathology and thus were not pathognomonic.
Elian in 1975 extended this work by studying 11 cases and following up patients up to 4
years [72]. The presence of repetitive complexes was correlated with poor prognosis, in
that all 7 with these died, and 4 without survived, although later work found bilateral
changes gave worse prognosis than unilateral [34]. Chi'en et al in 1977 reported
findings in support of Upton and Gumpert, in that a comparison of the pre-biopsy EEG's
of 5 cases of biopsy proven HSVE and 12 biopsy negative encephalitis cases, showed 3/5
HSVE had distinct high voltage periodic sharp waves, around 0.3-0.5 Hz, from the
temporal lobes with none of the controls showing these [38]. Furthermore, the EEG
localised the best site for brain biopsy, with the highest viral yield from the temporal
lobes showing the focus. These findings have been substantiated and extended since,
and although the temporal aspects vary, the patterns have remained constant [133, 34,
69].
It became apparent that EEG changes could be present early on in the disease, in some
cases focal abnormalities appearing from day 2 of the clinical neurological symptoms
[34, 97]. When compared with other neurodiagnostic tools, such as CT (see later) the
EEG was either the only abnormality or was abnormal earlier [69]. In many cases, the
EEG is the first abnormality detected [97, 125]. InWhitley's major studies on HSVE,
the EEG showed localisation more frequently than brain scanning, with 81% of patients
with biopsy proven HSVE having focal EEG abnormalities, versus 50% of technecium
brain scans and 59% of CT brain scans. 65% of proven cases showed the characteristics
spike and slow wave abnormality localised to the area proven by biopsy. It was
concluded that the EEG was the most useful neurodiagnostic evaluation, but that this
was not specific for HSVE, with up to 59% of non HSVE patients showing focal EEG
changes, the nature of which were unspecified.
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Although this apparent non specificity was confirmed in another study, where 13/25 non
HSVE patients showing focal temporal alteration, and only 4 showing periodic activity
[225] in some diseases such as EEE the EEG characteristically does not contain periodic
complexes, and can be used for differential diagnosis [204], Overall the EEG sensitivity
is good, but the specificity is poor in the early stages before periodic complexes appear,
and even then are not pathognomonic. However, it is consistently the earliest
investigative abnormality, suggesting that once neurological symptoms have appeared,
pathological damage must be fairly severe.
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5. Diagnosis by Neuroradiology
A. Angiography, Encephalography, Ventriculograms and Isotope Brain Scans
Because of the common presentation as a space occupying lesion, many early studies
employed one or more combinations of these investigations with mixed success [208,
263, 37]. In the review of Illis and Gostling of radiological investigations available until
1972, 46% of patients overall were normal, and 41% showed a temporal abnormality
[107]. Isotope brain scans and carotid arteriograms were better, at 47% and 57%
respectively, than ventriculograms and air encephalograms at 16% and 17% respectively.
Apart from localisation of the abnormality, they gave no indication of the pathology, and
have now been superceded by more sophisticated radiological techniques.
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B. Computed Tomography and Magnetic Resonance Imaging
The advent of computed tomographic scanning (CT) and subsequently magnetic
resonance imaging (MRI), has improved the role of radiological imaging in HSVE, but
not to the degree hoped. The first major study using CT scanning appeared in 1978
using 9 biopsy proven cases [54], The earliest abnormality was seen to be a bilateral
mass effect and abnormal contrast enhancement, with later low-absorption (attenuation)
changes in the temporal lobes. There were no localising features on any of the 6 scans
before day 5 of the neurological illness, with 4 being normal and only 2 having mass
effect at 1 and 3 days. All scans were abnormal, including with contrast enhancement,
by 7 days. A simultaneous report from another centre on 13 patients with HSVE showed
12 scans abnormal, with 10 having focal medial temporal or insular cortex low
attenuation [73]. However, scans were taken later into the illness, with the earliest scan
at 4 days. A comparison with cerebral angiography and radio-nucleotide imaging
showed a good concordance, with 90% of both studies being positive. The one patient
with an initially normal CT scan had an abnormal focal EEG. Three non HSVE patients
used as controls showed no focal temporal abnormalities. Follow up studies in these
patients showed worsening clinical states paralleled by evidence of increasing CT
involvement with haemorrhage often in the form of linear streaking, which was
considered characteristic. Progression on CT could last several weeks.
Other studies have confirmed the high incidence of focal CT abnormalities but also
confirmed that in the early stages the CT could be non-specific [133]. Table 11 shows
the results from several major studies of CT scanning in HSVE. Of 126 patients
scanned, 88 had focal temporal abnormalities (70%). When the timing of CT scanning
was given, the earliest focal CT abnormality was not evident before day 4, even though
many scans were performed before this time.
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Year Patient Focal Earliest Ref.
Number Abnormality seen (days)
1978 9 8 6 54
1978 13 10 4 73
1980 5 5 7 133
1982 6 6 5 34
1982 11 6 7 69
1982 56 33 N. A. 278
1987 6 6 4 97
1988 18 14 N. A. 125
TOTAL 126 88 4-7
TABLE 11 : Computed tomographic brain scan findings
in patients with Herpes Simplex Virus Encephalitis.
Presence of a significant focal abnormality and the
earliest at which a lesion was visible.
In comparative studies of EEG and CT, the EEG was invariably abnormal at an earlier
stage than CT [125, 97, 34], and in some studies was more frequently focally abnormal
(81% versus 59% [278]), but in most studies, similar ranges of abnormalities were found
(79% versus 77% [125], 64% versus 55% [69]). When both methods have been
combined diagnostically, the accuracy of focal abnormalities detected increases to 100%
[69], leading to suggestions that neither should be used in isolation. However, not all
cases of encephalitis with focal temporal abnormalities on CT will have HSVE [225], so
findings are not pathognomonic, and 30% of patients with HSVE will have no focal
abnormality.
Because of improved contrast sensitivity the imaging of limbic structures by MRI is far
superior to CT, so studies have now been reported comparing the two in HSVE. Schroth
et al in 1987 compared parallel MRI and CT scans in 4 cases of serological proven
HSVE [223, 224]. In all cases MRI showed T2 weighted image abnormalities much
earlier than CT, in earliest on day 4 of clinical symptoms, 6 days before CT. In most
patients the CT and MRI were both abnormal to some degree, but CT often showed
unilateral changes, whereas MRI changes were bilateral. Although showing greater
disease extent, the MRI only improved on diagnosis in 1/4 patients. A further report
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highlighted the improved detection of haemorrhage, and the discrimination of
abnormalities on both sides of the sylvian fissure, which are highly suggestive of HSVE
[190], but no improvement in early detection rates, with isolated case reports not
showing abnormalities before day 7 of the illness [190, 135].
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C. SPECT Scanning
Single Photon Emission Computed Tomography (SPECT) has been described as the poor
mans PET scam" Two reports have appeared in the literature now on a total of 17 patients
with HSVE. In the first report, 14 patients with acute encephalitis were studied, 6 of
whom were given a diagnosis of HSVE on the basis of a 4-fold rise in CSF titres, or high
static CSF titres alone [151]. All 6 had distinct areas of tracer accumulation in the
affected temporal lobe, the earliest visible at day 4, which increased up to day 13, then
diminished to hypoperfusion from day 37 to day 165. The 8 other non HSVE patients
did not show focal hyperperfusion or progress to hypoperfusion. The second report
studied 3 patients, 1 of which had a diagnosis of HSVE which was made on increased
CSF titres only, and all had unilateral temporal and frontal hyperperfusion [68].
None of these cases fulfilled the criteria set down by convention for the diagnosis of
HSVE, so the findings must be treated with caution. However, on the assumption that
some may have been HSVE, the inference looks interesting, but the technique is not
sufficiently well developed to be considered for routine use.
* PET = Positron Emission Tomography
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6. Diagnosis by Brain Biopsy
Recovery of virus is the only definitive way to guarantee a diagnosis of HSVE. Brain
biopsy is therefore the only direct way of making certain the diagnosis in life. As
mentioned in the introduction, brain biopsy, first attempted in 1956 [63], was not
successful in life until 1964 [162], Virus presence can be inferred by cytological
examination for intranuclear inclusions immunofluorescence and immunocytochemistry,
electron microscopy or tissue culture [84, 40, 215, 158, 5].
For immediate results, immunofluorescence provides quick and sensitive results, with
81% sensitivity in 21 culture positive cases with only 1 false positive test [84, 5].
Immunocytochemistry became more popular because of the improved sensitivity [61, 76,
141] and reported up to 100% sensitivity [40]. The use of Cowdrey type A inclusions as
a marker for HSVE has fallen from favour, since they are not specific for HSVE but are
present in SSPE and other viral encephalitides [116]. Culture provides the definitive
result, but takes 2-3 days [84, 5, 215].
The incidence of false negative results from biopsy is difficult to ascertain. Olson et al
reported no cases of negative biopsy and positive postmortem findings, but noted that the
site of biopsy was critical, in that virus was not recoverable from some sites that had
gross pathological changes, and timing was also important with 1 patient having positive
culture from biopsy on day 18 and negative post mortem cultures on day 24 [193].
Whitley et al in one study reported 3/79 patients with negative specimens at biopsy,
positive at autopsy: these 3 had been biopsied at the "wrong site" [277], A further 4/41
negative culture patients had other evidence of active herpes virus infections such as
serology, histology, EEG and radiology. In a second study 3/109 (2%) biopsy negative
patients had CSF and serum antibodies suggestive of HSVE but no patients were
reported biopsy negative and post mortem positive or vice versa [274], In Skoldenberg's
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study, 47 patients underwent brain biopsy, 8 had positive antigen detection by
immunofluorescence or ELISA but negative culture, and 6/25 biopsy negative patients
had local synthesis of specific IgG, 5/6 having been biopsied from the frontal lobe [233].
Table 12 summarises brain biopsy reports, and shows that brain biopsy missed 16/254







1967 7 4 193
1981 120 7** 277
1984 25 6 233
1986 139 3 274
TOTAL 284 16
* - antibody titres in CSF and/or serum,
histology, radiology, EEG, post-mortem
** - includes 3 positive at post-mortem
TABLE 12 : False-negative biopsy results in
patients with Herpes Simplex Virus Encephalitis.
The morbidity of brain biopsy is open to considerable question. Whitley et al reported
an acute morbidity of 2% [274, 277] with 3 cases of cerebral oedema and 3 cases of
haemorrhage in 340 cases. They did not attribute any long term neurological sequelae to
biopsy. Barza et al attributed 0.5%-2% morbidity from biopsy in encephalitis [17].
Biopsy will demonstrate other diagnoses which may be missed and are treatable, but
brain biopsy will be performed in up to two-thirds of patients who turn out not to have
HSVE [274].
Page 79
The controversy to biopsy or not to biopsy remains with each major study, followed by a
plethora of correspondence [5, 36, 244, 90, 180, 275, 269, 17, 32, 101, 83, 99].
Essentially, in European centres, brain biopsy is not favoured as it is not considered an
innocuous procedure and cannot be justified in patients who do not have HSVE.
Reliance is thus placed on non invasive diagnosis of high sensitivity such as evidence for
local synthesis of herpes specific IgG and clinical findings. In the United States
however, belief in the negligible morbidity and the absolute requirement for viral
isolation to prove the diagnosis, makes brain biopsy the diagnostic tool of choice.
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CHAPTER 3: TREATMENT OF HERPES SIMPLEX VIRUS
ENCEPHALITIS AND ITS OUTCOME
1. Introduction
Before the development of specific anti-viral agents, there was a little effective treatment
for HSVE, reflected in the paucity of information in the literature on the subject.
Surgical decompression, medical decompression using steroids, mannitol or urea and
supportive therapy were all used, without much convincing evidence of any significant
overall effect on outcome [215, 206], and indeed steroids may have a deleterious effect
[206]. Many reports of the benefit of surgical decompression were isolated cases [63], or
the surgery performed in combination with anti-viral agents, so outcome could not be
ascribed to one or the other alone [207].
The introduction of specific anti-viral agents have radically altered the mortality and
morbidity of HSVE, although some of the early agents did not live up to their promise.
Four anti-viral agents have been used over the last 20 years in the treatment of HSVE.





Idoxuridine (iodo-deoxyuridine, 5-iodo-2-deoxyuridine, IUDR) is a thymidine analogue,
which acts by inhibiting DNA synthesis. Initially prepared for studies on cancer therapy,
it was found effective in viral DNA inhibition [146]. Unfortunately it is also cytocidal,
and thus affects rapidly proliferating cells such as bone marrow, hair follicles and oral
mucosa [206, 89].
Isolated case reports in HSVE appeared to confirm that efficacy, but in a review of the
literature by Rappel in 1973 of 25 cases of acute necrotising encephalitis due to HSVE
treated with idoxuridine, 12 (48%) died [206]. Table 13a outlines the results from the
major studies reporting idoxuridine therapy on biopsy proven cases since Rappel's
review of 1973.
Overall 54 patients, nearly all brain biopsy definite, were treated with idoxuridine.
Mortality was 56%, with 19% suffering severe sequelae, 6% moderate sequelae and 24%
mild or none. Only 24% had a reasonable outcome. Moreover, the BIH study [30],
showed that not only was morbidity and mortality not much different to untreated





Dead Sequelae in survivors Ref.
Sev Mod Mild None
1970 8 4 1 3 250
1971 11 3 2 1 5 207
1972 1 1 112
1973 14 8 4 2 3
1973 4 4 194
1975 7 3 1 1 2 72
1975 8 6 2 30
1978 15* 8* 4* 2* 1* 280
1988 1 1 125
TOTAL 54 30 10 1 8 5
* - patients were treated with either idoxuridine,
ara-A or ara-C but outcome was not specified for
each, so results are not included in the total
Pat. no. - patient number
Sev - severe
Mod - moderate
TABLE 13 : Mortality and morbidity after treatment in




Cytarabine (cytosine arabinoside, Ara-C) is another pyrimidine analogue, again initially
used as an anti-cancer compound, but rapidly became used as an anti-viral agent [206,
146]. Like idoxuridine, it inhibits DNA synthesis, but is also cytotoxic, and
myelosuppression may be severe [89].
In Rappel's review of cytarabine in 1973 [206], of 9 cases reported, 8 died. There have
been few studies since then in the use of the drug, and only 7 patients could be found
treated with the drug (Table 13b), of which 1 died, 1 had a severe outcome, 2 a moderate
outcome, and 3 a mild or no residual damage resulting. Overall with the high mortality
(56% overall), the marrow toxicity, and the development of alternative agents, no further
studies were ever performed and the use of the drug discontinued.
Year Pat.
No.
Dead Sequelae in survivors Ref.
Sev Mod Mild None
1972 1 1 77
1973 9** 8 1 206
1973 2 1 1 194
1973 1 1 156
1978 15* 8* 4* 2* 1* 280
1982 2 1 1 34
1983 1 1 56
TOTAL 16 10 2 2 2 1
** - review
* and other abbreeviations - as for Table 13a
Table 13 : Mortality and morbidity after treatment in




Vidarabine (adenine arabinoside, 9-P-D-arabinofuranosyl adenine, Ara-A) is a purine
analogue, which first came prominence when a double blind placebo trial of biopsy
proven cases of HSVE in 1977 [276] showed that 30 day follow-up of 18 patients treated
with vidarabine resulted in only 5 deaths (30%) versus 7 of the 10 (70%) in the placebo
treated group. The morbidity in vidarabine survivors was consequently much higher
than in the placebo group, and only 4 patients treated returned to normal or near normal,
versus 1 in the placebo group. Mild myelosuppression was the only side effect of
treatment. Apart from therapy, the only other predictor of outcome was conscious state
at the time of treatment institution. Those patients in lethargy had 0% mortality,
semi-coma 25% mortality and if in coma 57% mortality in the treated group.
The study was heavily critisised, because of the early termination "for ethical reasons",
the short follow-up period, and the small numbers used [244, 90]. The same group was
sufficiently confident of its results however, to embark on an uncontrolled trial of
vidarabine alone on 75 biopsy proven cases with longer follow-up and data amalgamated
from a previous trial [277]. Of 93 patients in total, by 1 year 37 had died (40%), 10 were
severely damaged (11%), 16 moderately damaged (17%), and 30 were normal (32%)
although normal meant only returning home with minor debilities. In this larger group,
apart from conscious state at the onset of therapy, age of the patient had a significant
effect on outcome, with patients over the age of 30 having significantly worse mortality
and morbidity.
Thereafter, 2 major trials were undertaken comparing acyclovir and vidarabine. Before





Dead Sequelae in survivors Ref.
Sev Mod Mild None
1978 11 5 ** ** ** ** 72
1978 15* 8* 4* 2* 1* 280
1980 5 1 4 133
1981 93 37 10 16 7 23 277
1982 4 3 1 34
1982 1 1 69
1984 24 12 7 2 3 233
1986 37 20 4 8 5 274
1988 5 2 1 2 125
TOTAL 180 81 27 26 14 26
** - 6 survivors were not ascribed outcomes and are
excluded from the relevant totals
* and other abbreviations - as for Table 13a
TABLE 13 : Mortality and morbidity after treatment in
patients with Herpes Simplex Virus Encephalitis,
.c) Vidarabine therapy.
Of 180 cases treated with vidarabine, there was an overall mortality of 45%, with 15%
severe morbidity, 14% moderate morbidity, and 22% with mild or no sequelae. So,
although mortality was reduced, the number of survivors approaching normality was no
better than with idoxuridine treatment, but with much fewer side effects from the drug.
With vidarabine set as the standard, the next development was the introduction of
acyclovir, whose value in other herpetic infections was being established.
Page 86
D. Acyclovir
Acyclovir (9-(2-hydroxyethoxymethyl) guanine) was released for clinical use in 1982. It is
an acyclic analogue of guanosine, discovered to have an activity against HSV in 1974. The
molecular biology has been well reviewed [65] but essentially, its activation and uptake
explains the selective anti-viral activity. It requires phosphorylation to the monophosphate
form by a viral thymidine kinase. HSV1, 2 and varicella zoster all contain thymidine
kinase, therefore acyclovir is selectively phosphorylated by infected cells. Therein it is
coverted to the triphosphate by guanylate kinase, and it is the triphosphate which is a
competitive inhibitor of viral DNA polymerase. It does this by being incorporated into
DNA, acting as a chain terminator, which cannot be excised by an endonuclease. There are
little or no toxic effects, except mild reversible renal impairment in man.
Two major studies investigated the role of acyclovir in HSVE [233, 274], Both
compared acyclovir with vidarabine, since ethical reasons were put forward for not using
placebo treatment. In the Swedish study [233] acyclovir 10 mg/kg/8 hourly for 10 days
was compared with standard vidarabine therapy in 53 patients, 22 of which were biopsy
proven. Mortality was 19% for acyclovir, with 56% of patients returning to normal life
by 6 months, whereas vidarabine had 50% mortality, with only 13% returning to normal.
In the NIAID collaborative study [274], 69 patients, all biopsy proven, received
acyclovir 30 mg/kg/day for 10 days, versus standard vidarabine therapy. Mortality was
28% for acyclovir, with 38% returning to normal by 6 months, whereas vidarabine had
54% mortality, and only 14% returning to normal by 6 months.
Despite differences in study entry criteria, with the Swedish group accepting CSF
antibody evidence as well as biopsy evidence, the mortality and morbidity figures for
acyclovir and vidarabine in the 2 studies were very similar. Both studies again
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demonstrated that conscious state at the onset of therapy determined prognosis - no
acyclovir treated patient with a Glasgow coma scale great than 10 in the NIAID trail
died. However, only the NIAID study was able to show that patients under 30 years of
age had a better outlook than over 30.
Apart from these 2 trials, there are few other studies in the literature using acyclovir,
presumably because the data were so conclusive. Summarising the data in Table 13d, of
74 patients treated, 24% died, 23% had severe sequelae, 8% moderate sequelae, and 45%
were left with only mild disability or returned to normal life.
Year Pat.
No.
Dead Sequelae in survivors Ref.
Sev Mod Mild None
1984 27 5 4 3 15 233
1986 32 9 8 3 12 274
1987 8 2 2 2 2 97
1988 7 2 3 2 125
TOTAL 74 18 17 6 16 17
Abbreviations as for Table 13a
TABLE 13 : Mortality and morbidity after treatment in
patients with Herpes Simplex Virus Encephalitis,
d) Acyclovir therapy.
Acyclovir is now the drug of choice for HSVE, and should be given empirically since
side effects are negligible. It has now been used safely in pregnancy in the third
trimester, with no adverse effects on the foetus and a good outcome in the mother [100].
Resistance to acyclovir is now being reported, with thymidine kinase defective mutant
viruses reported [51], but such mutants tend to have low virulence, and so far no resistant
strains causing HSVE have been reported. The emergence of mutants has prompted
some clinicians to combine acyclovir with vidarabine in the treatment of HSVE as a
safety measure [24], Another problem has been the reporting of relapse following
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acyclovir therapy at conventional doses of 10mg/kg/8 hourly for 10 days in
immunocompetent individuals [260], in a patient with lymphoma [216], and in a child
[16], although in the last case only 8 days treatment was given. In the first case
subsequent brain biopsy recovered acyclovir sensitive HSV1 and further acyclovir
treatment led to recovery. These relapses, and others reviewed by Barthes [16], leads to
the suggestion that treatment with acyclovir should either be for longer, perhaps 14-21
days or that any deterioration after treatment should be considered a relapse until proven
otherwise.
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3. Morbidity After Therapy
The comparative studies suggest that morbidity after therapy takes the same form as
morbidity without therapy, but because of the improved survival, many more patients
will be left with sequelae. In severe cases, patients are devastated and institutionalised.
In moderate cases, the commonest sequelae appear to be epilepsy, hemiparesis and
speech problems, either aphasia or dysphasia. What may be considered the most
distressing problem, is the number of patients with defects of memory, personality
changes and behavioural problems, which often go unrecorded because they have
returned home to a "normal life". Some of the severe problems have been bizarre limbic
system abnormalities, resembling the Kluver-Bucy syndrome [94], or amnesic
syndromes [198, 119], but many have mild personality or behavioural changes indicative
of irreversible limbic system damage, even when the encephalitis is arrested at an early
stage. This makes the need for an early, quick and reliable diagnostic test of even more
paramount importance.
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CHAPTER 4: PATHOLOGY, AETIOLOGY AND PATHOGENESIS
1. The Herpes Simplex Virus
A. Structure
There are six herpes viruses that infect humans: HSV1, HSV2, varicella,
cytomegalovirus, Epstein-Bar virus and human herpes virus 6. Herpes viruses are
defined on the basis of the design of their virions. All have a core consisting of double
stranded DNA, and DNA binding proteins, surrounded by a capsid of 162 capsomeres in
the form of an icosahedron. Around this is an amorphous mass of proteins called the
tegument, whose properties and functions are unknown, and enclosing all is the
envelope, which is acquired as the DNA containing capsid buds through the inner
nuclear membrane of the host cell. This envelope contains only virally derived proteins
[197],
Herpes viruses exhibit great differences in the size of their DNA and base ratios. HSV1
and 2 contain linear DNA, with a molecular weight of approximately 100 x 106 Daltons
coiled into a doughnut shape. There is about 50% homology between the HSV1 and 2
genomes, and sufficient variability of nucleotide sequences between strains that
restriction enzymes can be used to differentiate isolates from separate individuals. The
envelope of the virus contains embedded within it at least 5 glycoproteins which mediate
attachment and penetration into the cell. Glycoprotein B is required for infectivity,
glycoprotein C binds to C3b component of complement, glycoprotein D is the most
potent inducer of neutralising antibodies, glycoprotein E binds the Fc fraction of IgG,




The HSV genome is 152 kilobase pairs in size, and consists of 2 components, the L and
S sequences containing unique sequences, flanked by inverted repeats [197]. The 2
components can invert relative to each other, thus creating 4 isomers, present in
equimolar proportions in infected cells. The function of the isomerisation is unknown,
but does not affect infectivity or latency. The genome codes for a number of proteins
and about 70 are expressed during productive infection, and are grouped on the basis of a
highly regulated cascade of expression. The a genes code for proteins and are expressed
earliest in infections. They are induced by one of the tegument proteins (a trans
inducing factor or a TIF). The function ofmost of the proteins is unknown, but the a4 is
required for the expression of subsequent protein groups. The P genes are expressed
after 5-7 hr., require prior synthesis of a proteins, are mainly involved in nucleic acid
metabolism, and code for the regulatory proteins and enzymes, including the alkaline
nuclease. The y genes code for the structural proteins, some of which are completely
dependent on viral DNA being synthesised, like glycoproteins C and E, and others are
expressed irrespective of the presence of replicating viral DNA, such as glycoproteins B
and D, a TIF and capsid proteins. Once the cascade is set off, autoregulation probably
plays a role in determining how much viral synthesis and cell destruction takes place.
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C. Infectivity
The virus attaches itself to the cell via the glycoprotein spikes. It is likely that cell
receptors exist, but are difficult to identify. In neurones, the receptors are located on the
synaptosome [258, 259]. Once attached, fusion occurs, and virion components move
through the cytoplasm. The capsid moves to nuclear pores, and virus DNA is ejected
into the nucleus Circularisation of viral DNA occurs immediately, then the
transcription cascade commences, beginning with the a genes, a mRNA's are
transported to cytoplasm and translated, the resulting proteins initiating p genes
transcription. Once (3 genes are transcribed and a proteins synthesises, viral DNA
replications occurs via a rolling circle mechanism. The assembly of viral capsid occurs
in the y phase, the capsids are filled with viral DNA and proteins, the tegument attaches
and then buds through the nuclear membrane acquiring the glycoprotein envelope. As
the virion moves through the cytoplasm using the endoplasmic reticulum and golgi
apparatus, glycoprotein processing occurs and the final complete virus leaves the cell.




A. Latency in Humans
Even before the causative agent of herpes simplex cutaneous infections was known, the
association of recurrences with peripheral nerve trauma was observed by Cushing in
1905 as a result of the use of nerve section to treat trigeminal neuralgia [52]. In between
recurrences, biopsy of tissue consistently failed to yield any virus, thus leading to the
conclusion that vims may remain in a latent state in the ganglia after the local lesion had
healed [212], Latency is defined as the need to induce a virus to multiply, without it
being recoverable in infectious form. Although animal studies suggested that the
trigeminal ganglion was capable of harbouring herpes simplex vims, isolation from
human cadavers was not shown until 1972, with the cocultivation of explants from the
trigeminal ganglion from 2 of 23 autopsied patients, one of whom had no evidence of
herpetic infection at the time [18]. No vims was recovered from the choroid plexus in
any of the patients studied. The relatively poor recovery was likely due to the
cocultivation technique, as in 1973, using direct culturing of ganglion cells, 6 of 7
ganglia from autopsied patients produced HSV. Two of the patients had a history of
either trigeminal neuralgia or oral herpes, but none had evidence of herpes at the time of
death [13].
Latency in trigeminal ganglia has been confirmed by other workers using both culture
[211, 267, 11] and detection of viral RNA [ 50 >, 71]. Other sensory and autonomic
ganglia have also successfully yielded cultures of HSV, including sacral [11], superior
cervical and vagus [267], and autonomic [212] - see table 14. The yield from the
trigeminal ganglia however, is by far the highest at up to 80%. Careful studies show the
neurones to be the source of the virus, but they do not display any known virally coded
polypeptides and infectious virus cannot be recovered directly from the ganglia. Herpes
virus has since been detected in other neural tissues, including brain smears from elderly
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patients with psychiatric illnesses using DNA probes [228], and in temporal lobe smears
from immunosuppressed patients with a history of HSV infection, but not in
non-immunosuppressed patients or immunosuppressed patients without a history of
herpetic infections [219].
Site of detection Method of detection Ref.
Culture DNA-probe
Trigeminal ganglia + + 18
Sacral ganglia + 11
Cervical ganglia + 267
Vagal ganglia + 267
Autonomic ganglia + 212
Whole brain smears + 228
Temporal lobe smears* + 219
Hippocampus** 76
* - Immunosuppressed patients only
** - Immunohistochemical detection
TABLE 14 : Sites of detection for latent human herpes
simplex virus.
These findings suggest that viral latency may be more widespread in neural tissue, or
that in the cases of extra ganglionic detection, they represent reactivation secondary to
immunosuppression and aging. The finding of HSV antigen in the granule cell layer of
the hippocampus in one case of Alzheimer's disease opens up further the debate on how
widespread herpes virus may be, latent or otherwise [76]. So far other
immunohistochemical studies on temporal lobes for HSV antigens have failed to find
evidence of herpes in Alzheimer's patients, but this does not preclude latency [209].
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B. Latency in Animal Models
Proof that the trigeminal ganglion could harbour latent virus came initially from studies
in mice [238] and it was the development of the mouse model system that has led to
most of the understanding of latency and the definitions that apply to the concept.
Recovery of virus by cocultivation and explantation from experimental animals has
shown that both sensory and autonomic ganglia can support latent virus infection [200,
139], but in addition in-situ hybridisation with DNA probes has shown virus in the
central nervous system in up to 50% of mice with latently infected trigeminal ganglia
[35, 205], and infectious virus can be recovered from brain following massive
immunosuppression [120]. Subsequent studies have also shown that mRNA indicative
of some transcription can be detected in latently infected trigeminal ganglia [247, 243],
and that only one particular mRNA transcript is found in latency, the infected cell
protein O (ICP-O) transcript [243].
Establishment of latent infection using inoculation takes place via 3 methods, peripheral,
intracerebral or systemic. By far the most productive route is peripheral, using the eye
[212], but the ear, nose, lip, footpad and vagina have all been successfully used. Initially
viral replication occurs at the inoculation site, but within a few days the respective
ganglia may show infective virus. In surviving animals, once virus disappears from the
peripheral site, the ganglia no longer contain infectious virus, and only techniques for
reactivation show viral presence. It was these observations that led to the working
definition of latency described at the beginning of section A. With herpes simplex
viruses, it would appear that only neurons can harbour latent virus with no other tissue so
far being shown to do so.
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C. Genetics and Mechanisms of Latency and reactivation
How latency is achieved, what maintains it and what switches on viral replication has not
yet been fully explained. Less than 1% of the neurones in a ganglion harbour virus in the
latent form [212], and what determines what neurones are infected is unknown. There
is some evidence to suggest that host factors may determine susceptibility to latency.
Mice and rabbits infected via identical routes and identical HSV1 strains produce
differing proportions of neurones infected as well as differing levels of latency. Virus
DNA present in latent neurones is in a different form to that present in actively infected
cells. The DNA is non-linear, either circular or concatameric (i.e. end to end) and each
cell may contain hundreds of copies. Whether the DNA is integrated or episomal is still
not clear [91]. Studies on viral mutants, such as temperature sensitive, thymidine kinase
deficient and 'dispensable gene' mutants have not yielded any specific feature that is
essential for viral latency [212]. Studies using complementary DNA probes have
identified latency associated transcripts. An ICPO probe was the only one to react with
mRNA during latent infection, and the sequences expressed were 'anti-sense', that is, on
the opposite strand of the ICPO encoding gene [50, 239]. Latent HSV2 has been shown
to behave in an identical fashion with the same transcripts being evident [243, 247].
ICPO is an immediate early a gene, thus restriction of transcription of the genome to
this region may be the mechanism ofmaintenance of latency, by preventing initiation of
the normal cascade.
Numerous insults cause reactivation of latent infection, including surgery, emotional
stress, febrile illnesses, x-rays, ultraviolet light and minor trauma [113, 48, 186]. Even
asymptomatic patients can shed HSV into the oropharynx, so one must be careful in
using the criteria of viral isolation from non neurological sites as evidence of causation
for neurological illness, and more importantly, coincidental reactivation of ganglionic
and possible cerebral or brain stem lesions may accompany other pathology. The
likelihood of reactivation may be viral dependent and neurone dependent. Studies of
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recurrence rates of HSV1 and 2 affecting both trigeminal and sacral ganglia, showed that
sacral ganglia were more likely to harbour reactivating virus than trigeminal, and HSV2
infections more likely to recur than HSV1 [144],
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3. Pathogenesis of Herpes Simplex Virus Encephalitis
A. Evidence from Human Studies
For many years HSVE was thought to be a primary infection because of the assumption
in early insensitive serological studies that only primary infections were associated
with a rise in serum titre of antibodies [154], It is now knownthat encephalitis may result
from a primary infection, reinfection or reactivation of latent infection [271]. Restriction
endonuclease analysis of HSV DNA isolated from the brain and orolabial sites in 8
patients from this study, showed paired isolates were identical in 5 but different in 3
others. One patient had unequivocal evidence of primary infection, with identical
isolates, 5 had a history of recurrent labial herpes, 3 with identical isolates, and 2 had no
history but a serological response, 1 with identical isolates. In addition there wereno
obvious similarities between isolates from different patients to suggest a common
denominator for neurovirulence. The association of encephalitis with reactivated latent
infection was first suggested in a review of 18 patients with HSVE, 3 of which had
recurrent herpes labialis [154]. Since then, other studies have confirmed the association,
but since 90% of adults have serological evidence of infection in the past, and up to 80%
of autopsied cases have latent herpes virus in the trigeminal ganglion, and up to 47% of
patients give a history of recurrent cold sores, a history of labial herpes in encephalitis
given the prevalence in the community is not surprising [227].
The route of viral entry into the brain is still speculative in humans, and table 15
illustrates various routes proposed [114, 115, 91]. Pathological studies have
demonstrated that limbic structures are preferably infected, and that fronto orbital,
medial and inferior temporal lobes are severely damaged. This observation led Hurst in
1936 to postulate that the virus gained entry via the olfactory nerves [106], but little
objective evidence was available from human encephalitis studies to confirm this [114].
Several pathological studies since then, have shown that not only herpes virus
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recoverable from the olfactory mucosa and bulbs [84, 60, 254], but also olfactory tracts
[61], with confluent involvement of limbic structures [76]. This is not a universal
finding however, and it has been postulated that the involvement of the olfactory system
may be secondary [76] although proposals of brain stem projection to olfactory routes as
the explanation are unconvincing [53].
Origin Pathway Destination












TABLE 15 : Possible routes of spread of herpes simplex
virus into the human central nervous system.
An alternative or complementary route has been postulated on the basis of latency of
HSV in the trigeminal ganglion, and the observation of selective frontal and temporal
lobe involvements. Penfield and McNaughton in 1940 showed that the dura in the
middle and anterior fossa is innervated by the tentorial branches of the trigeminal nerve
[196]. It has thus been postulated that latent virus is reactivated and travels along these
branches to the dura in the appropriate fossa, and thence, 'comes into contact' with the
brain [55, 113]. This does not satisfactorily explain the strict limbic anatomical
boundaries that HSVE respects [76], and why other areas equally well supplied by the
trigeminal nerve divisions in the middle and anterior fossa are spared. An alternative
hypothesis proposes that the localisation is due to spread from the trigeminal ganglia to
the brain stem nuclei, from whence virus connects trans-neuronally to limbic structures
by well documented pathways [53]. Those pathways are specifically mono-amine
containing, and it may be that these neuronal types are particularly susceptible to viral
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infection and spread, at least in animals, if not humans [189]. Evidence for brain stem
involvement in humans is recorded, but does not appear to be that common, and in one
large immunohistological study of 29 cases of HSVE, there was no evidence of any viral
antigens in the meninges, trigeminal ganglia or route entry zones of the trigeminal nerve
[76].
As described earlier, latent DNA has been isolated from brain smears and viral antigen
found in autopsies of 'normal control brains' so it is possible that infection could result
from reactivation from these sites. As yet then, there is no proven mechanism for HSVE,
but as one reviewer has commented, it is reassuring to know that since most of us
harbour a potentially fatal virus in the trigeminal ganglion, the occurrence of oral herpes
means at least the reactivation has not gone in the reverse direction [55].
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B. Evidence from Animal Models
It was Goodpasture and Teague in 1923 who first demonstrated that HSY could be
transmitted along peripheral nerves to the CNS in a rabbit model [93]. By corneal and
masseter inoculation, localised brain stem lesions were produced in appropriate sensory
and motor areas, and further experiments suggested that the'axis-cylinders'provided the
route, with viral propagation within the axon causing spread [92]. This model
successfully showed that the trigeminal nerve branches acted as a portal of entry to the
trigeminal ganglion and thence trigeminal root entry zone and connections [12], but the
actual means of transfer of virus from periphery to CNS remained speculative, with the
axon itself, perineural and endoneural cells lymphatics and perineural spaces all being
proposed [114]. Baringer and Griffiths showed that it was the transport centripetally
along the 'axis-cylinders' that was the primary event in a corneal inoculation model in the
rabbit, and that Schwann cell and satellite cell infection was secondary. Virus then
spread to neurones and astrocytes in the associated tracts [12]. This primary axonal
transport mechanism was confirmed in mice [136]. Within the central nervous system,
spread of virus has been shown to take place intra-axonally in a retrograde fashion [67,
142], and in a rat model adjacent neuronal structures which were not axonally connected
were unaffected [8],
Many other animal models have now appeared in addition to examine the pathogenesis
ofHSV invasion of the CNS and are summarised in Table 16. All show that the transfer
of virus takes place along anatomically connected pathways from 1st to 2nd and 3rd





Sites of pathology Ref.
Rabbit Cornea Brain stem 93
Rabbit Masseter Brain stem 93




Mouse Snout Trigeminal pathways
Basal ganglia
137
Mouse Olfactory Olfactory bulb
Trigeminal pathways
75




Mouse* Hippocampus Limbic system
Olfactory route
171





* - pathology similar to human distribution
TABLE 16 : Animal models of pathogenesis of spread of
herpes simplex virus to the central nervous system.
None of the peripheral inoculation models however, have produced pathology which in
any way resembles that seen in the human. This lack of appropriate pathology has
prompted some groups to try more invasive methods of infection in order to create a
more representative model. Thus intra-ocular inoculation [43] and direct injection into
the hippocampus [171, 169] result in extensive encephalitic changes, which, especially in
the latter model, affect predominantly the limbic structures, with notably involvement of
the olfactory nucleus in some cases, indicating that olfactory bulb involvement could be
a secondary phenomenon. There has only been one model developed, however, that
reproduces a 'physiological route' of viral invasion with pathology that more closely
reproduces human limbic system involvement. This model involves direct inoculation
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into the olfactory bulb in rabbits [221] and resulted in a predominantly limbic
involvement with temporal lobe seizures, and although brain stem pathology was
present, it was rarely severe or showed much in the way of destruction. Thus, animal
models are getting close to supplying a model of human disease in terms of pathology,
but there are other factors involved in determining how and why neurones get infected,
and determining the differing patterns of pathology.
The neurotropism of HSY has now been shown to result from specific viral receptors
located probably on synaptosones of neurones and glia [258, 259], and not by pinocytotic
vesicles as was suggested earlier [138]. In fact the virus has a greater affinity for glial
cells than neuronal bodies, perhaps secondary to receptor density, and thus may explain
the ready uptake of virus from glia from neurones, but not in the reverse fashion [255].
Entry into the sensory or motor nerve ending in the primary infection is thus relatively
easy, given a sufficient inoculum, and cell to cell transfer along synaptic routes explain
the pathological distribution. This may also explain the abrupt border seen at the
trigeminal root entry zone, where peripheral nervous system and central nervous system
abut.
Table 17 summarises those factors which are shown to influence the neurotropism and
pathogenesis of HSV viral infections in animal models. Differing cell types have
different susceptibilities to infection. Although the peripheral Schwann cell in the
trigeminal model contains virus, there is rarely destruction, whereas neurones and
astrocytes on the CNS side of the trigeminal root are readily infected and frequently
excite a destructive demyelinating response [253, 102, 157]. Despite human
pathological reports, in animal studies oligodendrocytes show only rarely viral infection
[253] but where they do, there appears to be differential susceptibility of oligodendrocyte
populations to HSV infections [121, 122], The peripheral nerve also contains fibres with













































TABLE17:Factorsinfluencingtheneur tropisma dpath genesis ofherpessimplexviruinf ctionsnanimalmod l .
Different neuronal cell populations have selective vulnerabilities to HSV infection with
hippocampal injection resulting in widespread infection of some projections and not
others [171] and cerebellar injection resulting in little or no pathological changes [169],
Large neurones appear to take up viral antigen more avidly than small neurones [8]. The
basis for neuronal preference may lie in the density or distribution of receptors [170] or
in particular, neurotransmitter related structures, with monoaminergic neurones
preferentially involved [137, 189].
The virus itself displays strains of differing neurovirulence, probably related to distinct
genetic loci as demonstrated by the elegant work of Stevens and co-workers [283, 286, 287],
with some reports linking also the regions coding for glycoprotein B and DNA polymerase
[91, 221, 43]. Seizure production is related to the use of highly virulent strains. Host-
genetic factors also determine the level of resistance to infection, with at least 3 genes
responsible in mice, and the effect probably mediated through immune mechanisms [160].
Knowledgeof the role of HSV in demyelination associated with the encephalitis has stemmed
from animal model work. Following trigeminal inoculation in mice, demyelinated areas
appear within the trigeminal pathways relatively late and persist for months [139] with
peripheral myelin preserved. Different strains ofmice have different susceptibilities to
demyelination with resistant strains having very focal areas and susceptible strains
widespread multifocal involvement [121, 122]. The absence of recoverable virus at the
time of demyelination suggests an immune mediated mechanism. Antibodies to myelin
basic protein (MBP), and delayed type hypersensitivity reactions to HSV and MBP are
found in mice models to induce demyelination, supporting the concept of immune
mediated responses. Studies of the immune cell infiltrates into the brain and
perivascular area in mouse models shows that although oligodendrocytes, astrocytes and
microglial cells are infected, the demyelination present by far outweighs the
oligodendrocyte involvement, and the perivascular infiltrates of T-cells and macrophages
were close to areas of massive myelin loss, suggesting immune mediated myelin damage
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accounted for as much of the pathology as direct viral cytolysis and inhibition of cellular
function. Re-myelination can take place, at least in the spinal cord, and appears to be
mediated by both Schwann cells and oligodendrocytes to such an extent that complete
recovery can be possible [237].
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C. Animal Models for Diagnosis and Therapy
Since animal models are proving successful in at least partially reproducing human
pathogenesis and pathology, attempts are being made to extrapolate results for diagnostic
purposes. Radiolabelling of anti-viral compounds to 'locate' virally infected cells is
possible [218], and with SPECT scanning offers a promising avenue of research now that
reasonable models are available [43]. In preliminary work, a rat model has been
successful in radiolabelling infected areas of brain and the radioactivity detected with a
gamma camera [42], Cell culture work also suggests that acyclovir therapy would not
interfere with radiolabelled anti-viral drug uptake in the early stages, thus the use of such
diagnostic tools would not compromise therapy [252],
A resurgence in interest in using CSF cells has been prompted by the detection of viral
specific antigen in CSF cells using immunofluorescence in mice [27]. Seventy-five
percent sensitivity was reported, but specificity not tested, and observers may disagree
on border line cases. However, it must be stressed that it is yet to be proven that this
animal model can successfully translate into human cases given the outcome of previous
work with CSF cells.
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4. Pathology of Herpes Simplex Encephalitis
Pathological studies, both macroscopic and microscopic, of the changes in adult HSVE
are numerous and only a brief summary is warranted. Since only severe cases come to
post mortem, findings usually reflect the severe devastation. Macroscopically, the brain
is often swollen [21] with softness and mushiness of parts of the cortex [103], and
sometimes the entire brain is very soft [236]. There are haemorrhagic necrotic areas,
often cavitated, most frequent in the medial temporal lobes and fronto-orbital area and
less so occipital and parietal areas [177], with changes being unilateral or more
frequently bilateral. The cingulate gyri and insula are invariably involved, the thalamus
and pons regularly involved, and the brain stem and cerebellum infrequently and
sometimes never affected [177]. The hippocampus and basal ganglia, if not
macroscopically involved, are invariably microscopically involved [4]. In sections,
multiple haemorrhagic foci with marked necrosis are present, especially in the cortex and
adjacent white matter. These changes can suddenly demarcate to relatively normal
tissue, although in general there is some gradation. Overlying involved areas is a severe
leptomeningitis, with amainly lymphocytic macrophage infiltrate. The microscopic
changes parallel macroscopic, but are often more extensive. Histologically, changes are
diffuse with selective necrosis of grey matter and spread into white matter adjacent to
most severely affected areas. The marked necrotic changes present could, like the
macroscopic view, suddenly demarcate microscopically to relatively normal tissue with
just scant inflammatory border changes. Changes are often perivascular with
lymphocytic cuffing, and neuronophagia is common with sometimes whole areas
replaced by phagocytes and plasma cells [103]. Microscopic involvement of the brain
stem, though recognised, is often disputed as being primary, and attributed to secondary
tentorial herniation [4], Intranuclear inclusions (Cowdry Type A) are commonly found
throughout the histologically involved areas, mainly in oligodendroglia, less commonly
in ganglia cells neurones and astrocytes [103, 177, 66].
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The first study to look systematically for this distribution of viral antigen in brain, was
that of Esiri in 1982 [76], although 2 studies prior to this had demonstrated viral antigen
in brain, these had been limited to temporal and frontal lobes [141, 20]. In the study of
Esiri, the unilateral origin of the disease was confirmed, and the limbic system shown to
be primarily infected with viral antigen staining, although occasionally other structures
contained viral antigen such as the post central cortex. The asymmetry of involvement
was preserved, even though most changes were bilateral. Those areas showing the most
severe destruction and inflammation were not necessarily those containing viral antigen.
By the 3rd week of illness, viral antigen could no-longer be detected. Viral antigen was
found in all types of glial cells as well and neurones.
In terms of disease progression, the disease appeared to start in one temporal lobe,
hippocampus, amygdaloid nucleus complex, and cortex close to the entry of the lateral
olfactory stria, insula and cingulate gyrus. No clear indication of the initial structures
infected could be definitely found, although the olfactory pathway was frequently
involved early. There was never any evidence of viral antigen in the trigeminal pathway,
so this study tended to support the concept of olfactory entry rather than trigeminal. One
area of brain severely involved in patients and in one control brain also, was the granular
cell layer of the dentate fascia in the hippocampus. The possibility was raised that this
could be an area of latency.
Later studies, using more sensitive methods, have confirmed these findings [40], with
immunostaining in all glial and neuronal cell types, but none in perivascular and
leptomeningeal lymphocytes. The macroscopic distribution was the same, with sharp
demarcation away from limbic system structures and patchiness of antigen presence.
Viral antigen has however, been confirmed in the brain stem in two pathological studies,
one exclusively in the spinal trigeminal tract and associated nuclei with no antigen
detection above or below, suggesting trigeminal route of entry [143], and one confined to
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nuclei and tracts associated with the glossopharyngeal and vagus nerves, with no
involvement above and below [213]. Only one other study has reported brain stem
pathology as part of the more typical limbic picture [58].
Thus, both macroscopically, microscopically and immunohistochemically, the limbic
system is the first and predominantly involved area, initially unilaterally, but very
quickly bilaterally. The route of entry in difficult to ascertain, with olfactory being
either primarily or secondarily involved, and despite brain stem microscopic changes,
viral antigen is only occasionally reported as found. Viral antigen can disappear from
undoubtedly affected sites, which may explain the disagreements between some
pathological studies. Antigen is found in anatomically and functionally contiguous
areas, suggesting cell to cell transfer. The disappearance of antigen, and also the patchy
nature of involvement of the disease process, could explain the negative biopsy results
seen and perhaps the difficulty in recovering vims from the CSF.
One final point sometimes raised as the question of demyelination, with some authors
reporting patchy demyelination in white matter [207], while most fail to report this or
report that what is seen in secondary disintegration in perivascular areas occupied by
mononuclear cells [103]. One report of a case of HSV brain stem encephalitis, found a
secondary acute haemorrhagic leukoencephalitis distant from the site of infection and
postulated immune mechanisms [143]. A further report documented a post-viral
encephalomyelitis following successful treatment of HSVE with vidarabine [130]. HSV
antigens have been sought in demyelinated areas in multiple sclerosis without success




A. Definition of Luminescence
Luminescence is the chemical production of light. It is the only reaction where chemical
energy is converted into light quanta, the decay of the molecule from an excited state
back to ground state being accompanied by light emission. Two main forms of interest
exist: bioluminescence, which is the form found in biological systems, where catalytic
proteins increase the efficiency of the system to above 90% in some cases, and
chemiluminescence, the purely "chemical form", whose efficiency is under 1% for many
reactions [281], where efficiency is defined as the actual yield of photons versus the
theoretical yield.
Luminescence must be distinguished from fluorescence and phosphorescence. In the
former, irradiation of the substance with the light of a given wave length results in a
promotion of the molecule to an excited singlet state and the release of radiation of a
longer wave length (with lower energy). No chemical reaction takes place. In
phosphorescence, which is a special form of fluorescence, light emission is long lived,




References to luminescence are dotted throughout ancient texts, with theChinese
describing fire-flies (glow-worms) around 1500 BC, and Aristotle describing the
bioluminescence of dead fish and fungi in De Anima in the 4th century BC. Observation
gave way to experimentation in Robert Boyles major work on bioluminescence
published in 1667 by the Royal Society, which showed that oxygen was an essential
factor for luminescence. A century ago, luciferin and luciferase were described by
Dubois, who later lit a room at the Paris exposition in 1901 with bioluminescence.
Chemiluminescence has a relatively short history. Lophine and pyrogallol were not
described until 1877 and 1887 respectively, and luminol and lucigenin not until 1928 and
1935 respectively [270], Despite this, luminescence has gained wider acceptance than
bioluminescence for reasons given in the next section.
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C. Bioluminescence
The original role of bioluminescence has been suggested to be a detoxification
mechanism to eliminate oxygen radicals [281]. This suggestion appears to be confirmed
by the fact that bioluminescence is confined to lower organisms, and is absent in reptiles,
bird, marsupials and mammals, as well as the more evolved members of the plant
















TABLE 18 : Luminescent organisms. (From Wood281 )
Although the firefly and glow-worm are the best known luminescent organisms, the
majority are sea-living organisms, ranging from bacteria and plankton to fish. Two thirds
of the organisms in the upper 2,000 metres of oceanic waters are bioluminescent, but
fewer than 1% have been studied. The enzymes involved are all named luciferases, and
the substrates luciferins. The colour of light emitted is dependent on the luciferase;
spontaneous decay of luciferins always produces blue light. Five different
bioluminescence chemical systems exist [270]. The pyridine-nucleotide link system
(e.g. marine bacteria); adenine-nucleotide link systems (e.g. the fire-fly);
enzyme-substrate systems (e.g. the clam); peroxidase systems; and "pre-charge" systems
(e.g. jellyfish). The two most widely applied to analytical chemistry are the
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adenine-nucleotide and pyridine nucleotide based systems. These have been extensively
reviewed [14, 270, 281], and since they are not of relevance to this study no more time
will be devoted to these, except to explain the limitations of their usage.
Although applied to the analysis ofmany substances, both substrates and enzymes, use
of bioluminescence in vitro is limited by the sensitivity of the systems to anti-microbial
agents in laboratory reagents (such as merthiolate and sodium azide). In addition,
reagents are often expensive and label synthesis complicated. This limits the storage and
stability of bioluminescent reagents sufficiently for the much less energy efficient system
of chemiluminescence to be the method of choice.
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D. Chemiluminescence
Many organic compounds are chemiluminescent upon oxidation, and it is probably a
universal property, albeit very weak for most [270]. Chemiluminescence can be based
on gas, liquid or solid phases, but liquid phase is the most useful. Several systems are
used in analytical work.
1. Cyclic Hydrazides.
Luminol, a cyclic diacylhydrazide, was the first described, and is the only type to
luminesce. Most derivatives, such as isoluminol, have reduced efficiency (10%
of luminol) but occasionally some, like annelated analogues, are more efficient.
2. Aminonaphthyl hydrazides.
These have not found great usage analytically.
3. Acridinium derivatives.
These have the attraction of requiring only hydrogen peroxide for activation and
thus are simple and cheap, but the consequence of this is a less stable compound.
Their quantum efficiency is low at l%-2%. They can however, be catalysed by
some metal ions ineffective on luminol, and some acridinium phenyl
carboxylates can be tailored to suit different pH environments.
4. Diaryl oxalates.
These have high quantum efficiencies, often above 30%, but the compounds
themselves are not chemiluminescent, and an additional fluorescent molecule is
needed for energy to be transferred to. Their light output lasts several hours, so
they have been used for cold light sticks in camping and caving.
Page 116
The advantages of chemiluminescent reagents is their stability over long periods of time,
even in the presence of anti-microbial agents. They are cheap, and because the
molecules are small, do not interfere unduly with the structure of antigens or antibodies.
Full control of light emission is possible, unlike radioactivity. However, their quantum
efficiency is low, at only l%-2% for some acridinium salts, up to 50% for some
acridinium esters. The measurements cannot be repeated, and quenching occurs with
most, although acridinium derivatives can have this minimised.
Overall the benefits outweigh the drawbacks, so chemiluminescent assays are more
widespread in use. Because the chemistry has been extensively studies, the luminol and
isoluminol systems were first choice reagents and will be considered in more detail.
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2. Luminol and Isoluminol based chemiluminescence
A. Labelling
Both luminol and isoluminol may be bound to proteins or haptens by a variety of
methods [282, 87, 270]. Diazotisation of luminol and isoluminol have been advocated as
an effective means of labelling IgG, with no resulting loss of luminescence when bound
to the antibody [270], However, several reports show that such labelling, and especially
the pH required to label, results in greatly reduced binding capacities of the antibodies
[87, 282]. Bi-functional coupling agents, such as gluteraldehyde can be effective, or
with luminol the conversion of the aromatic amino group into an isothiocyanate group.
Isoluminol derivatives appear useful for labelling, particularly
6-(N-(4-aminobutyl-N-ethyl) 2,3-dihydrophthalazine l,4dione) hemisuccinamide
(ABEI-H), and 7-N-(4-aminobutyl-N-ethyl) naphthalene 1,2 dicarboxylic acid hydrazide
(ABEN), the hemisuccinamide form being used (ABEN-H). Esterification of the label is
the best method of coupling, via N-hydroxysuccinamide and dicyclohexyl carbodiimide.
When used as labels, they are stable, not affected by azide or detergents, and can be
bound to a variety of haptens and proteins, including IgG, without apparently affecting
biological activity or reducing luminescence. Indeed in some systems, luminescence has
been increased, especially with isoluminol-biotin conjugate when bound to avidin. In
some however, such as binding to thyroxin, light output may be decreased up to 50-fold.
One disadvantage in using the chemiluminescent molecule as the probe, is that its
concentration will always be limited, therefore the light output is short-lived, producing
a flash of light. An alternative to this is to use an horseradish peroxidase as the label,
and using this to catalyse the reaction of the luminescent substrate which is in excess.
This method can be applied to luminol, and has potential light output 10 times that of
isoluminol.
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B. The Chemical Reaction
Light production in chemiluminescence is dependent on an oxidation step, and each
luminogen has its own optimal oxidation system. Luminol and isoluminol and derivative
can use a variety of catalysts, such as Cu2+ and Fe(CN6)3~, but the most efficient is haem.
Haem catalysts include peroxidases, such as horseradish peroxidase, cytochrome C and a
derivative of cytochrome C known as microperoxidase MP11 (both pseudoperoxidases),
hematoprotoporophyrin IX, and finally hemin. Horseradish peroxidase and hemin are
relatively cheap, even if less efficient than some of the others.
The pH of the system is fairly critical, but varies from system to system. For most, pH
11 is the optimum, and is best supplied using sodium hydroxide, sodium tetraborate or
sodium triphosphate. The higher the pH, the higher the light output and the slower the
kinetics. A supplier of nascent oxygen is the final requirement: hydrogen peroxide is
the commonest used, but perborates and persulphates have been successful.
The chemical reaction proceeds as detailed in Figure 3. Because the reaction is
instantaneous, the addition of oxygen or the O" radical usually takes place in the
measurement device. For each system, reagents, pH, timing, proportions have to be
optimised, as there is no predictable response if one varies any of the components.
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FIGURE 3 : Chemical reaction of luminol and isolu'minol chemiluminescence
a) luminol
b) isoluminol - Ri= H
- R2 = H - isoluminol
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C. Assay Systems
Many assay systems exist, based on both solid and liquid phases. The disadvantage of
liquid phase systems, is that prior extraction of the substance of interest is usually
required, as many biological samples contain materials that quench light output or have
nascent oxidisers, such as haemoglobin. The terminology used to describe assays is also
not yet uniformly applied, but is similar to that used in radioimmunoassay.
1. Chemiluminescent immunoassay (CELIA).
Labelled antigens are used in competition with test antigen for specific antibody.
This can be either solid or liquid phase, but prior extraction is required. This has
been applied to steroids and their derivatives in plasma and urine. '284!
2. Immunoluminometric assay (ILMA).
This solid phase sandwich assay has a labelled first antibody, and has been used
for a foeto-protein, and (31 pregnancy specific glycoprotein.[288, 289j
3. Immunoluminometric labelled second antibody (ILSA).
As for ELMA, but a labelled second antibody is used for further amplification,
and where the first antibody cannot be labelled, such as when loss of sensitivity
occurs. This has been applied in addition to thyrotropin analysis. [289j
4. Solid phase antigen luminescence techniques (SPALT).
In this antigens, or particularly haptens with only one antigenic determinant in
non extractable samples are coupled to the solid phase. The first antibody is then
detected by a labelled second antibody.
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5. Chemiluminescence enzyme immunoassay (CELISA).
Peroxidase conjugated antibodies are used to catalyse luminescence in the
presence or absence of enhancing agents to prolong light output. These have
been extensively used in competitive assays and sandwich assays and have been
adapted for use in the detection of herpes virus antigen in biological materials.
[202, 203].
Other assay systems do exist, using cofactors, such as the measurement of biotin,
or enzyme multiplied immunoassays, for drug measurements, but are not of
relevance to work described here.
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D. Sensitivity of Luminol and Isoluminol Chemiluminescence
Assays using chemiluminescence were introduced as alternatives to radioimmunoassays,
to help dispense with the need for radioactive sources and handling of radioactive
materials. To gain acceptance, they have had to be of similar, if not greater sensitivity,
and this is now becoming the case. For example, commercial RIA's for TSH have a
sensitivity of 0.3 mU/litre with a working range of 1-50 mU/litre and at best a sensitivity
of 0.07 mU/litre [268]. Monoclonal based immunoradiometric assays, have at best a
sensitivity of 0.08 mU/litre, and a range of 0.5 to 200 mU/litre. A monoclonal
immunochemiluminometric assay has a sensitivity of 0.004 mU/litre and a range of 0.6
to 200 mU/litre [268]. Similarly assays for thyroxin, IgG, insulin, digoxin, biotin and
testosterone all compare favourably with other methods. Very small quantities of
substances can now be analysed with only 500 attomoles of a2 macroglobulin and 75
attomoles of ferritin being detected.
The alternative to using chemiluminescent labelled antibody or antigen, using enzyme
labelled antibody and chemiluminescent substrate, may confer even greater sensitivity.
As little as 100,000 molecule/ml (5 femtograms or 0.125 attomoles) of horseradish
peroxidase are detectable using luciferin substrate [205], and thus the problems of
labelling IgG are avoided, but luminol substrate was much less sensitive. A comparison
between assays employing luminescent labelling and peroxidase labelling shows that the
latter method may yield better results [270]. For example, insulin labelled with luminol
in a competitive assay gives a range of 5-25 ng/litre, and using an HRP label, 4 ng/litre.
HRP catalysed colorimetric analysis has also been compared with HRP
chemiluminometric analysis using isoluminol for quantification of serum proteins [201],
which showed an increased sensitivity of up to 95-fold for IgG, using a competitive
binding assay. A comparison of a sandwich ELISA, using absorptiometric and
chemiluminometric detection for HSV again using isoluminol, showed that the
chemiluminescence based assay was 64-fold more sensitive, with 40 pfu/sample detected
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versus 2,500 pfu, and when applied to clinical specimens, detected 15/17 specimens
positive on culture versus 12/17 on ELISA [201]. However, no CSF specimens were
positive [203, 202]. Chemiluminescence assays have similarly been used for other
viruses, such as cytomegalovirus [201], and Venezuelan equine encephalomyelitis virus
[178], with results equal to or better than RIA and absorptiometric analysis.
In the work presented later, therefore;two systems of chemiluminescence were to be
compared. The system based on luminol was using the chemiluminescent material
purely as a substrate for an enzyme catalysed reaction. In contrast, the system based on
isoluminol was using the chemiluminescent material as the label.
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E. Techniques for improving light output for isoluminol and luminol
The light output from HRP catalysed oxidation of cyclic diacylhydrazides tends to be
short-lived and inefficient. Reactions can be enhanced by the addition of other
compounds such as luciferin or other 6-hydroxybenzothiazole derivatives, but by far the
best enhancement has been obtained with phenol derivatives, particularly p-iodophenol
[248]. With the addition of this to luminol, light emission is increased by 2,500-fold,
with not only greater intensity, but much more prolonged output over many minutes. For
isoluminol, the enhancement was about 100-fold. Enhancement was pH dependent, the
optimum being pH 8.5, with rapid tail off either side of pH 8 and 9, and enhancement
was also dependent on p-iodophenol concentration, p-iodophenol inhibits haem
catalysed light emission. The effectiveness of enhancement was not influenced by the
solid phase, or the type of assay, but each assay required its own optimisation of
conditions.
One factor affecting the enhancement is the purity of the luminescent reagent.
Commercial luminol is a very heterogeneous material with up to 20 components, and
purification methods are needed to ensure maximum enhancement [240], Purified
luminols give up to 100-fold improvement on unpurified preparations.
Both luminol and isoluminol are light and temperature sensitive. Light induces chemical
changes to produce products that are inhibitory to enhanced luminescence, and luminol
is thermally unstable, although usually high temperatures (> 200°C) are needed.
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3. Detection Systems
Detection systems for light output can be simple or complex. At the simplest level a
dark adapted eye can see luminescence in the reaction tube as a blue light, but large
amounts of luminescent material are required, and for assay systems requiring
sensitivity, the light output is usually not visible.
The simplest materials which can be used are photographic film [248], which results in a
permanent, though only semi-quantitative record. Since multiple reactions can be
recorded at one time, this however could be used for screening. Results are only useful
for measuring quantities of substances in a known range, not for sensitive detection.
X-ray plates have also been used [145], as the film is more sensitive to light than to
gamma rays, and can be used for imaging immunoblots, but again results are only
semi-quantitative.
For quantitative results, commercial equipment can be modified, including photometers,
photomultipliers [205], fluorimeters and scintillation counters [270]. In recent years
purpose built equipment has become available, and such luminometers are capable of
measuring not only peak signals, but integrate signals over a range of times, measure
slopes and end points. They have also the facility to add reagents to the photomultiplier
chamber, for those reactions with immediate light responses. The main drawback is that
multiple measurements can only be made sequentially, thus the mechanics of ensuring
identical incubation times, temperature control, light control etc become cumbersome
when large numbers ofmeasurements have to be made.
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SECTION 2
MATERIALS, METHODS AND RESULTS
Correction Statement
Dilutions throughout this section should be read as 1 in X, not 1:X as given.
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Chapter 6: ASSESSMENT OF ISOLUMINOL AND LUMINOL
BASED CHEMILUMINESCENCE
1. Materials and Methods
A. Setting up reagents for Isoluminol Chemiluminescence
i) Manufacture of Isoluminol Ester
The method of manufacture of the active isoluminol ester is taken from Wood et
al.[282], with minor modifications as detailed. This method was followed for all
subsequent manufacture of isoluminol labelled antibodies. All reactions were carried out
in foil covered glassware which had been acetone cleaned and air dried. 10 mg of
6-N-(4-aminobutyl)-N-ethyl-isoluminol (ABEI) (Sigma, Poole, Dorset) was suspended
in 3 ml of dimethyl formamide (DMF) (Sigma, Poole, Dorset), giving a concentration of
12 mM, and agitated until dispersed evenly. Then 25 mg of succinic anhydride (Sigma,
Poole, Dorset) was dissolved in 1 ml of DMF at room temperature (RT), giving a
concentration of 0.25 M, and 0.15 ml of this solution was mixed with the ABEI
suspension with agitation, left at 4°C overnight, heated to 45°C for 3 hr, and then 60°C
for 1 hr to completely dissolve the precipitate. 20 mg of N-hydroxy succinamide (NHS)
(Sigma, Poole, Dorset) was dissolved in 1 ml ofDMF at RT to give a concentration of
0.17 M, and 0.15 ml of this was mixed with the ABEI solution at RT. 28 mg of dicyclo
hexyl carbodiimide (DCCI) (Sigma, Poole, Dorset) was dissolved in 1 ml DMF at 60°C,
to give a concentration of 0.14 M, and 0.6 ml of this added to the ABEI-NHS and left at
RT overnight. This active ABEI ester was stored at 4°C in the dark until conjugation to
protein.
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ii) Conjugation of Isoluminol to protein
The method of conjugation of the active ABEI ester to antibody was taken from Wood et
al. [282] and was applied to all the antibodies subsequently labelled, the only variation
being made was the molar ratio of label to antibody in conjugation. For the initial
studies, 0.5 ml of rabbit anti-HSVl IgG (Maclntyre strain, Dakopatts, High Wycombe,
Bucks) was diluted in 5ml 0.05 M Phosphate Buffered Saline solution (PBS) pH 8.0. To
this, 0.2 ml of ABEI-NHS was added with mixing, and left at RT overnight to allow
conjugation. The solution was transferred to visking tubing (BDH, Poole, Dorset),
dialysed against PBS for 3 exchanges for 2 hr each and one overnight exchange to
remove unbound label. The dialysed conjugate was aliquoted and stored at -35°C, being
thawed only once before use.
iii) Optimisation of Chemiluminescence system
All reactions involving chemiluminescence were carried out using an LKB 1251
luminometer (LKB/Pharmacia, Milton Keynes). The reaction was initiated within the
measurement chamber by an automatic dispenser which released measured aliquots of
the source of O radicals. Output was displayed both digitally on the luminometer and
graphically using an Omniscribe chart recorder (Houston Instruments, Houston, Texas).
Numerical values were taken from either peak readings or time integrated displays from
the luminometer, and light output kinetics from the chart recorder.
a) Hematin concentration
100 ul of 1:1000 ABEI labelled rabbit anti-HSVl IgG in 0.15 M NaCl was mixed with
0.5 ml hematin (Sigma, Poole, Dorset), at a range of concentrations from 0.1875-750
uM, and the luminescence initiated with 50 ul 18mM H202 in 0.33 M NaOH. Because of
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the kinetics of the light response (a sudden flash and a rapid tail off - see figure 11), the
peak light output value for each combination was plotted, and by using mixtures without
labelled IgG and volume made up by NaCl, a signal to noise ratio was achieved.
b) Choice of 0~ producer
The hematin calibration curve was repeated replacing the H202 with 18 mM NaB03, and
the average of 10 peak readings taken and plotted as before.
c) Response curve for labelled IgG
100 ul aliquots of ABEI labelled rabbit anti-HSVl IgG, diluted from 1:3625-1:130,000
in 0.15 M NaCl were mixed with 0.5 ml of 0.75 uM hematin in 0.15 M NaCl and
luminescence initiated by 50 ul of 18 mM H202. An average of 4 readings was made for
each dilution and the peak light output plotted.
iv) Calibration of Isoluminol ester base
The optimised concentrations were used to set up a calibration curve for the light output
of the ABEI ester. 0-100 ul of a 1:4 x 106 dilution of stock ABEI-NHS in 0.15 M NaCl
was mixed with 0.5 ml 0.75 uM hematin in 0.15 M NaCl and light output initiated as
above. The total volume was made up to 0.65 ml with 0.15 M NaCl. This range of
ABEI-NHS was chosen because it gave a light output within the range of detection of the
luminometer. Light output was plotted against molar concentration of ABEI-NHS
manufactured in experiment 1 A which had a concentration of 0.25 pmol/lOOul (2.5 nM).
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B. Assessment of commercial anti-HSYl IgG labelling
i) Purification of IgG by Rivanol extraction and Calculation of the Protein content
The method of Rivanol (diamino acridine lactate) extraction was taken from the
Handbook of Experimental Immunology [104], and is detailed in Appendix 2. 500 ul of
rabbit anti-HSVl IgG was purified, and stored at 4°C until use.
The standard Biuret method for plasma protein estimation [1] was used to estimate the
IgG content of the purified antibody solutions. Protein calibrant no.4 (ATAB, Winnersh,
Berks.) with a protein content of 52 g/1 was used to construct a calibration curve and
absorbance was measured at 555 nm in a Uvikon 810 spectrophotometer (Kontron
Instruments, Watford).
ii) Assessment of optimum Isoluminol to IgG ratio
Conjugation of ABEI-NHS to rabbit anti-HSY1 IgG was performed as in 1 A with the
volume of purified IgG being varied from 0.05-0.5 ml (0.5-5 mg) and the reaction
volume remaining constant by varying the PBS volume. After dialysis the final solutions
were then diluted by 1:500-1:5000 to achieve an equal IgG final concentration in PBS,
and a lOOul of each was read in the luminometer. An average of 10 peak light output
readings was made for each conjugate, and the specific activity plotted by converting the
light output value into moles of ABEI-NHS and dividing by the molar values for IgG.
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iii) Immunoprecipitation of labelled IgG
20 ul of the optimum ABEI IgG was incubated at RT overnight with an excess (40 ul)
goat anti-rabbit IgG (ATAB, Winnersh, Berks.) in a total volume of 200 ul made up with
PBS. The mixture was centrifuged at 8000 g in an Eppendorf microfuge 5413 (source to
enter) for 45 min, the supernatant decanted and 100 ul of a 1:5000 dilution in PBS
counted in the luminometer. A control of ABEI IgG identically treated, but without the
goat antisera, was run in parallel.
Page 132
C. Assessment of immunological function of the Isoluminol conjugated IgG
In these experiments preservation of the immunological function of the labelled IgG was
assessed by coupling HSY antigen to a solid phase, and incubating labelled IgG with the
bound antigen. An initial attempt at eluting IgG bound to the column was also made
with the intention of using this affinity purified antibody in the assay system.
i) Estimation of protein concentration of HSV1 antigen
The protein concentration of commercial HSV1 antigen (Behring Diagnostics, Hoescht
UK Ltd, Hounslow, Middsx) was estimated using the Biuret method.
ii) Coupling of commercial HSV1 antigen to Cyanogen Bromide activated Sepharose 4B
The method was taken from Affinity Chromatography, Principles and Methods, an
application guide provided by Pharmacia [2]. This method was followed in all
subsequent couplings with only minor variations detailed where appropriate in the text.
1 g freeze-dried Cyanogen Bromide activated Sepharose 4B (CNBr-Seph) was activated
by mixing with 10 ml ImM HC1, left for 15 min to swell and then transferred to a
sintered glass filter, where, under vacuum, the gel was washed with 200 ml 1 mM HC1 in
several aliquots. 1 ml of HSV1 antigen was mixed with 6 ml coupling buffer, consisting
of 0.1 M NaHC03 and 0.1 M Na^Oj in 0.5 M NaCL mixed to a pH of 8.35. The gel
was vacuum washed with 5 ml coupling buffer and immediately transferred to the HSV1
antigen solution where it was mixed by rocking for 2 hr at RT. The remaining active
groups on the CNBr-Seph were blocked with 0.2 M glycine in coupling buffer which
was left with occasional mixing at 4°C for 16 hr. The blocked gel was vacuum washed
on the sintered glass filter alternately with coupling buffer and 0.1 M acetate buffer in
0.5 M NaCl pH 5.2. Washing took place 4-5 times to remove protein ionically bound,
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the final wash being coupling buffer. The gel was finally suspended in 7 ml coupling
buffer, a few drops of 1% Sodium Azide added as a bacteriostatic agent, and the
suspension stored at 4°C for immediate use.
iii) Binding of labelled IgG to Sepharose coupled HSV1 antigen
Incubation of labelled antibodyandcoupled antigen would enable the proportion of
specific labelled and immunologically functional antibody to be estimated by comparing
the free to bound ratio. The use of a range of dilutions of labelled antibody would ensure
that the antigen was saturated and thus optimum proportions obtained for later attempted
elution of bound antibody.
100 ul ABEI labelled rabbit anti-HSVl IgG diluted from neat to 1:5,000 in PBS pH 8
was incubated with 20 ul CNBr-Seph-HSV1 for 2 hr at RT with continual slow mixing.
Each mixture was then centrifuged for 5 min, the supernatant eluted, the gel washed 5
times with PBS and the supernatants read immediately in the luminometer, using the
previously optimised reagents. Appropriate dilutions were made for those supernatants
whose readings initially overloaded the photomultiplier. Finally the gels were read, all
the values corrected for background, and the final results expressed as a percentage of
gel counts over the total counts added.
iv) Affinity purification of labelled IgG
Two methods of producing affinity purified labelled IgG were attempted. In the first,pre
labelled IgG was bound to a CNBr-Seph-HSVI column and the second unlabelled IgG
was bound and labelled in-situ; the latter method was tried to improve the yield of
immunologically active labelled IgG by covering the Fab site. In addition a modification
of the binding of the antigen to the Seph-4B column was made by pretreating the antigen
with 8M Urea/Triton X100 to improve the exposure of epitopes [81].
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50 ul rabbit N-IgG (Dakopatts, High Wycombe, Bucks) and anti-HSVl IgG were diluted
to equal the IgG content of labelled IgG and incubated with 100 ul of CNBr-Seph-HSVl
for 30 min at RT. After washing x 5 with PBS pH 8.0, and centrifugation, 100 ul
ABEI-NHS was added in 1.5 ml PBS and incubated at 4°C for 72 hr with mixing before
washing excess. 50 ul of rabbit N-IgG was labelled with ABEI-NHS as before,
and together with labelled anti-HSVl IgG were both incubated with CNBr-Seph-HSVl
for 30 min at RT. After washing all the gels were then incubated with 1.5 ml of
increasing concentrations of NaSCN (106- 4 M), mixed for 15 min at RT, centrifuged
and the supernatants eluted. In between steps the gels were washed with PBS. 100 ul
1:100 in PBS of each supernatant was counted in the luminometer, using standard
reagents.
1 ml control HSV antigen (Behring diagnostics, Hoescht UK Ltd., Hounslow, Middsx.)
and 1 ml HSV1 antigen were each pretreated with 10 ml 8 M Urea/1% Triton X100 for 1
hr at RT before coupling to sepharose as standard. Antibodies, both labelled and
unlabelled, were incubated with sepharose bound antigen ,the NaSCN elution and
supernatant counting performed as above.
v) Dialysis of eluants from affinity purification
Because eluants from the antibodies labelled in-situ may have contained free isoluminol
each of the eluants from the previous experiment was dialysed using visking tubing
against PBS for 24 hr with 4 changes. 100 ul of each eluant was then counted in the
luminometer, initially at a 1:100 dilution, but because the counts were so low, the eluants
were counted undiluted using standard reagents,
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D. Setting up reagents for luminol chemiluminescence.
i) Manufacture of purified luminol base
Enhancement of light output of luminol by purification was performed by the methods
described [240]. All reactions were performed in foil covered glassware and incubations
took place in the dark. 3.25 g 3-aminophthalhydrazide (luminol) (Aldrich, Gillingham,
Dorset) was dissolved in 18 ml of 5% NaOH at RT until saturation was reached. After
filtration through a 0.2 um Millipore filter (Millipore (UK) Ltd., Watford) to remove
undissolved luminol, the solution was cooled to 4°C and kept for 16 hr whilst
crystallisation took place. After drying on Whatman No 1 filter paper (Whatman,
Maidstone, Kent), the crystals were redissolved at RT in a minimal volume of 5% NaOH
(10 ml), refiltered through the Millipore filter and the solution cooled to 4°C for 72 hr
whilst crystallisation occurred. The crystals were washed on Whatman filter paper with
ice-cold 5% NaOH, and left to dry. The final yield was 1.7 g of white crystals.
Luminol base was prepared by dissolving the purified luminol in distilled HzO to a
concentration of 100 mg/ml, then adding drops of concentrated HC1 until no further
precipitation formed. The supernatant was discarded and the crystals dried at RT. The
final yield was 0.5 g and the purified luminol base stored in a stoppered bottle at 4°C in
the dark.
ii) Initial assessment of Iodophenol enhancement
The method of enhancement using iodophenol was modified from that described by
Thorpe et al. [248]. Stock p-Iodophenol (Aldrich, Gillingham, Dorset) was made by
dissolving 17 mg in 0.5 ml dimethyl sulphoxide (DMSO) (BDH, Poole, Dorset), and
making up to 5 ml with 0.05 M PBS pH 7.4. Working solutions were diluted further in
PBS. Stock luminol solution was made by dissolving 10 mg purified luminol base in 0.5
ml 0.33 M NaOH and making up to 5 ml with PBS. Working solutions were diluted
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further in PBS. To catalyse the reaction, goat anti-rabbit IgG HRP conjugate
(Miles-Yeda, ICN Biomedicals Ltd, High Wycombe, Bucks.) was diluted as appropriate
for use in PBS. 20 ul of appropriate dilutions of iodophenol, luminol and HRP conjugate
were mixed in 300 ul of PBS and luminescence initiated using 50 ul 18 mM H202 in 0.33
M NaOH.
The kinetics of light output from luminol differed from that produced by isoluminol, in
that there was an initial flash followed by a prolonged plateau phase whose shape varied
depending on the reagent proportions (see Figure 11 later). Both plateau phase and peak
light output were measured, but only the plateau phase showed any relationship with
reagent concentrations. Unless otherwise indicated, for luminol the 120 s integrated area
curves were used. Light output was then measured using a variety of luminol and HRP
concentrations, and once these were optimised, a range of iodophenol dilutions was then
applied to establish its optimum.
iii) Choice of O
As with isoluminol based chemiluminescence, the choice of 0~ source was H202 or
NaBOs. 100 ul of dilutions of goat anti-rabbit IgG HRP conjugate were mixed with 100
ul 1:20 stock iodophenol and 100 ul 1:50 stock purified luminol base.
Chemiluminescence was initiated with 30 ul of dilutions of either of the O" sources. In
this experiment the 40 s integrated time was plotted for each of the sources.
iv) Calibration curve for iodophenol enhanced luminol chemiluminescence
20 ul aliquots of 1:4 iodophenol, 1:2000 luminol and 1:100-1:50,000 goat anti-rabbit
HRP conjugate and rabbit anti-goat IgG HRP conjugate (Dakopatts, High Wycombe,
Bucks.) were all diluted in 400 ul PBS and the reaction initiated with H202 as above.
The 120 s integrated count was recorded with values corrected for background.
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v) Reagent stability
a) Effect of Time
Reactions mixes were as for section iii) with standard 1:2000 goat anti-rabbit IgG HRP
conjugate being used. The mixture was incubated at RT for up to 1 hr before initiation
of chemiluminescence, and a parallel was also incubated, but with the iodophenol added
immediately prior to reading. A 40 s integrated time result was plotted.
b) Effect of Temperature
The reaction mix was made up as for a) but were kept at 4°C or RT or combinations for
up to 75 min and chemiluminescence initiated.
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2. Results
A. Isoluminol based Chemiluminescence
i) Optimisation of Chemiluminescence
a) Hematin concentration
Figure 4 shows that 0.75 uM of hematin gave the best signahnoise at 3.5:1. Note that
marked quenching of light output occurred at higher concentrations, the solution being a
dark red colour.
b) Choice of 0~ producer
The curve for NaB03 paralleled that for H202, but although light output was greater,




" No antibody I Labelled antibody tstsj Signahnoise ratio
Figure 4: Optimisation curve for
Hematin catalysed luminescence
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Log peak light output mv/s
Figure 5 : Calibration curve for
Isoluminol labelled IgG
c) Response curve of labelled IgG
Figure 5 shows a straight line log:log relationship over the range of light output detection
range of the luminometer. Sensitivity was high, with 1:130,000 dilution showing counts
> 100% above background. This dilution of labelled IgG was equivalent to 4.6 x 10~15
mol.
All subsequent experiments were conducted using 0.5 ml of 0.75 uM hematin and 50 ul
of 18 mM H202 unless otherwise indicated.
ii) Calibration of isoluminol ester base
Figure 6 shows the peak light output plotted against the absolute amount of ABEI-NHS
in moles. The graph shows a linear relationship with a slope of 4.5 x 1012 volts/s/mol
ABEI-NHS.
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Isoluminol cone (xlO—15 Moles)
Figure 6 : Calibration curve for
isoluminol light output
iii) Assessment of IgG labelling
a) Optimum Isoluminol :IgG ratio
The IgG content of purified commercial rabbit anti-HSVl IgG was 10 g/1. Table 19









0. 05 568 126 1.14
0.10 370 82 0.74
0.25 415 92 0. 84
0.50 315 70 0. 64
* - Identical IgG ammounts from each combination
(110 x 10"15 moles)
TABLE 19 : Resultant specific activity from varying
Isoluminol and IgG conjugation proportions
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The best mix was 0.05 ml antibody to 200 ul isoluminol ester. This gave a specific
activity of 1.14, thus indicating that on average one molecule of isoluminol label was
attached to each molecule of IgG. The lower the isoluminolTgG ratio, the worse the
specific activity.
b) Immunoprecipitation of labelled IgG
Immunoprecipitating labelled IgG with goat anti-rabbit antiserum resulted in a 74%
reduction in chemiluminescence output from the supernatant, suggesting there was
predominantly labelled IgG present in the solution.
iv) Assessment of Immunological function of labelled IgG
a) Binding of labelled IgG to Sepharose coupled HSY1 antigen
The total protein content of the antigen was 19 g/1 and appropriate volumes used for
coupling to the seph-4B. Table 20 shows that labelled antibody never achieved
saturation of antigen, with the average proportion of labelled IgG immunoreactive with
HSV1 at only 1.7%, with at best 4.2% being bound.
b) Affinity purification of labelled IgG
Attempted elution was completely unsuccessful. There was no difference between
control labelled antibody and anti-HSVl labelled antibody with both seph-4B-HSVl
columns and U/T control and HSV1 treated antigen seph-4B columns at any
concentration of NaSCN, irrespective of whether the antibody was incubated prelabelled
or after attachment to the column. Prelabelled antibody supernatant counts were overall
much lower than when labelling was attempted after binding to the column, particularly










55000 171600 4621 2 . 6
27500 57025 1044 1.8
11000 32400 659 2 . 0
7330 23359 352 1.5
5500 19590 249 1.3
3670 12324 80 0.6
2750 8441 102 1.2
2200 6962 302 4.2
1100 3483 10 0.3
550 1510 21 1.4
275 1335 0 0
138 891 0 0
110 476 0 0
55 209 0 0
22 91 0 0
11 26 0 0
TABLE 20 : Binding of labelled anti-HSVl IgG to an
HSV1 coated sepharose 4B column.
c) Dialysis of eluants from affinity purification
Dialysis of eluants from those columns where isoluminol labelling occurred after antibody
binding showed a large reduction in chemiluminescent activity by about 95%. There
was no difference between normal IgG and anti-HSVl IgG in either control or HSV1
antigen columns at any of the NaSCN dilutions, and no specific increase in
chemiluminescence above 1 M concentrations.
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B. Luminol based Chemiluminescence
Log 120s I Time mV/s
Log reciprocal HRP dilution
* 1:1000 luminol 1 1:1000 luminol+iodo * 1:2000 luminol
D 1:2000 luminol+iodo x 1:10000 luminol ^ 1:10000 luminol+iodo
Figure 7 : Iodophenol enhancement of
Luminol chemiluminescence
i) Iodophenol enhancement
Figure 7 shows that iodophenol enhancement is dependent on concentration of both
luminol and the HRP conjugate, with luminol dilutions > 1:10,000 giving no response
and HRP enhancement being more marked at dilutions < 1:50,000. High concentrations
of luminol overload the system as a result of the initial flash and not the plateau phase.
A 1:2000 dilution of luminol base was the best substrate concentration for iodophenol
enhancement.
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X axis value of 5 = luminometer overload
log 120s I Time mV/s
Reciprocal Iodophenol dilution
—— 1:1000 HRP* —1:1500 HRP* 1:2000 HRP* 1:1000 HRP**
* - 1:2000 luminol, ** - 1:4000 luminol
Figure 8 : Optimisation of Iodophenol
concentration
Figure 8 shows that enhancement was not only dependent on the concentration of
luminol and HRP, but also varied depending on the concentration of iodophenol. A 1:8
dilution of iodophenol was optimum for a 1:4000 dilution of luminol and a 1:1000
dilution ofHRP, with higher concentrations of iodophenol resulting in less enhancement.
As the concentration of luminol was increased to 1:2000, which was the best initial
working concentration, the luminometer system overloaded below 1:4 dilutions of
iodophenol because of the initial flash, so the optimum measurable was 1:4. As the HRP
concentration was reduced, the optimum dilution of iodophenol appeared to be between
1:4 and 1:8. However the maximum recordable enhancement for iodophenol was only
4-fold, somewhat less than the 100-fold enhancement reported in the literature [248].
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ii) Choice of O source
Figure 9a shows the curves for H202 dilutions. A 1:2 dilution of stock 18 mM solution
gave better responses at higher concentrations, but little improvement at lower
concentrations ofHRP conjugates. Below a 1:4 dilution, the response was much poorer.
Figure 9b shows curves for NaB03 dilutions. A 1:4 dilution of stock gave the best range
of sensitivities of all the dilutions, and also gave a smoother curve than H202, but the
background counts were all much increased as with isoluminol and the initial spike was
higher. Overall the sensitivity was less than H202 at either stock or 1:2 dilutions.
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Log Reciprocal HRP dilution
Neat -+— 1:2 din. 1:4 din. 1:8 din.
Figure 9a : Optimisation of Hydrogen
Peroxide concentration for Luminescence
— Neat —1:2 din. 1:4 din. 1:8 din.
Figure 9b : Optimisation of Sodium
Perborate concentration for Luminescence
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Log reciprocal HRP dilution
Goat HRP Rabbit HRP
Figure 10 : Calibration curve for
iodophenol enhanced luminol luminescence
iii) Calibration curve for iodophenol enhanced luminol chemiluminescence
Figure 10 shows that there was a linear relationship between light output and iodophenol
enhanced luminol based HRP conjugate catalysed chemiluminescence. However the
sensitivity of the luminescence was poor, with dilutions > 1:6400 (1.8 xlO"13 moles HRP
conjugated IgG) giving < 100% counts above background. This would appear not to be
sensitive enough for a sandwich assay.
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iv) Reagent stability
a) Effect of Time
After 1 hr at RT without iodophenol in the mix there was a 40% reduction in light
output, but with iodophenol an 88% reduction occurred, indicating that iodophenol
inhibited light output and thus should only be added at the last moment.
b) Effect of Temperature
At 4°C there was no reduction in light output after 30 min, and only 10% after 75 min,
compared with RT values of 35% and 61% respectively. If the luminol was kept at 4°C
and the HRP at RT, the reduction was 30%, indicating that 50% of the reduction was due
to instability of luminol and 50% the HRP at the dilutions used.
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3. Discussion
Commercial rabbit anti-HSVl IgG was successfully labelled with isoluminol to produce
an immunologically active antibody,with a specific activity of 1.14, but a relatively low
yield at 1.7% of the total IgG labelled* The response curve of the isoluminol labelled
IgG was shown to be a linear relationship, and thus suitable for calibration purposes,
with a sensitivity of 4.6 x 1015 moles of IgG. Attempts at affinity purification of the
labelled IgG were all unsuccessful, irrespective of the method of labelling. The reasons
for this were not clear, although the possibilities included the inactivation of the label by
the chaotropic agent used or the failure of the chaotropic agent to separate high affinity
antibody from the column. This latter option seemed unlikely to account for a total
failure, as one would have expected a commercial polyclonal antibody to have contained
a wide range of antibody affinities.
Despite the evidence from the literature indicating the higher sensitivity of iodophenol
enhanced luminol luminescence, the results here were disappointing, with poor
enhancement (only 4-fold versus 100-fold in the literature) and consequently poor
sensitivity compared to isoluminol at 1.8 x 10~13 moles of IgG, a factor of 100-fold less
sensitive. The kinetics of light output differed between the 2 substrates, with isoluminol
giving a sudden short lived predictable peak light output and luminol giving an
unpredictable initial flash followed by a long lived predictable plateau phase (Figure 11).
These kinetics of the luminol chemiluminescence appeared mainly to blame for its poor
performance. The initial flash did not result from impurities in the luminol or relate to
HRP conjugate concentration, but appeared to be due to an instability in the reaction
system. In addition, each reaction mix for luminol required individual optimisation. As
a result, isoluminol labelling of antibodies was the preferred method.
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Figure 11: Kinetics of Chemiluminescence
a) Luminol - p-Iodophenol enhanced
b) Isoluminol
Temperature and incubation time were both shown to be important in influencing light
output, so all subsequent reactions were carried out with reagents kept at 4°C and reagent
mixing times kept as short as possible before initiating chemiluminescence.
* This figure of 1.7% represents the proportion of immunologically functional labelled IgG
compared to the total known to be labelled. The poor yield may have resulted from the
binding of isoluminol close to, or on, the Fab site of the IgG molecule, thus sterically
hindering immunological function. The Fab site would have to contain a disproportionate
number of isoluminol conjugation sites for this to happen.
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CHAPTER 7: ISOLUMINOL LABELLING OF ANTIBODIES
FOR USE IN AN ASSAY SYSTEM
In this section a range of antibodies of potential use in an assay system were labelled,
and the effectiveness of labelling and immunoreactivity assessed using a
non-commercial HSV1 strain whose viral content was known and thus the sensitivity of
the antibodies could be determined.
1. Materials and methods
A. Use of HSV Kos in affinity purification of labelled commercial anti-HSYl IgG
i) Use of NaSCN and NaCl to elute antibody
HSV Kos was gifted by Dr. Robert Honess from Mill Hill MRC research laboratories.
Unpurified virus grown in vero cells and vero cell controls were used. The whole virus
preparation was initially disrupted by sonication and solubilised using 1% Triton XI00,
with some also being disrupted by 8M Urea for particular antibody studies. The treated
virus was then centrifuged at 8000g in an Eppendorf microfuge 5413 for 5 mins to clear
cell debris, and the supernatant virus count estimated at 1010 infected cell products per
ml (ICP/ml). The total protein content of the supernatant was 50g/l by biuret method.
The vero cell control was treated identically.
Coupling of HSV Kos and vero cell control to Seph-4B was performed as in Chapter 6.
Preliminary work showed that 8M urea treatment destroyed the immunoreactivity with
the commercial antibody, so this was omitted. Incubation of lOOul gel with lOOul
isoluminol labelled commercial rabbit anti-HSV 1 IgG, serial elution of antibody with
NaSCN and luminescence of eluants were all performed as in Chapter 6. In addition, the
use of NaCl of increasing molarity as a chaotropic agent was also attempted. Counts
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were corrected for background and expressed as a percentage of the total added.
Because the counts added for the NaSCN elution gave high eluant values which needed
dilution for counting, a 1:5 dilution of the labelled IgG was used for the NaCl stage.
ii) Effect of NaSCN on chemiluminescence
100 ul of NaSCN concentrations from 10~6-4 M were mixed with 100 ul 1:10 isoluminol
labelled IgG made up to a total volume of 600 ul with PBS and the chemiluminescence
initiated as standard.
iii) Assessment of IgG content of eluants by Immunoblotting.
25 ul of eluants from the affinity elution were air dried onto nitrocellulose membranes
(Sartorius Ltd, Epsom, Surrey). The membrane was blocked with 1% bovine albumin
(Sigma, Poole, Dorset) in 0.15 M NaCl for 1 hr, washed x 5 with distilled water,
incubated with 50 ul goat anti-rabbit IgG HRP conjugate (Dako, High Wycombe,
Bucks.) in 50 ml 0.1% albumin in 0.15 M NaCl for 1 hr, washed again, and then
visualised with 10 mg 3-amino-9-ethylcarbazole (Sigma, Poole, Dorset) in 6 ml
methanol and 44 ml 0.02 M acetate buffer pH 5.1.
iv) Viral content of HSV Kos preparation
The viral content of the HSV Kos preparation had been verified by Dr. Honess in his
laboratory using standard techniques, and the details of this will not be described further.
Page 153
B. Labelling and purification ofHyper-Immune rabbit antisera alpha-T2.
i) Use of pH to elute antibody
Two polyclonal hyper-immune rabbit anti-HSVl IgG antibodies, alpha-Tl and alpha-T2,
together with a pre-immune control serum were gifted by Dr. Sandy Buchan from the
University of Birmingham. The IgG content of the antisera was estimated, after IgG
purification, by modified rocket method [152] and labelling of the antibodies with
isoluminol performed as in chapter 6. Incubation of labelled control antibody and
alpha-T2 (which had the highest IgG content) with HSV Kos or vero cell control
Seph-4B were performed as standard before elution of antibody by washing first with
0.05% Tween 20, then incubating the gel with 1 ml 0.1 M Glycine in 0.2 M HC1 pH 2.7
for 8 min, the supernatant removed, neutralised with solid Tris to pH 9.0, and then 100 ul
counted as before. The effect of acid treatment and neutralisation on chemiluminescence
was first assessed, in view of the effect of NaSCN, by incubating aliquots of ABEI-NHS
with glycine/HCl for a range of times before counting, and also counting after
neutralisation, both immediately and after a delay of 30 min.
ii) Assessment of IgG content of eluants by immunoblotting
The procedure was identical to that followed above (section A iii).
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C. Labelling and purification of a commercial monoclonal anti-HSVl IgG
i) Labelling of antibody, Sephadex chromatography and assessment of specific activity
Dialysis of labelled antibody to remove unbound isoluminol was time consuming, so
after labelling antibody as in Chapter 6, the dialysis step was replaced by a separation
stage using sephadex chromatography. A 27 cm column of sephadex G-100 (Pharmacia,
Milton Keynes, Bucks.) was thoroughly washed with 0.05 M PBS, and an ISCO UV
detector, automatic fraction collector and chart recorder (ISCO, Lincoln, Nebraska) were
calibrated and stabilised at a pump flow of 2 units, the fractions set at 0.5 ml. 1.2 ml of
freshly prepared isoluminol labelled antibody was applied to the top of the column, and
the fractions collected and marked on the chart recorder. The chart recorder was
calibrated using 2 standard IgG solutions (0.15 and 0.3 g/1). Confirmation of the IgG
content of the fractions was performed by immunoblotting as above (section A iii), with
the use of goat anti-mouse IgG (Cappel laboratories, Cochranville, P.A., USA) and
rabbit anti-goat IgG HRP conjugate, and the IgG value obtained from the calibration on
the chart recorder. Chemiluminescence of each fraction was performed as standard on
100 ul of 1:10 or 1:100 dilutions.The specific activity was calculated by using the
calibration curve for isoluminol in chapter 6.
ii) Affinity purification of labelled IgG using pH and NaSCN
The immunoreactivity of the labelled antibody, and an indication of the affinity was
assessed by pH elution from the antigen coated seph-4B column. Preliminary
experiments suggested that the monoclonal was directed against structural, non-envelope
protein, and that pre-treatment of the antigen with 8M urea was necessary before coating
the gel. 10 ul of labelled antibody from the optimum fractions (9 and 10 pooled) was
incubated with 200 ul of control or HSV Kos seph-4B, with a minor modification, in that
a mini-column of gel was made by loading a pasteur pipette stoppered with glass wool.
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Centrifugation steps were thus eliminated. The column was washed with 0.05 M PBS,
then 0.2 M glycine/HCl pH 2.7, and the eluant neutralised with solid tris. Washings
eluants and the gel were all counted with standard chemiluminescence reagents.
In parallel, increasing molarities of NaSCN were used to elute antibody from identical
control and HSV Kos columns, and the eluants immunoblotted for IgG content as above
(section A iii) as well as chemiluminescence counted (since NaSCN inhibited
chemiluminescence, immunoblots were needed to show successful elution).
D. Labelling and purification of human anti-HSVl IgG
A serum from a survivor of HSVE with high titre of anti-HSVl antibody (>1:32,000)
was purified for IgG, labelled with isoluminol, separated by sephadex chromatography,
IgG content estimated, chemiluminescence performed and specific activity of the
optimum fraction calculated as above (section C i). Affinity elution of labelled IgG




A. Use of HSV Kos in affinity purification of commercial anti-HSVl IgG
i) Use of NaSCN and NaCl to elute antibody
Table 21 shows that with NaSCN there appeared not only to be poor elution of antibody
with chemiluminescent activity, but the counts dramatically dropped with the higher
molarities. 6% of the added counts appeared to be unaccounted for with the HSV Kos







Added 160000 (100.0) 160000 (100.0)
Nil 147600 (92.0) 136500 (85.3)
10'6 4500 (2.8) 4335 (2.7)
10"4 2865 (1.8) 2895 (1.8)
10"1 3675 (2.3) 4875 (3.0)
1 465 (0.3) 855 (0.5)
4 240 (0.15) 765 (0.5)
Seph 0 (0.0) 0 (0.0)
Total 159345 (99.6) 150225 (94.0)
Unacc 655 (0.4) 9775 (6.0)
Unacc - chemiluminescence unaccounted for
Seph - sepharose 4B
TABLE 21 : Elution of Isoluminol labelled anti-HSVl IgG
from antigen coated sepharose 4B column using NaSCN.
Table 22 shows that with NaCl, all the added counts were accounted for, and 3 M NaCl
eluted 8.3% of the added counts to the HSV Kos column and 4% for the control column,








Added 30000 (100.0) 30000 (100.0)
Nil 27465 (91.5) 26070 (87.0)
0.15 0 (0.0) 0 (0.0)
0.5 660 (2.2) 420 (1.4)
1.0 285 (0.9) 510 (1.7)
1.5 210 (0.7) 345 (1.2)
3 . 0 1260 (4.0) 2475 (8.3)
Seph 0 (0.0) 0 (0.0)
Total 29880 (99.6) 29820 (99.4)
Unacc 120 (0.4) 180 (0.6)
Unacc - chemiluminescence unaccounted for
Seph - sepharose 4B
TABLE 22 : Elution of Isoluminol labelled anti-HSVl IgG
from an antigen coated sepharose 4B column using NaCl
Thus there appeared to be a discrepancy in the results of NaSCN elution with respect to
the chemiluminescence counts detected, the reason for which became apparent below.
ii) Effect of NaSCN on chemiluminescence
Table 23 shows that NaSCN inhibited chemiluminescence significantly above 0.1 M,
and so the apparent poor yield from affinity purification may have been due to this
effect. This inhibition was permanent, and not due to active interference, since in













TABLE 23 : Inhibition of chemiluminescence by NaSCN
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iii) Assessment of IgG content of NaSCN eluants by immunoblotting
Figure 12 shows that the 4 M NaSCN eluants from the HSV Kos column contained
significant IgG staining, confirming that high affinity antibody was present whose
chemiluminescence was inhibited by the NaSCN. Apart from the initial washings
containing unbound IgG there was little or no significant staining in any other fraction.
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Is, 2s - First and fifth washings
10-6, 10-4, 10-1, 1, 4 - NaSCN Molarity
C, H - Control and Herpes Simplex columns
Figure 12 : Immunoblots of Isoluminol labelled antibody eluted from
control and HSV Kos sepharose-4B columns with NaSCN
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B. Labelling and purification ofHyper-Immune rabbit antisera alpha-T2
i) Use of pH to elute antibody
The immediate effect of the addition of glycine/HCl to isoluminol was a 12% reduction
in light output, with full recovery of light output by 5 minutes. Neutralisation with solid
Tris resulted in an immediate reduction in light output by 30-80%, depending on how
long the acid had been incubating with isoluminol, but delaying initiation of light output
by 30 minutes following neutralisation resulted in recovery of light output to 100%.
Table 24 shows that less than 1% of labelled anti-HSVl antibody bound to the control
column, but 5.35% bound to the HSV1 column. However, nearly all the
chemiluminescence was eluted by the Tween 20 washing, with only 0.15% being eluted
by pH 2.7, suggesting that labelling of antibody was unsuccessful,immunoreactivity was
destroyed, or the antibody was rendered lower affinity.
Eluant Control antigen HSV1 antigen
Control Anti-HSVl Control Anti-HSVl
Ab* Ab* Ab* Ab*
Unbound 99.00 99.27 99. 53 94 . 65
Tween 0. 94 0. 60 0.40 5.20
pH 2.7 0. 06 0. 03 0 . 07 0 . 15
Seph 4B 0. 00 0. 00 0 . 00 0 . 00
* - percentage of total chemiluminescence added (mV/s)
Seph 4B - residual chemiluminescence in sepharose 4B
TABLE 24 : Elution of Isoluminol labelled alpha-T2 from
an antigen coated sepharose 4B column using pH.
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ii) Assessment of IgG content of eluants by immunoblotting
pH elution did contain significant amounts of IgG from the alpha-T2 and HSV1 antigen
incubation, with much less in the Tween 20 eluant and the majority of the antibody
unbound in the washings. This suggested that labelling reduced the immunoreactivity of
the antibody considerably.
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C. Labelling and purification of a commercial monoclonal anti-HSVl IgG
i) Sephadex chromatography and specific activity
Sephadex chromatography showed successful separation of the free and antibody-bound
isoluminol into two distinct peaks (data not shown), and IgG immunoblotting confirmed
the IgG content to be in the first peak, with a maximum concentration of 38 mg/1. The
chemiluminescent activity of the first peak was confirmed, and the specific activity of
the isoluminol labelled fractions was calculated at between 2.2 and 2.8.
ii) Affinity purification using pH and NaSCN
Table 25 shows that 52% of the chemiluminescent activity remained bound to the gel





Added 4100 (100.0) 4500 (100.0)
Unbound 3552 (86.6) 2112 (46.9)
pH 2.7 50 (1.2) 27 (0.6)
Seph 4B 478 (11.6) 2331 (51.8)
Total 4098 (99.4) 4470 (99.3)
Seph 4B - residual counts in sepharose 4B
TABLE 25 : Elution of Isoluminol labelled monoclonal
anti-HSVl IgG from an antigen coated sepharose 4B
column using pH.
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Despite the inhibitory effect of NaSCN on chemiluminescence, Table 26 shows that 1 M





Added 4150 (100.0) 3850 (100.0)
Unbound 3950 (95.0) 1560 (40.5)
10-6 100 (2.4) 180 (4.7)
10"3 45 (1.1) 680 (17.7)
1 0 (0.0) 600 (15.6)
2 0 (0.0) 0 (0.0)
3 0 (0.0) 0 (0.0)
4 0 (0.0) 0 (0.0)
Seph 4B 0 (0.0) 0 (0.0)
Total 4095 (98.5) 3020 (78.4)
Unacc 55 (1.5) 830 (21.6)
Unacc - chemiluminescence unaccounted for
Seph 4B - residual counts in sepharose 4B
TABLE 26 : Elution of Isoluminol labelled monoclonal
anti-HSVl IgG from an antigen coated sepharose 4B
column using NaSCN.
The IgG immunoblots showed that the bulk of the IgG was in this 1 M NaSCN eluant.
Thus successful elution of labelled IgG was achieved.
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D. Labelling and purification of human anti-HSVl IgG
The IgG content of the purified serum was 28 g/1. Sephadex chromatography of the
labelled antibody resulted in two peaks, the first of which showed IgG immunostaining
only, and contained chemiluminescent fractions. The specific activity of the isoluminol
labelled antibody was calculated at between 0.3 and 0.5.
Table 27 shows that pH eluted 4.8% of added chemiluminescence, with NaSCN eluting
no counts above background, and 8.1% of chemiluminescence unaccounted for. IgG
immunoblots, however showed that most of the IgG was in the 1 M to 4 M NaSCN





Added 16000 (100.0) 16000 (100.0)
Unbound 8540 (53.4) 6000 (37.5)
Tween 7140 (44.6) 7310 (45.7)
pH 2.7 135 (0.8) 764 (4.8)
NaSCN 0 (0.0) 0 (0.0)
Seph 4B 87 (0.5) 630 (3.9)
Total 15902 (99.3) 14704 (91.9)
Unacc 98 (0.7) 1396 (8.1)
Unacc - chemiluminescence unaccounted for
Seph 4B - residual counts in sepharose 4B
TABLE 27 : Elution of Isoluminol labelled human anti-HSVl
IgG from an antigen coated sepharose 4B column using pH
and NaSCN sequentially.
Thus the labelled IgG appeared to be of moderate to high affinity, and although there
was no chemiluminescence in the NaSCN eluants, one could presume that the missing




Four antibodies were labelled and immunological and chemiluminescent functions
assessed. Approximately 4-6% of labelled commercial antibody had immunological
activity against HSV1 of high affinity; only 0.15% of labelled alpha-T2 antibody had
immunoreactivity; labelled commercial monoclonal antibody contained at least 15%, and
possibly 50% high affinity antibody; human labelled antibody showed between 4 and
12% moderate to high affinity antibody.
Chaotropic agents active enough to dissociate antigen-antibody complexes destroyed
chemiluminescence and possibly immunoreactivity. NaSCN was the most effective
chaotrope, but destroyed chemiluminescence at concentrations above 0.1 M. pH and
NaCl were both less effective, but did not interfere with chemiluminescence if
appropriate measures were taken with the former method. Affinity purification overall
conferred no advantage over unpurified labelled antibody as a result. Labelling of the
antibody also reduced the immunoreactivity considerably in some cases, presumably due
to steric hindrance, partially explaining the low yields. Each antibody, therefore, had to
be assessed fully, as prediction of outcome was difficult. The monoclonal antibody
appeared to give the best yield of active labelled antibody of high affinity, and the
highest specific activity of those 3 antibodies where this was assessed.
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CHAPTER 8: CHOICE OF SOLID PHASE FOR THE ASSAY SYSTEM
In this chapter, 3 different solid phases were examined for suitability in a sandwich
assay: Sepharose 4B, 5mm Polystyrene balls and polyvinyl microtitre plates (ELISA
plates). The assays were performed initially using isoluminol labelled antibodies
prepared in the previous sections, but as will be seen, and for reasons that will become
apparent, luminol based chemiluminescence using HRP conjugates was reintroduced.
1. Materials and methods
A. Sepharose 4B as solid phase
i) Sandwich assay using alpha-T2 coupled sepharose 4B
IgG purified alpha-T2 antibody was coupled to sepharose 4B as in chapter 6. This
choice of captor antibody was made because preliminary immunoblotting studies had
shown this to contain the largest amount of high affinity anti-HSY1 antibody, next to the
commercial monoclonal. 100 ul of the gel was incubated with 10 ul of 1:20, 1:220 and
1:2420 dilutions in PBS ofHSY1 Kos pre-treated with 8M urea/1% triton X100 (U/T)
(to expose epitopes for the detector antibody), or similarly treated measles antigen
(Behring diagnostics, Hoescht UK Ltd., Hounslow, Middsx.) as control. Following
incubation for 30 min at RT, gels were washed x 5 with PBS, then 10 ul of isoluminol
labelled monoclonal anti-HSVl IgG in 500ul PBS was incubated for 30 min at RT. The
gels were washed x 5 in PBS, then 0.05% Tween 20 in PBS, the washings and the gels
being counted using standard chemiluminescence reagents.
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The lowest limit of detection (sensitivity) of the assay was taken as being when the HSV
average counts of duplicate analyses failed to exceed the means of either the control or
background counts by more than 2 SD of these values. The dilution immediately above
this was taken as the limit.
Background cross reactivity between the rabbit and mouse antibodies and the mechanical
effect of entrapment within the gel was established by incubating a range of amounts of
the labelled monoclonal with 100 ul of gel for 40 min at RT, washing with PBS and
Tween 20 as before and counting the gel.
ii) Effect of sepharose on light output
Mechanical interference in the light detection by the luminometer due to the sepharose
gel was examined by mixing 100 ul gel with 100 ul of the isoluminol base at 1:10 6 or
1:10"5 dilutions in PBS or 10 ul of labelled monoclonal antibody, counting using standard
reagents, and comparing with the chemiluminescence without the gel.
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B. Polystyrene balls as solid phase
Several combinations of antibodies examined in previous sections were used, initially
isoluminol labelled, but then luminol chemiluminescence was introduced, and a new set
of antibodies was examined. Polystyrene balls, 5 mm diameter, were found to fit in the
reaction cuvettes neatly, and the balls were later modified by coating with
poly-phenyllysine and protein A to improve antibody binding.
i) Sandwich assay using isoluminol labelled antibodies
a) Coating balls with captor antibody
The method of ball coating was adapted from Wood et al [282], All subsequent coating
methods followed this, with minor modifications. 100 5mm polystyrene balls
(Euro-matic Ltd, London, England) were mixed by intermittent agitation with 0.3 mg of
purified alpha-Tl or 0.3 mg commercial monoclonal anti-HSVl IgG in 12.5 ml 0.05 M
carbonate buffer pH 9.5 at 4°C for 108 hr. The unbound sites were blocked by adding 1
ml of 20 mg/ml albumin, mixing for 24 hr at 4°C and adding a spatula tip of
tris(hydroxymethyl)aminomethane buffer (tris; Sigma, Poole, Dorset) and mixing for a
further 24 hr at 4°C. The excess was washed off with 0.15 M NaCl in a continuous flow,
then distilled water, before drying in a stream of compressed air and storing in an airtight
container at 4°C before use.
A rough indication of the success of protein uptake was made by incubating coated balls
with goat anti-rabbit IgG HRP conjugate or rabbit anti-mouse IgG HRP conjugate
(Atlantic antibodies, Winnersh, Berks.) 500 ul 1:2500 dilution in PBS, in 60 well
macrotitre plates (Abbott laboratories, North Chicago, Illinois) pre blocked with 1%
gelatin (Sigma, Poole, Dorset)/l% albumin for 1 hr. The balls were washed with a
Pentawash II automated ball washer (Abbott laboratories, North Chicago, Illinois), and
200 ul 10 mg ortho-phenylenediamine (OPD) (Sigma, Poole, Dorset) in 10 ml 0.1 M
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PBS pH 6 activated with 10 ul neat H202 added to each well. The reaction was
terminated by the addition of 200 ul 1 M H2S04. Balls were removed and the colour
assessed on a visual scale (later studies were assessed spectrophotometrically).
b) Sandwich assay
Alpha-Tl or monoclonal antibody coated balls were incubated with 500 ul of 10-fold
dilutions of U/T disrupted HSV Kos or measles antigen in macrotitre wells for 1 hr at
RT. After washing as above, 500 ul of 1:50 dilution of isoluminol labelled monoclonal
or alpha-T2 antibody was added for 1 hr, the balls washed, transferred to reaction
cuvettes, and chemiluminescence initiated with standard reagents.
ii) Sandwich assay using luminol based chemiluminescence
a) Re-evaluation of luminol chemiluminescence
Preliminary attempts at a sandwich assay were unsuccessful, mainly due to the high
background and unpredictable kinetics of the luminol spike described in chapter 6. The
effect of light and temperature had previously been examined, replacement with fresh
reagents did not influence the reaction, but the effect of blocking agents, the mechanical
influence of the ball and the use of 0.33 M NaOH in the on chemiluminescence had
not been examined.
Standard iodophenol enhanced luminol chemiluminescence was set up with a constant
1:4000 dilution goat anti-rabbit IgG HRP conjugate used as catalyst. Concentrations of
albumin and gelatin from 0 - 0.05% were included, reactions with and without the ball
were performed, and chemiluminescence initiated with and without NaOH in the H202.
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b) Sandwich assay
Macrotitre wells were blocked with 1% gelatin in PBS for 2 hr at RT, washed, then
alpha-Tl coated balls incubated overnight at 4°C in 400 ul of 1:2000 - 1:128000
dilutions ofU/T treated HSV Kos or measles in PBS. After washing, 450 ul of 1:500
commercial monoclonal in 0.1% gelatin in PBS was incubated for 1 hr at RT, washed
with 0.1% tween 20/PBS then H20, 450 ul 1:500 affinity purified rabbit anti-mouse IgG
HRP conjugate was incubated for 1 hr at RT, washed as before, then the balls read in the
luminometer with 400 ul PBS, 20 ul 1:10 purified luminol, 20 ul 1:2 iodophenol and 50
ul H202 in H20, and counts integrated over 120 s.
Stability of the balls used in the assay was investigated by repeating the 1:5000 antigen
incubation with the same batch of balls over a 2 week period, using fresh luminescence
reagents each time.
iii) Poly-phenyllysine coating of balls
a) Ball coating
Poly-phenyllysine (PPL) covalently binds protein to polystyrene, and its use was hoped
to improve the stability of the protein bound balls.The method of coating was taken from
Wood et al. [282], 2.5 mg PPL (Sigma, Poole, Dorset) was dissolved in 125 ml double
distilled H20 and enough to cover 100 balls used to coat with frequent agitation at RT
overnight. 250 ul of 250 g/1 glutaraldehyde in 15 ml H20 was incubated for 40 min to
activate the PPL, the balls washed, then protein coating with alpha-Tl took place as
before (section B i) with gelatin substituted for albumin.
A rough assessment of protein uptake was also made as before (section B i), but using
affinity purified goat anti-rabbit IgG HRP conjugate, and with the transference of 50 ul
of the final colour product to a Dynatech ELISA plate reader (Dynatech laboratories
Ltd., Billingshurst, Sussex) and reading at 425 nm..
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b) Sandwich assay
The sandwich assay for HSV1 and measles was identical to section B ii, except antibody
dilutions were 1:800 not 1:500, and the range of antigen dilutions was 1:4,000 -
1:32,000.
iv) Protein A as a surface binding agent
Protein A has been reported to enhance binding of IgG to surfaces and reduce inter-assay
variability in similar systems [222]. The optimisation of coating with Protein A depends
on the IgG coating concentration and has to be worked out empirically. Protein A
coating would also improve the capture efficiency of the system by aligning the IgG
molecule Fab portion 'upwards'. Because of the unsatisfactory results from the previous
antibodies, a new range of antibodies was evaluated. A breakdown in the luminometer
meant that many of the experiments relied upon conventional colorimetric analysis, but
this later proved to be a more convenient screening tool, since large numbers of samples
could be analysed it one time, rather than the sequential analysis required by the
luminometer.
a) Optimisation of Protein A and IgG coating
Polystyrene balls were coated with Protein A (Seralab, Crawley Down, Sussex) by
incubating with an appropriate amount in 50 ml 0.05 M carbonate buffer pH 9.5 at RT
overnight to give a ball coating of 0.1 ug, 0.25 ug or 1.0 ug per ball. After washing, the
balls were then coated as before (section B i) with human anti-HSV1 IgG to give a ball
coating of 1 ul, 3 ul or 10 ul per ball (lOug, 30 ug or 100 ug), available protein A sites
were saturated with normal human serum and unoccupied protein binding sites blocked
as before but with gelatin in place of albumin.
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IgG uptake was assessed by incubating the balls with goat anti-human IgG Fab specific,
150 ul of 1:1000 dilution in PBS for 1 hr at RT, then 150 ul rabbit anti-goat IgG HRP
conjugate, 1:1000 in PBS, before visualisation with OPD as before and 100 ul of the
solution transferred to the plate reader.
Effectiveness of antigen capture was examined by incubating the Protein A/IgG coated
balls with 200 ul U/T treated HSV Kos or measles virus 1:100 in PBS for 3 hr at RT,
washed as standard. The detector antibody was a rabbit R38/5 polyclonal IgG against
nearly all HSY1 proteins (gifted by Dr. David Meredith from Leeds University), 150 ul
at 1:1000 in PBS for 1 hr, and after washing 150 ul of 1:1000 in PBS goat anti-rabbit Fab
fragment HRP conjugate (Sigma, Poole, Dorset) incubated for 1 hr at RT, then visualised
with OPD and 100 ul read in a plate reader.
Reduction in background noise was attempted by incorporating 0.1% gelatin blocker in
all the antibody stages and using ethylenediaminetetra-acetic acid disodium salt (EDTA)
(Sigma, Poole, Dorset) at a variety of concentrations in the detector antibody incubation
to reduce non-specific binding.
b) Sandwich assay
The sandwich assay was performed as above (section B iv a), using 0.1 ug/ball protein A
coating, the 3 IgG coatings, 1:1000 - 1:50,000 U/T treated HSV Kos or measles, 0.1%
gelatin in the incubation mixes, and 0.1 mM EDTA in the detector antibody. OPD
staining was stopped at 10 min by 2 M HC1. The assay was repeated with the same
batch of balls over a 6 week period to assess stability. In addition 3 new rabbit
anti-HSVl antibodies and a mouse monoclonal antibody were introduced into the assay
system as both captors and detectors: rabbit 205/5 IgG polyclonal against non-envelope
structural proteins and 220/3 IgG polyclonal against late protein VP 13/14 (ICP 22), both
gifted by Dr. David Meredith from Leeds University), rabbit 50/4 IgG polyclonal against
Page 172
alkaline nuclease and mouse monoclonal IgG Q2 against alkaline nuclease, both gifted
by Dr. Ken Powell of Wellcome Research Laboratories. The appropriate normal serum
was used to saturate the protein A sites in each batch.
v) Polyphenyl lysine and Protein A coating of balls
a) Optimisation and sandwich assay
Since PPL gave stability to protein coating, and protein A improved antibody coating,
combining the two was assessed in the sandwich assay. Coating procedures took place
as described above for both PPL (section B iii) and protein A (section B iv) using the 3
coating amounts for each, and all the antibodies used above as captor. A fixed 1:100
dilution U/T HSV Kos or measles virus was used to compare assays, with the
appropriate species antibody as detector, and HRP Fab fragment conjugates as final
antibody, goat anti-rabbit, sheep anti-mouse (Sigma,Poole, Dorset), or goat anti-human
(Sigma, Poole, Dorset). OPD staining , neutralisation and reading was as before.
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C. Microtitre (ELISA) plates as solid phase
i) Optimisation of reagents
The detector portion of the assay was first to be optimised. At the time of these
experiments, only the early anti-HSVl antibodies were available, but in the next chapter
the full range were investigated.
96 well microtitre plates (Falcon 3912 microtest III, Becton Dickson Labware, Oxnard,
California) were coated with 50 ul U/T treated HSV or measles antigen diluted in PBS
from 1:100 to 1:10,000 for 2 hr at RT. Wells were then blocked with either 2% gelatin,
1% gelatin, 1% albumin, 1% casein, or an equimolar mixture of 1% gelatin and
l%albumin, or 1% gelatin and 1% casein in PBS for 1 hr at RT, the plates washed with
0.1% blocker in PBS with a final H20 wash, then incubated with 50 ul 1:100 to 1:1000
dilutions in 0.1% blocker in PBS of commercial rabbit anti-HSVl, commercial mouse
monoclonal or alpha-Tl for 1 hr at RT. After washing as before, a final incubation with
50 ul 1:500 to 1:5,000 in 0.1% blocker in PBS of non-affinity purified goat anti-rabbit
IgG HRP conjugate or rabbit anti-mouse IgG HRP conjugate (Atlantic antibodies,
Winnersh, Berks.), or affinity purified sheep anti-mouse IgG Fab fragment HRP
conjugate (Sigma, Poole, Dorset) or goat anti-rabbit IgG Fab fragment HRP conjugate
(Sigma, Poole, Dorset) for 1 hr at RT, washed again, then OPD added, neutralised after
20 min with 2 M HC1 and read in the Dynatech plate reader.
ii) Sandwich assay comparison of colorimetric and chemiluminometric detection
50 ul of 1:50 dilution of alpha-Tl in 0.05 m carbonate buffer pH 9.6 was incubated in
each well of a microtitre plate at 4°C overnight.Wells were then blocked with 150 ul 1%
gelatin in PBS, washed with 0.1% gelatin in PBS then H20 and duplicate wells
incubated with serial dilutions ofU/T HSV or measles in 1% gelatin in PBS for 1 hr at
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RT. After washing 50 ul 1:50 in 1% gelatin in PBS mouse monoclonal was incubated
for 1 hr at RT, washed,then 1:1000 rabbit anti-mouse IgG HRP in 1% gelatin in PBS
incubated for 1 hr at RT, washed, then either colorimetric or chemiluminometric analysis
standard reagents added. The wells for chemiluminescence were cut from the plate and
placed into the reaction cuvettes, where the feasibility of using such wells had already
been established without any reduction in light output from mechanical interference.
Wells so examined were kept on ice until read.
The optical density and chemiluminescence counts were corrected for background +2SD,
and plotted against the plaque forming units (PFU) content of the dilutions. The average of
three duplicate wells for each dilution was calculated. If one value differed by more than
50% of the mean of the other two it was discarded.
In the subsequent text, figures and tables, where PFU is given, it is to be read as equivalent
to 10~2 infected cell products (ICP) i.e. 1ICP = 102 PFU.
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2. Results
A. Sepharose 4B as solid phase
i) Sandwich assay using alpha-T2 coupled sepharose 4B
The gel reduced light detection by between 25-47%, presumably through quenching, but
this effect would act equally on control and test specimens. Cross-reactivity between the
labelled mouse monoclonal and the rabbit antisera coated gel was less than 0.5% for all
concentrations of labelled antibody.
Figure 13 shows that sensitivity of the sandwich assay was poor at only 1:220 dilution of
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Figure 13 : Sensitivity of sepharose 4B
Isoluminol based antigen capture assay
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B. Polystyrene balls as solid phase
i) Sandwich assay using isoluminol labelled antibodies
Significant antibody coating of the balls was confirmed by OPD staining for both
alpha-Tl and mouse monoclonal antibodies.
The sandwich assay showed very poor sensitivity with only a 1:100 dilution of HSV Kos
(5 x 107 PFU) being detected by alpha-Tl captor, and no significant detection when the
monoclonal antibody was the captor. However background binding was low in this
system.
ii) Sandwich assay using luminol based chemiluminescence
a) Re-evaluation of luminol chemiluminescence
Albumin inhibited chemiluminescence by >50%, even at 0.005% concentrations,
whereas gelatin resulted in only 7% inhibition at the same concentrations. The
mechanical interference by the ball resulted in between 30-40% reduction in light
detection.
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Figure 14 shows, however that the major cause of the poor performance of luminol was
the presence of NaOH in the Removal resulted in abolition of the initial spike,
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Figure 14 : Effect of NaOH on the kinetics of p-Iodophenol enhanced
Luminol chemiluminescence
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Figure 15 : Sensitivity of polystyrene
ball Luminol based antigen capture assay
b) Sandwich assay
Figure 15 shows that the assay sensitivity was improved considerably, with a 1; 128000
dilution of HSV Kos detected (3 x 104 PFU). The cross reactivity with measles was low,
and only the maximum concentration of measles exceeded the any of the HSV Kos
results. The use of affinity purified HRP conjugates reduced the background levels
considerably.
The assay was, however, unstable, with the complete loss of sensitivity by 2 weeks, and
the HSVmeasles counts reduced to 1.1 for the 1:5000 antigen dilution.
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iii) Poly-phenyllysine coated balls sandwich assay
PPL improved the coating with IgG by 25%, but the sandwich assay was a failure with
only a 1:4000 dilution ofHSV Kos detected (106 PFU), mainly because of a huge
increase in background counts.The assay results were repeatable over a 2 week period,
so although PPL did improve stability, it reduced sensitivity 30-fold.
iv) Protein A coated balls sandwich assay
The optimum protein A coating was 0.1 ug per ball, and the optimum IgG coating for
maximal IgG uptake was 1 ul (10 ug). The optimum HSV antigen capture at 1:100
dilution of antigen was achieved by the 0.1 ug protein A/10 ug IgG coated ball.
Incorporation of 0.1% gelatin blocker into all incubations, and the use of 0.1 mM EDTA
in the detector antibody incubation, reduced background by 58% and 10% respectively
for the optimum ball coating.
The best assay combination, which was unexpectedly the 30 ug/ball human IgG coating,
produced a sensitivity of only 1:10,000 HSV Kos (4 x 105 PFU). All other protein A and
antibody coating concentrations, for all the other appropriate combinations of captor and
detector antibodies used failed to give a sensitivity above 1:1000 HSV Kos (4 x 106
PFU). Repeat assays with the best assay over 6 weeks saw a complete loss of sensitivity.
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v) Poly-phenyllysine and protein A coated balls sandwich assay
Only 0.25 ug protein A with 10 ug human IgG or 30 ug rabbit 205/5 were successful in
capturing HSV Kos at 1:100 dilution. All other combinations gave negative results. The
human IgG gave a 1:1000 sensitivity finally (4 X 106 PFU), but the 205/5 could not
improve on 1:100. The background counts were again all high accounting for much of
this poor sensitivity.
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C. Microtitre (ELISA) plates as solid phase
i) Optimisation of reagents
1% gelatin blocking gave the lowest background counts of the 6 blocking mixtures. The
best signal to noise for detector antibodies was obtained with 1:500 dilutions of the
alpha-Tl and monoclonal, and 1:1000 dilution of commercial antibody. The non-affinity
purified anti-mouse HRP conjugate gave better results than the affinity purified Fab
fragment HRP conjugate, and 1:500 dilution was optimum. The affinity purified Fab
fragment anti-rabbit HRP conjugate was better than the non purified HRP conjugate, and
1:1000 dilution was optimum. Overall the best combination for signaknoise was the
alpha-Tl detector and affinity purified Fab fragment HRP conjugate which also had the
best sensitivity of 1:10,000 antigen bound to the plate. However the monoclonal
antibody gave the lowest and cleanest background signal. In the sandwich assay, the
alpha-Tl was thus used as the captor, and the monoclonal as the detector.
ii) Sandwich assay comparison of colorimetric and chemiluminometric detection
Figure 16 shows that, using alpha-Tl as captor and commercial monoclonal as detector,
both methods were relatively insensitive, with the colorimetric particularly giving a poor
slope, due in part to high background counts. Chemiluminescence achieved a sensitivity
of 1:20,000 dilution of HSV Kos, or 2.5 x 104 PFU, and colorimetry 1:10,000 dilution, or
5 x 104 PFU, although the curves were irregular and somewhat inconsistent.
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OPD 1 Luminol
Figure 16 : Comparison of colorimetric
and chemiluminometric detection of HSV
using alpha—T1 captor, Q2 detector
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3. Discussion
Sepharose was difficult to handle, required multiple wash-centrifugation steps, and so
was time consuming and only limited numbers of assays could be performed
concurrently. The coupling of antibody was efficient, but again was time consuming,
although the stability of the gel was good. The assay was not sensitive enough using
isoluminol labelled antisera, although it must be pointed out that luminol luminescence
was not attempted with sepharose and the range of antibodies available at the time of
these experiments was limited.
Polystyrene balls were much easier to handle, especially with the automated ballwasher,
but sample volumes would have had to have been adjusted to a minimum of 200 ul and
preferably 400 ul for effective ball coverage, thus introducing a further dilution step.
Despite the promise offered by coating the balls with protein A and PPL the assay results
were much worse than untreated balls, although the instability of the latter made what
initially looked to be the most promising assay unsuitable. The failure of protein A lay
partly in the difficulty in blocking all the unbound sites after the initial captor antibody
binding, since steric hindrance occurred if the coating concentration was too high, and
detector antibody binding took place if the concentration was too low. The breakdown
of the luminometer meant that strictly accurate comparisons could not be made using
protein A and PPL with other assays based on chemiluminescence, but as was seen with
the ELISA plate based assay, the colorimetric analysis had similar sensitivity. The
failure of PPL to improve the assay was unexpected, since it did improve stability of the
protein binding. Mechanical interference had an effect greater than that seen with
sepharose, and thus reduced sensitivity.
Page 184
Luminol chemiluminescence was found to have been undervalued in the previous
chapters because of the adverse effect of NaOH on the light kinetics. It was likely that
the NaOH was generating free O" and so initiating the spike which was independent of
the HRP catalysed O" production. Enhancement with iodophenol was returned to the
levels expected, and resulted in a 1000-fold improvement in sensitivity of the assay.
Microtitre plates were easy to handle, coped with multiple assays in parallel, and the
wells did not interfere with light detection when individual wells were cut out and placed
in the reaction cuvettes. Although the assessment of antibodies was limited to only a
few, the resulting sensitivity was equal to that seen with the polystyrene balls, and
chemiluminescence achieved slightly better sensitivity than colorimetric detection.
Table 28 summarises the sensitivities achieved by the different assay systems. Overall,
the microtitre based system offered the greatest promise, so the further development of
the assay was based on this as a solid phase.
Solid Phase Detector Sensitivity
system (PFU)
Sepharose 4B gel Isoluminol 5 X 105
Polystyrene ball Isoluminol 5 X 107
Luminol 3 X 104
+PPL OPD 1 X 106
+P-A OPD 4 X 105
+PPL,P-A OPD 4 X 106
Microtitre plate OPD 5 X 104
Luminol 2.5 X 104
P-A - protein A
TABLE 28 : Comparison of HSV1 assay sensitivities
using different solid phases and detector systems
Page 185
CHAPTER 9: OPTIMISATION OF THE MICROTITRE PLATE
BASED CAPTURE ASSAY
This chapter describes further the sandwich assay based on the microtitre plate using
antibodies not previously assessed using this solid phase. The assay conditions were
optimised, and a detachable well suitable for chemiluminometry was introduced. The
comparison between colorimetric and chemiluminometric detection was made after
initial work based on colorimetry, because of the ease of screening using this method.
1. Materials and methods
A. Optimum captor-detector combination
i) Monoclonal Q anti-alkaline nuclease as captor
Mouse monoclonal Q2 (Q2) against HSV alkaline nuclease was initially used in
conjunction with 50/4 rabbit polyclonal (50/4) against the same alkaline nuclease. As
mentioned in chapter 4 of the introduction, alkaline nuclease is one of the most abundant
polypeptides produced during active replication of HSV, and results from transcription
by B-genes in the second phase of viral replication. When 50/4 was used as the captor,
the results were poor, so the assay was reversed, and in addition, the human and rabbit
polyclonal antisera introduced to compare.
The microtitre plate assay conditions were set as finally achieved in chapter 8, with the
following modifications. The coating concentration of Q2 was optimised at 1:1000
dilution.The incubation of Q2 was overnight at 4°C, first blocking was for 3 hr at RT.
HSV Kos was treated by either sonication or 0.1% tween 20 (as preliminary experiments
showed that U/T destroyed immunoreactivity of the relevant epitopes), and measles virus
and vero cells (cells uninfected by HSV Kos, gifted by Dr. Robert Honess) were used as
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controls and similarly treated. Antigens were diluted 10-fold and incubation was for 2 hr
at 45°C, and detector antibodies 50/4 and R38/5 were optimised at a dilution of 1:400,
human anti-HSVl IgG at 1:100. The HRP conjugates were affinity purified Fab
fragment antibodies, and the dilutions optimised at 1:1000. The OPD reaction was
terminated at 30 min.
All assays were done in triplicate, the average readings taken, and if one value differed
by more than 50% from the mean of the other two, it was discarded. The resulting
optical densities were plotted as the ratio of the HSV:control value. The control values
for measles virus were identical to those for vero cells, so in all later experiments vero
cells alone were used as controls, with the advantage that the relevant dilutions could be
exactly matched to HSV Kos. The blank value was the average of 10 readings, and
cutoff was set at +- 2SD. Ratios below 1.25 were judged to be negative.
ii) R38/5, 205/5, 220/3 and human anti-HSVl IgG as captors
Methods were as above, with antigen 0.1% tween 20 treated, and with antibody dilutions
modified to those detailed by experimentation:
R38/5 when captor was used at 1:500 dilution, detectors Q2 1:1000 and human IgG at
1:500;
205/5 when captor used at 1:500 dilution, detector human IgG at 1:1000;
220/3 when captor used at 1:1000 dilution, detector human IgG at 1:1000;
Human IgG when captor used at 1:1000 dilution, detectors 50/4, 220/3 at 1:400, R38/5,
205/5 at 1:1000 and Q2 at 1:2000.
HRP conjugates were all affinity purified Fab fragment antibodies, except when Q2 was
a detector, when the non purified conjugate was used.
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B. Use of Immulon detachable wells
Immulon I removawell strips (Dynatech Laboratories, Billingshurst, Sussex) are
detachable microwells with a precoating of a polymer for covalent binding of proteins.
The convenience of easy handling and correct size for the reaction cuvettes made them
the ideal choice for the chemiluminometric assay.
i) Comparison of Immulon wells with microtitre plates
The assay was run using Immulon wells and microtitre plates in parallel using the
materials and methods optimised in section A, but as the Immulon wells were larger
volume, 350 ul blocker was needed. Test: control ratios were plotted as before.
ii) Comparison of colorimetric and chemiluminometric detection
The assay was run as optimised on microtitre plates and duplicated on Immulon wells.
One set of the Immulon wells to be used in the luminometer were kept on ice after the
HRP incubation until read using standard iodophenol enhanced chemiluminescence. The
other set and the microtitre plate were conventionally assayed with OPD. Signaknoise
ratios were then plotted.
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2. Results
A. Optimum captor-detector combination
i) Monoclonal Q2 as captor
Figure 17 shows that Q2 captor and 50/4 detector had the best sensitivity at 1:106
dilution of 0.1% tween treated HSV Kos (20 PFU). Without Tween 20 the assay was
less sensitive, by a factor of 10, presumably because Tween 20 was required to disrupt
the intact cells and virions. Figure 18 shows the other detector antibodies were not as
sensitive, with only 205/5 and R38/5 just achieving 1:105 detection (200 PFU).
Background counts were not as low as in preliminary experiments, because of the altered
conditions of incubation to achieve higher sensitivity.
ii) Other antibodies as captors
Figures 19 to 21 show the results from the other antibody combinations. None achieved
the sensitivity of Q2 and 50/4 combination, with the best being R38/5 captor and human
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Figure 17 : HSV colorimetric sandwich
assay with Q2 captor, 50/4 detector.
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Log HSV PFU
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Figure 18 : HSV colorimetric sandwich
assay using Q2 captor, and detectors






Figure 19 : HSV colorimetric sandwich
assay with R38/5 captor, Q2 and Human
antisera detector
TestiControl ratio
— 50/4 -+- 220/3 R38/5 Q2 205/5
Figure 20 : HSV colorimetric sandwich
assay with human antiserum captor, 50/4




205/5 + human 1 220/3 + human
Figure 21 : HSV colorimetric sandwich
assay with 205/5 or 220/3 captors,
human antiserum detector
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B. Use of Immulon detachable wells
i) Comparison of Immulon wells with microtitre plates
Figure 22 shows that using the colorimetric assay the Immulon wells performed as well
as the microtitre plates in sensitivity, with an almost identical curve profile and a lower
background.
ii) Comparison of colorimetric and chemiluminometric detection
Figure 23 shows that chemiluminescence was no more sensitive than OPD, although at
higher HSV Kos concentrations, the signaknoise ratio was much better using
chemiluminescence.
The latter experiments and figures show an apparent loss of sensitivity in the assay, as a
result of a flattening of the curve. This was subsequently found to be due to destruction
of the alkaline nuclease in the calibrant HSV Kos from prolonged incubation in Tween
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Figure 22 : Comparison of colorimetric
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Figure 23 : Comparison of colorimetric




Q2 mouse monoclonal anti-alkaline nuclease and rabbit polyclonal anti-alkaline nuclease
were the most sensitive combination, able to detect 20 PFU of HSV. This paradoxical
superiority of a monoclonal capture system probably reflected the 'cleanness' of the
antibody, and because the polyclonal had other epitopes to link with there was no
interference with binding which obviously took place when the assay was reversed. No
other antibody combination achieved this sensitivity. Prolonged incubation beyond 2 hr
for antigen did not result in better sensitivity, but raising the incubation temperature did,
even though background was increased as a result. Measles virus in this assay gave the
same counts as the vero cell control, which were at or near the background, again
reflecting the specificity of the monoclonal, and the use of affinity purified Fab fragment
HRP conjugate. For the remainder of the experiments vero cell controls alone were
used. Gelatin blocker was, fortuitously for chemiluminescence, the most efficient.
The performance of chemiluminescence was a major disappointment. The sensitivity in
the assay was no better than colorimetric analysis, and the mechanics of luminometry far
more time consuming and prone to external influence. So saying, the colorimetric assay
was extremely sensitive and it would have been more than one could reasonably expect
to improve upon it. Chemiluminescence was thus abandoned in favour of colorimetric
detection.
The requirement for Tween 20 pre-treatment of antigen to access the alkaline nuclease
would hopefully not be required in the working assay, as necrotic tissue would release
large amounts of non cellular or virion associated protein. This assumption could only
be tested by running the assay on human specimens, and its validity would be apparent if
the results were negative.
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CHAPTER 10: DISSOCIATION OF ANTIGEN-ANTIBODY
IMMUNE COMPLEXES
In chapter 2 it was proposed that part of the reason for the difficulty in the detection of
antigen in CSF and the failure of culture of viruses from CSF was the result of immune
complex formation. A variety of ways of dissociating antigen from antibody have
already been described in Chapters 6 and 7 of this materials, methods and results section,
and acid elution was found to be effective, without necessarily destroying antibody.
Whether antigenicity of the viral epitopes was retained was not evaluated.
Acid dissociation of immune complexes in serum for HIV 1 antigen detection has been
incorporated into standard assays [266], so the next experiments were designed to see if
this could be done with HSV antigen-antibody complexes created in vitro. Initially, acid
elution was performed as described, then subsequently modified.
1. Materials and methods
A. Use of HC1 to dissociate antibody from bound antigen
By coating microtitre plates with HSV, immune complexes could be generated by the
addition of anti-HSVl antibodies. The effect of acid on dissociation, and the retention of
the antigenicity of the bound HSV was examined in this section. First, the effect of acid
on a protein coated plate was examined.
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i) Resistance of bound protein to acid removal
Duplicate wells of microtitre plates were coated with 10-fold dilutions of 50 ul goat
anti-human IgG (Fc specific) (Atlantic antibodies, Winnersh, Berks.) in 0.1% gelatin in
PBS for 1 hr at RT. 50 ul of 0.5 M HC1 was applied to one set of wells for 90 min at RT,
then washed; one set had no acid applied and one set no coating antibody or acid. 50 ul
1:1000 dilution in 0.1% gelatin in PBS of rabbit anti-goat IgG HRP conjugate was added
for 30 min to all wells, washed, then stained with OPD as standard and read in the plate
reader.
ii) Dissociation of antibody from bound antigen
50 ul of 1:50 dilution HSY Kos in 0.05 M carbonate buffer pH 9.6 was used to coat
overnight each well of a microtitre plate. Wells were then blocked with 1% gelatin in
PBS, and after washing 50 ul of 10-fold dilutions of human anti-HSVl IgG in 0.1%
gelatin in PBS were incubated in duplicate wells for 90 min at RT. After washing, 50 ul
0.5 M HC1 was added for 90 min to one set of wells, the other set left in 0.1% gelatin,
then both washed. 50 ul of 1:1000 rabbit anti-human IgG HRP conjugate (Dako, High
Wycombe, Bucks.) in 0.1% gelatin in PBS was added to each well and incubated for 1 hr
at RT, then the wells were washed, stained with OPD as standard and read in a plate
reader.
iii) Retention of antigenicity after acid treatment
Methods were as for section ii), with the exception that the human anti-HSV IgG was
reapplied at the same dilution after acid treatment, and 0.1 M HC1 was compared with
0.5 M. To ensure that the antibody was removed, not inactivated, 10-fold dilutions of
HSV Kos were applied to wells, and a single 1:1000 dilution of human anti-HSVl IgG
added, to ensure that at some stage antibody was in excess. 0.1 M HC1 only was used.
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B. Sandwich assay to detect antigen dissociated from immune complexes
Arbitrary amounts of antigen and antibody were incubated together to form complexes.
With antigen in excess, little change would be seen after acid dissociation, but with
antibody in excess, despite competition with antibody bound to the plate for free antigen,
any change after acid treatment would indicate successful disruption of antigenically
active epitopes.
i) Assay of dissociated antigen
200 ul of 1:1000 or 1:10,000 dilutions of HSV Kos in 0.05 M PBS were incubated with
200 ul of human anti-HSVl IgG at 1:100, 1:1000 and 1:10,000 dilutions in PBS for 1 hr
at RT. 100 ul of the mixture was then treated with 25 ul 0.5 M HC1 (making final
concentration HC1 0.1 M) at RT for 90 min, then neutralised with exactly 25 ul of 0.5 M
NaOH and made up to 200 ul with H20, so the final dilution was 1:2. Controls without
antibody added or acid incubation were also diluted 1:2. Samples were added to the
standard Q2 captor, 50/4 detector assay system as soon as possible after neutralisation to
prevent undue reformation of immune complexes, then the assay run as standard.
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2. Results
A. Use of HC1 to dissociate antibody from bound antigen
O.D.
Log Reciprocal IgG din
' Pre—acid 1 Post-acid * Blank
Figure 24 : Effect of 0.5 M HC1 on IgG
bound to microtitre well
Figure 24 shows that acid treatment made no difference to the to the amount of IgG
coating the well, with identical calibration curves, and since the higher antibody
dilutions gave lower O.D. readings than the controls with only the HRP conjugate added,
no protein was being stripped from the wells.
Figure 25 shows that acid treatment successfully reduced the O.D. readings for each
antibody dilution added to the fixed dilution of bound antigen, suggesting that the
antibody was either eluted, the Fc portion rendered unrecognisable without dissociation,
or the antigen rendered unrecognisable. The re-application of the first antibody restored
the O.D. to pre-acid treatment levels, indicating that the HSV antigen was not destroyed
or inactivated, and that the antibody was not inactivated, but eluted. However this
experiment did not take into account the possibility that antigen may have been in such
excess that second application of antibody was merely binding to previously unoccupied
sites. Figure 26 shows that using a range of antigen concentrations and a fixed antibody
concentration, even at great antibody excess, acid dissociated immune complexes, then
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re-application of antibody resulted in a return to the previous O.D. levels, and not
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Figure 25 : Dissociation of Ab from Ag
bound to microtitre well using 0.5 M HCI
and retention of antigenicity
O.D.
Log Reciprocal HSV dilution
"
Pre—acid 1 Post acid * Post—acid + antibody
Figure 26 : Dissociation of Ab from Ag
dilutions bound to microtitre wells with
0.1 M HCI and retention of antigenicity
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Figure 27 : Sandwich assay of 1:1000 HSV
complexed with antibody dilutions before
and after dissociation with 0.1 M HC1
Figure 27 shows that there was recovery of antigen from immune complexing between
the 1:1000 dilution of antigen and 1:1000 and 1:10,000 dilutions of antibody. Recovery
was low, at best being 14% of the bound antigen.
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3. Discussion
The use of acid to dissociate immune complexed HSV Kos with human anti-HSVl IgG
was shown to be possible, and to leave the epitopes recognisable by the same antisera.
The use of 0.1 M HC1 was as effective as 0.5 M HC1. The low yield of recovered
antigen may still indicate irreversible damage to the viral epitopes, or the failure to
separate antibody of high affinity from the antigen. In any case having established the
principle, the next stage was to assay the human CSF samples.
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CHAPTER 11: CSF ANTIGEN ASSAY FROM PATIENTS WITH HSVE
1. Materials and methods
A. Patients
In the standard assay the following patients were studied:
12 CSF samples from 9 patients with definite HSVE were obtained from in patients at
the National Hospitals for Nervous Diseases, and direct referrals from local hospitals in
the region. Although initially promised samples held in a specimen library at the
virology department of the University of Manchester, permission to use them was
refused at a later date. Clinical and laboratory details of these patients is given in
appendix 1. Only one patient had isolation of virus from CSF, none underwent brain
biopsy, but the remaining 8 fulfilled the immunological criteria by having paired sera
and CSF showing rising titres and local synthesis of specific IgG, although some had the
diagnoses based on samples not available for this study.
A total of 35 control patients were used, all in-patients at the National Hospitals for
Nervous Diseases, and consisted of 10 patients with infections of the nervous system,
including one HSV myelitis, one tuberculous meningitis (TBM) with reactivation of
HSV and one post HSV Guillain-Barre syndrome (GBS), 6 patients with demyelinating
disease, all clinically definite multiple sclerosis (MS), 2 with inflammatory CNS
disorders, 7 with a variety of neurological diseases, such as dementia, cerebral tumours
or degenerations, and 5 patients with non-CNS disorders, such as headache or prolapsed
intervertebral discs. Finally a group of 5 patients with suspected HSV infections, 4
encephalitis and one myeloradiculopathy, were included, with clinical features consistent
with the diagnosis, but without sufficient laboratory supportive evidence.
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For the HSV1 antigen index an overlapping population of patients was used, consisting
of 4 CSF samples from 3 of the definite F1SVE patients above, and 37 control patients,
again all in-patients at the National Hospitals for Nervous Diseases. The control group
consisted of 19 patients with CNS infectious disorders, 2 patients with MS, 4 patients
with inflammatory diseases of the CNS, 4 patients with other neurological diseases and 8
patients with suspected HSVE. Of these 37 patients, 7 with infections, both cases of MS,
1 inflammatory, all 4 other neurological diseases and 3 suspected HSVE had also been
examined by the standard ELISA assay below.
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B. Sandwich capture assay
i) The standard assay
The assay was set up as optimised in chapter 9. Each plate incorporated a standard HSV
Kos and vero cell calibration curve. Once a positive CSF had been identified with
sufficient sample volume, all subsequent plates contained this as a positive control. CSF
samples from the patients with HSVE were treated identically to the CSF samples from
control patients, which were all coded and then assayed blind.
50 ul of CSF was incubated with 25 ul 0.3 M HC1 (final concentration 0.1 M HC1), for
90 min at RT, then neutralised with 25 ul 0.3 M NaOH and immediately added to the
well. 100 ul of a 1:2 dilution in 0.15 M NaCl of untreated CSF was placed in the paired
well. The assay then proceeded as standard.
Assays were run several times, when sample volumes permitted, to ensure
reproducibility of the results, using a variety of control samples. Results were expressed
on the basis of comparison with the calibration curve corrected for background, and
reading the background corrected values for the samples against this curve. Test
readings below 2 SD of the mean above background were considered negative. Average
corrected values for duplicate samples were calculated.
ii) HSV1 antigen index
In chapter 2 , the use of an antigen index was described as proposed by Bos et al [29].
This attempted to correct for non-specific binding of antigens to antibody, and for
interspecies cross-reactivity of the antibodies in the sandwich, by coating a plate with
normal non-immune IgG from the same animal species, and running samples in parallel.
No control virus or calibration curve was needed.
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The final index was given by the formula
O.D. of sample bound to anti-HSV 1 IgG - Blank
O.D. of sample bound to non-immune IgG - Blank
The reported positive results on human CSF's prompted a reproduction of this assay, to
compare with the standard assay.
A duplicate plate was run identically to the assay described in section i), with the
modification of a mouse normal IgG diluted to the same IgG concentration as the
monoclonal Q2 (1:500) being used as the 'captor'. As a total of 200 ul of CSF was
needed for each complete assay, only 4 of the HSVE samples could be run in this way.
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C. Comparison of in-house assay with a commercial kit
Wellcome diagnostics had marketed an ELISA based HSV antigen detection kit,
primarily for use in genital scrapings from suspected herpetic lesions. From discussion
with the research team, anecdotal reports had been received of the success in childhood
HSVE CSF analysis on an individual basis, and one trial report in adults using a
modification of the kit has appeared in the literature, described in chapter 2 [6]. The
nature of the antibody specificity of the kit was not disclosed, but appeared to be
anti-glycoprotein C antibodies, common to HSV1 and 2. The positive control in the kit
was said to be inactivated whole virus preparation, but Wellcome also gifted positive and
negative controls which contained all the relevant antigens for both assays.
The control samples, both gifted and kit provided, were used neat and 0.1% Tween 20
treated in the in-house standard assay to ensure a positive response. Since the effect of
acid neutralisation on the commercial kit could not assessed, 4 HSVE CSF samples
positive for free antigen and 6 control specimens were run in the commercial assay as
per manufacturers instructions. Controls comprised one patient each with SSPE,
neurosarcoid, Lyme disease and dementia and 2 patients with MS. A standard HSV Kos
calibration curve was also included to compare the sensitivities of the assays.
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2. Results
A. Sandwich capture assay
i) The standard assay
Figure 28 shows the calibration curve, corrected for control values, for HSV antigen
detection. Plate to plate variability in blank background counts was moderate, at 0.046
to 0.086 O.D. units, but the corrected calibration curves were all identical in slope and
sensitivity. This background variability depended on the day of the run, as duplicates on
the same day had the same background. It was probably a result of the variability in the
ambient temperature, since the assays were all run in the summer, and the room
temperature could not be accurately controlled. Standardisation was also confirmed by
the positive control run on each plate, which showed a constant signaknoise ratio of
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Figure 28 : Calibration curve for HSV1
alkaline nuclease sandwich assay
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Table 29 shows the PFU values calculated from the calibration curves, for the HSVE and
control samples with and without acid treatment. The control patients were grouped into
diagnostic categories, including suspected herpetic infections.
All 12 CSF samples from the 9 confirmed cases of HSVE were positive for antigen,
either treated with acid, untreated or both. Values ranged from 44 to 946 PFU in each 50
ul sample. Acid dissociation in 7 of the 12 CSF's resulted in clear increases in O.D.
values, indicating the presence of immune complexed antigens. Indeed, in 5 of these
CSF's, there was only complexed antigen detected.
When the CSF's were ordered on the basis of time of LP from day of onset of clinical
symptoms (Table 30), it was found that before day 13 only free antigen (or
predominantly free antigen) was present, by day 13 immune complexes were forming,
and after day 14, save for two samples, there was no free antigen detected, all antigen
being bound. Free antigen was detected on day 1 of the clinical illness in one patient
with such an early CSF from LP. One patient with a prolonged prodrome to her illness
had a CSF sample on day 47 of the initial illness showing only complexed antigen, then
after a sudden acute deterioration a CSF taken after 7 days showed the presence of free
antigen, but inexplicably no bound. A second patient had been initially treated abroad
with a vidarabine to which he had initially responded. When transferred to the UK after
8 weeks, because of rapid deterioration, the CSF contained free and bound antigen, and
subsequently acyclovir was administered, with unfortunately only a modest response.
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For abbreviations see text
TABLE 29 : Results of sandwich ELISA assay for HSV
alkaline nuclease in 9 HSVE patients and 35 controls.
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Table 30 also shows the results of CSF analysis for locally synthesised oligoclonal
HSV1 specific IgG, local synthesis being defined as the presence of three or more clones
of IgG in the CSF not present in matching serum. Only 6 of the 12 CSF's had locally
synthesised anti-HSVl IgG, with 1 CSF showing an identical serum and CSF pattern, a
leakage pattern, indicative of passive transfer of IgG from serum. The earliest positive
response was on day 4 of the illness, and after day 14 only 2 of 5 CSF's were positive.
9 of the 35 non definite HSVE patients were positive for HSV alkaline nuclease, 5 of
these were from patients with definite infective pathologies: one was a herpes simplex
myelitis, one a case of TBM with suspected coincidental HSV reactivation, one a
post-HSV GBS and 2 were patients with subacute sclerosing panencephalitis (SSPE).
The remaining 4 patients had pathologies where the differential diagnosis included HSV
as a causative agent: 2 were brain stem encephalitides, 1 a generalised encephalitis, and
1 a myeloradiculopathy. None had positive viral isolation from CSF, paired CSF and







1 + — -ve
3a + - -ve
4 + - -ve
4 + - +ve
13 + + +ve
14a - + +ve
17 - + -ve
21b* - + -ve
28b* - + -ve
47c - + +ve
54c + - +ve
56 + + +ve
a,b,c - serial CSFs from individual patients
* - HSV1 isolated from CSF
TABLE 30 : Duration of clinical illness and result of
CSF antigen detection in patients with HSVE
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+ - HSV isolated or suspected




















HSVE SUS HSV INFECT MS INFLAMM OTHER NON-NEU
Disease Category
For abbreviations see text and Tables
Figure 29 : Alkaline nuclease assay
results for disease categories
Figure 29 shows the results plotted in the form of a distribution histogram, according to
category. In categories where infective causes could be excluded, none of the samples
produced a positive result. One control patient had herpes labialis, but was negative for
alkaline nuclease in CSF, suggesting that the antigen did not cross the intact blood CSF
barrier, and thus excluding serum as a possible source of false positives.
ii) The HSV1 antigen Index
Blank values for the test plate were all higher than the blank values for the control plate
by a factor of 1.33. This corroborated the findings of Bos et al [29]. Using the value of
1.5 as the cut-off recommended for the HSV standard to control standard, the minimum
acceptable value for a positive result was 1.5 x 1.33, or 1.995, which was rounded up to
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2.0 for convenience. Individual samples were duplicated up to 3 times if volume
permitted. For results that were at or below the blank value, an arbitrary value of 0.001
had to be allotted to allow an index to be calculated.
Table 31 shows the results of the antigen index so obtained. Some samples had also
been assayed by the standard ELISA, and those results were included. Only 2 of the 4
HSVE CSF samples from 3 patients were positive by the index; one agreed with only
finding complexed antigen, one agreed with finding free antigen but failed to find
complexed, and 2 failed to find complexed antigen.
Of the 37 non definite HSVE and control patients tested, there were 6 positive results.
Two were from cases of SSPE, both of whom had been positive by the standard ELISA,
and one was a suspected case of HSVE, which had not been previously assayed. Two
were from other infectious diseases, namely Lyme disease and tropical spastic
paraparesis (TSP), and one from a patient with MS, all of which had been negative by
standard ELISA. The remaining 31 samples were negative: 12 of these had been tested
by the standard ELISA, of which 4 had been positive.
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Diagnosis Antigen Index ELISA result
















































































































































For abbreviations see text
TABLE 31: Results of antigen index for HSV alkaline
nuclease in 3 patients with HSVE and 37 controls.
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B. Comparison of the in-house assay with a commercial kit
Corrected O.D.
Log PFU HSV1
Figure 30 : Calibration curve for HSV1
using commercial Wellcozyme assay
The antigen content of the kit and gifted positive controls was estimated at 100,000 and
20,000 PFU respectively. Figure 30 shows that the standard curve obtained using the
commercial kit was less sensitive than the alkaline nuclease based ELISA with at best
about 1500 PFU detection limit, a factor of 70-fold less sensitive. None of the HSVE
patients were positive using the kit, using the criteria defined by the manufacturers, and




In the standard ELISA assay, acid dissociation, when used on control samples that were
clear negatives, made no consistent difference to the values, with equal numbers showing
a slight increase or decrease in O.D., and never creating a positive result from a negative
result. Changes in O.D. were <10%, suggesting that there were negligible artefactual
effects on the ELISA assay component reagents. When an untreated CSF sample was
positive, either HSVE or control, acid dissociation often led to a reduction in O.D.
values (5 of 7 CSF's from confirmed HSVE patients, 3 of 4 from non-HSVE patients),
and in some cases rendered the count down to background. This may have been due to
poor neutralisation of acid with alkali, resulting in some continued chaotropic effect, or
to reduction in the immunological reactivity of the antigen in the CSF. This latter
explanation would seem unlikely considering the apparent lack of effect seen in the
preliminary experiments, but in any case, the end result made it difficult to predict the
'true' value for acid-dissociated antigen, which must have been higher than the
calculated value and also resulted in some cases with small amounts of only bound
antigen being undetectable.
There was a clear association between the development of a locally synthesised IgG
immune response and the presence of free or bound antigen. Of course, these were not
serial punctures in an individual patient, but a montage from many. The development of
the response is still of interest since it seems to parallel the early absence of any specific
IgG leaving only free antigen, then the development of specific IgG, and finally the
immune complex formation. The 3 post 14 day negative CSF's came from 2 patients,
both of whom produced a late antibody response after these CSF samples, and one of
these had HSV1 isolated from the CSF, illustrating that individual patients could produce
widely differing immunological responses. This reinforces the need to be cautious about
interpretation of combined data.
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Amongst the control patients studied by the ELISA, the greatest response from any
sample was in the CSF from the case of herpes simplex myelitis, and probably reflected
the proximity of the needle to the pathology. The results for SSPE were unexpected, but
were unlikely to represent cross reactivity since measles virus gave counts at background
level in the assay. The possibility of reactivation of latent HSV secondary to the measles
infection is likely, given that reactivation is stimulated by neurological insults, as
described in chapter 4. The result for post genital HSV GBS is of interest in that it
suggests either virus gains access to the CNS via a disrupted blood CSF barrier, or via
retrograde transportation of virions, resulting in disruption. Whether an underlying
myelitis was present would be impossible to assess in the presence of severe peripheral
nerve involvement.
The assay thus confirmed the clinical and laboratory diagnosis of HSVE by the detection
of HSV specific alkaline nuclease in all 9 patients, and in all CSF samples studied. In
addition in 2 patients with other HSV CNS infections, in 5 out of 6 samples with
suspected HSV pathologies, and both patients with SSPE, alkaline nuclease was also
detected. No control patient with a non-infective aetiology produced a positive result.
The specificity of the assay was thus 100% and the sensitivity in definite cases 100%.
The index, in contrast, had major drawbacks, mainly in the mathematical interpretation
of the results. Most of the problems lay in calculating the index from the blank O.D.
value. Although the difference between the control and test plate blanks was a constant
at 1.33, many CSF samples produced results at or below the blank on the control plate,
presumably as a result of the presence of other proteins in the CSF acting as blocking
agents, or binding to cross reacting antibodies. Calculations could not cope with
negative values, so an arbitrary value of 0.001 was assigned, which although in the main
did not result in unreasonable indices, in some cases resulted in indices far higher than
were consistent with the actual O.D. values. All other methods of correcting for
background produced wildly varying results for some samples, so were discarded, for
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example using the lowest test value in each group as the blank, calculating an
uncorrected ratio or calculating an average blank value based on all test values below the
'real' blank. There was also unacceptable variability in the duplicated results, probably
because 4 variables were being incorporated into the calculations instead of 2, so only
consistently positive or negative samples could have average values calculated with any
degree of certainty.
Overall, the index was not as robust or reproducible as the standard ELISA. In addition
it was expensive in sample volume required (200 ul per assay), and the results obtained
neither as internally consistent as the standard ELISA, nor consistent with the known
diagnoses, especially with the detection of known positive samples.
Comparing the two methods in the definite HSVE group, the index performed relatively
poorly, detecting a positive index in only 3 of the 4 specimens positive by the ELISA
assay. Comparing the non definite HSVE and control patients, there was agreement on 8
results (all negative), partial agreement on 2 (SSPE), but complete disagreement on 7 (3
positive by the index, 4 positive by the standard ELISA) of which 5 were fundamental
disagreements on certain diagnoses. The index thus had a false positive rate compared to





Chemiluminescence has been hailed as a major advance in assay systems, with
theoretical sensitivities of detection of chemiluminescent products approaching 100
molecules. These specialist studies have not however translated so effectively the
theoretical laboratories into the routine chemistry laboratories, with bioassay responses
more in line with conventional techniques. There are a wide variety of
chemiluminescence generating systems, ofwhich only two were used in this work, both
having been extensively evaluated by others.
Chemiluminescence is attractive because of the relative ease with which reagents can be
manufactured, and the assay times which are similar to conventional ELISA. Light
output can be measured using elaborate equipment such as photo-multipliers, or simply
using photographic film. The relative disadvantages are the multiplicity of extraneous
factors that can interfere with chemiluminescence such as proteins, detergents,
chaotropic agents, miscellaneous chemicals, temperature, light etc., and the cumbersome
recording of light output detection systems, where only one sample at a time can be
assayed, although this reflects the limits of available technology and may change.
In this study with chemiluminescence, it initially appeared that isoluminol based
chemiluminescence was more sensitive than luminol based assays, which prompted a
great deal of work conjugating antibodies, assessing specific activities, affinity purifying
the conjugates and attempting assays on a variety of systems. The problems of
conjugation however were the loss of biological activity which the label induced, and the
difficulty in affinity purification of labelled antibody without destroying the labels'
chemiluminescent activity. The loss of biological activity was probably related to
mechanical interference, since labelling was a random event, and thus as likely to occur
on the Fab region of the immunoglobulin molecule as the Fc region. Attempts to 'cover'
label by binding antibody to antigen fixed to a column, thus covering the Fab binding
site, and then labelling so that only sites not involved in antigen binding were the only
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ones available did not work, mainly because high affinity labelled antibody could not be
eluted which retained chemiluminescent activity. Although NaSCN had the most
inhibitory effect on chemiluminescence, lesser degrees were seen with pH, NaCl and
detergent, and the inhibition was the same irrespective of the antibody labelled.
Subsequently, luminol chemiluminescence was re-investigated, particularly when the
problems with the kinetics were discovered to be due to artefacts generated by free O"
radicals in the H202 from NaOH activity (despite this being recommended in the
literature), and the resulting sensitivity with iodophenol enhancement was found to be far
in excess of isoluminol. Another advantage was the use of commercial affinity purified
HRP conjugated antibodies, which meant that background activity was considerably
reduced. The increased sensitivity however was not always predictable. The molecular
basis for iodophenol enhancement has not yet been elucidated, but enhancement does not
result solely from action on the HRP molecule since colorimetric assays were not
enhanced by iodophenol (data not shown). In the absence of HRP, iodophenol inhibited
spontaneous luminol chemiluminescence, and when HRP concentrations were below a
particular threshold value, iodophenol inhibited chemiluminescence. This limit of
enhancement proved to be a major problem. Although in assays of sensitivity of
detection of the HRP catalysed response, up to 1:50 x 106 dilutions of stock non-purified
conjugates, this detection resulted from the unbound HRP molecules. When affinity
purified conjugates were used the limit of detection was greatly reduced at around 1:105.
Iodophenol appeared to be acting as a stabiliser on both the HRP and the luminol
molecules, but this was concentration dependent. This variability in the response was
also reflected by the optimum iodophenol concentration required for the assay, which
differed depending upon the concentration and type of HRP conjugate used.
Thus when calibration curves for HSV antigens with identical reagents were compared
using colorimetric and chemiluminometric detection, there was no difference in the
sensitivity, presumably because at the lower HRP concentrations iodophenol was unable
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to enhance, although at higher concentrations there was a much greater signal generated
for chemiluminescence enhanced by iodophenol. In practical terms, colorimetric
analysis became the preferred method, mainly because of the ease ofmeasurement, but
also because of the problems above.
The best solid phase for the assay was the microtitre plate. Although sepharose offered
the attraction of a larger surface area:volume for mixing and protein binding, the
handling of the material was cumbersome and washing the gel was not only time
consuming, but also less efficient because of the entrapment of small molecules within
the lattices of the gel. Polystyrene balls offered a larger surface area than the microtitre
well, and semi-automated ball and reaction tubes were readily available, but again the
method was cumbersome, relatively large amounts of sample were needed to cover the
balls, and reagents were unstable with time. Attempts to improve stability and
sensitivity with PPL and protein A coating were only partially successful with stability
improving but not the sensitivity. Although protein A had tremendous theoretical
advantages as a surface binding agent, in practice optimising the coating was difficult,
and blocking the unbound sites resulted in interference with the captor antibody coating.
Sensitivity achieved by this assay was much better than for sepharose, but was still only
at 1:100,000 dilution or 3 X 104 PFU. This may not have mattered when sensitivity was
not important, but for the purposes of antigen detection, which was expected to be at the
limits of sensitivity anyway this was unacceptable.
The use of microtitre plates is now widely established as a standard solid phase for
ELISA techniques. The convenience of handling, washing and result gathering,
especially with multi-channel pipetting and automated plate readers, makes it ideal for
screening and optimising assays. The availability of microtitre plates with detachable
wells meant that chemiluminescence could also be assessed using this solid phase. Plate
to plate variation in results was far more acceptable, and background counts were the
lowest of the three solid phases, resulting in consistent standard curves. There was some
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day to day variability resulting from variations in the ambient temperature. Only small
volumes of CSF were required (50 ul), and overall sensitivities achieved were the best of
the solid phases.
Altogether a total of 10 antibodies were tried in various combinations in the sandwich
assay: 2 were commercial, one polyclonal and one monoclonal, one was human IgG, 6
were high affinity rabbit polyclonals, all gifted, and one a mouse monoclonal also gifted.
Of all the sandwich systems tried, it came as somewhat of a surprise to find that the best
combination for the assay was to use a monoclonal captor and a polyclonal detector.
One would have anticipated that by capturing with a polyclonal, the chances of capturing
the epitope of interest would have been optimal, and the monoclonal as detector would
have provided greater specificity. The fact that the reverse was true meant that the logic
was incorrect. The polyclonal antibody must have occupied either the site necessary for
the binding of the monoclonal, or adjacent sites resulting in an adverse influence on the
binding. By capturing with the monoclonal, only one part of the molecule would have
become inaccessible, leaving the other sites still available for the relevant antibodies to
bind to.
The HSV alkaline nuclease turned out to be the best viral antigen to use as a marker of
viral presence. Antibodies against non-envelope structural proteins (205/5), structural
late proteins, including VP 13 (220/3), envelope glycoproteins (commercial monoclonal)
and pan-proteins (R38/5, human IgG, commercial polyclonal, alpha-Tl, alpha-T2) were
all less effective. Alkaline nuclease is synthesised in large quantities in productive
infection, and in the context ofHSVE, where virus is released from necrotic tissue, of all
the antigens produced it should be one of the easiest to detect. The humoral response to
glycoproteins, being much more prominent in serum, may more effectively dispose of
these antigens by immune complexing, thus reducing the sensitivity of any assay
attempting to detect these. Although the alkaline nuclease of HSV1 and HSV2 have
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common antigens, it is not important clinically to differentiate the two as treatment will
not be influenced, and serological responses can be used in retrospect to distinguish one
from the other.
The results of the assay run on patients CSF showed that free HSV antigen was detected
from day 1 of the clinical illness. By day 13 , antigen was becoming immune
complexed, and after this time immune complexed antigen predominated, with only two
patientsshowing free antigen, both of these undergoing acute deteriorations at the time.
This paralleled the immune response in HSVE described in Chapter 1, where the earliest
antibody production is IgM from days 3-4 and IgG from days 5-7, peaking at around day
10, and remaining elevated for months after the original illness [81, 188]. Thus, in the
early phase, free antigen predominates until the immune response is switched on
sufficiently to produce enough antibody to complex antigen by day 13, and then
overwhelm the antigen thereafter. This would account for the findings reported by other
workers, where antigen was only recoverable in the first 10-14 days, and thereafter could
not be detected, whereas immune complexes became apparent after day 10. This may
also explain the difficulties in culturing virus from CSF, despite overwhelming infection.
The virus has already been immune complexed by the the time most attempts at viral
isolation have been made, and only when the puncture is at a critical phase of sufficient
viral release into the CSF with minimum antibody production will culture be possible.
Of course, result interpretation is severely limited by the lack of numbers, and one could
argue that the pooling of data regarding time course of the response is not valid, since
each individual will behave in a unique fashion. This would more likely result in
negative correlations, rather than the positive findings here, even with the small number
of data points. Two of the patients did behave in an atypical way in terms of the immune
response, with delay of intrathecal specific IgG production until well after day 10. In
practical terms, serial CSF samples on individual patients in this country are extremely
unusual, as there is little ethical justification when a diagnosis has been made, treatment
Page 224
instituted and a response obtained. It is only when the diagnosis is in doubt that 2 or
more punctureswill be performed. In three years at the laboratory where this study was
performed, only one patient had 3 CSF samples during the course of the disease, and
normally only 2 LP's were performed, unless a patient relapsed. One late relapsing case
was included in this study, although only the CSF sample immediately after the onset of
the relapse was available. During the relapse free antigen again appeared in the CSF.
The recovery of complexed antigen after 47 days from the CSF further fuels the debate
as to the persistence of the specific IgG response in the CSF of patients who have
recovered from HSVE. It has been suggested that this reflects a failure of immune
surveillance mechanisms, with switching off after successful removal of antigen not
taking place, and that the abnormal immune response may underlie why such patients are
susceptible to CNS invasion in the first place. Others have suggested that persistence of
specific antibody must reflect persistence of the offending antigen, and that those
patients must have continual antigen presentation to sustain such a response. This may
mean persistence of active viral replication and shedding from an individual site within
the CNS, that does not manifest itself clinically, or continued antigen presentation of the
surface of lymphocytes. The results from this single patient would support this latter
view of antigen persistence, and if accepted as such means that the current regimes for
the treatment of HSVE may be inadequate. This possibility has been raised in recent
reports documenting the failure of the current 10 day course of Acyclovir, with relapses
shortly after discontinuation of the drug, and suggests that much longer courses are
necessary. In our group of 9 patients, all were treated with acyclovir for the full 10 day
course, yet 3 relapsed and responded to a repeat course, and one despite initial response
to cytarabine relapsed and made some response to acyclovir. Only by studying CSF
taken from patients without clinical relapse at times distant from the initial event will
this question of persistence be resolved. Since ethical approval is likely to be difficult to
come by for such a study in the UK, this issue will likely remain the subject of
conjecture. One way or the other, it may be prudent to revise the schedule for acyclovir
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administration, erring on the side of caution in assuming current undertreatment,
especially in view of the low toxicity of the drug, and by the 10th day of the illness the
diagnosis should be confirmed.
The other problem in the collection of specimens which was apparent from this study
was the poor quality of the clinical and laboratory diagnosis. More than 20 patients were
referred with the diagnosis of HSVE during the period of the study. The majority had
only a single CSF sample taken, and the diagnosis based solely on a rising titre of serum
antibodies, or even static low titres! All patients were treated with acyclovir, so clinical
improvement in some, which was attributed to therapy, could equally have been
coincidental, and thus should not have been taken as evidence of HSV infection. No
patient referred had brain biopsy performed, and in 2 cases retrospectively diagnosed as
HSVE from post mortem analysis, no CSF was saved. The cases may have been genuine
HSVE, but the lack of definitive virological or immunological proofmeant that these had
to be excluded. This problem with inadequate data may partly explain the shortfall in
the cases documented by the PHLS.
The use of acid dissociation of immune complexes has been shown to be feasible and
very effective, as with HIV p24 antigen detection. This study showed that the same
technique could be applied to HSV1 immune complexes, with successful dissociation
and detection in the sandwich assay. However there did appear to be a reduction in the
capture of antigen after acid treatment, so that immune complexed results represented an
underestimation of the amounts present. This may have been due to technical failure, or
may indicate the fragility or susceptibility of the alkaline nuclease to hydrolysis. Lower
concentrations of acid and alkali were not used, mainly because of the unexpected nature
of the result, considering the early studies gave no indication of any effect on the
antigen, and little CSF was available to try variations on patients' samples. Whether any
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other means of disrupting immune complexes would be less damaging to antigen is
uncertain, and may not be practicable since some means of neutralising the effect must
be available to use a capture antibody system.
The best means of interpreting the results was by a straight plot of the corrected O.D.
against a standard calibration curve. This gave reproducible results, even when the
background count varied as described. The alternative method, proposed by Bos et al,
was found to be poorly reproducible and results inconsistent with the standard assay,
mainly because of the mathematics involved in the calculation, and possibly also because
of the assumption that a polyclonal control antibody would behave as an effective
control for a monoclonal antibody. More importantly, the assay resulted in false positive
results in the control patients who did not have herpetic infections, as well as false
negative results in the definite HSVE patients. For these reasons, and also because of the
requirement for double the volume of CSF, the method was completely unreliable, and
so was discarded.
In contrast, the standard assay involving a calibration curve produced no positive results
in the control patients without suspected herpetic aetiologies. In the 5 patients with
suspected herpetic CNS infections, 4 proved positive by the assay, and all 3 control
patients with non primary HSVE herpetic infections were positive. The most unexpected
finding was the positive results in the 2 SSPE patients,which suggests that intercurrent
disease may reactivate latent HSV, or be permissible for primary invasion of the CNS by
HSV. At least some component of what is a universally fatal disorder may thus be
treatable, and although this is unlikely to affect the outcome, since the reason for
reactivation of measles and the relentless progression is unknown, and co-factors may be
important (as with HIV infection), therapy of any treatable component may be
worthwhile.
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The importance of being able to detect antigen as early as possible has already been
stressed in the introductory chapters. Since this was accomplished in this study in every
CSF from all patients, and from day 1, treatment of suspected cases can be initiated
immediately and a result for antigen detection be available by the following working
day. The patients reported here all had unequivocal HSVE - there are likely to be a
larger number of patients with HSVE in whom the diagnosis is never made, because of
'atypical' clinical signs, insufficient laboratory data in clinically likely cases or mild
forms that are overlooked. The application of this or similar antigen detection
techniques to these forms would be of value. In some ways, these groups would be the
more important to study, since these are likely to remain untreated, especially if
conventional techniques such as CT or EEG are negative, and morbidity advanced before
HSVE is considered. With the increased numbers of patients immunosuppressed by
HIV, the presentation of HSVE may become more atypical, and perhaps these should be
also be screened.
In conclusion, although only one of the two aims of this work were fulfilled, it was the
more important of the two, that is, the development of a method of detection of HSV
specific antigen in the CSF of patients with HSVE. Further work is needed on a larger
number of patients to establish the limits of the system, before it can be applied
clinically. Even if the method does not prove to be as robust as it seems so far, so that it
cannot in its present form be used for large scale screening, the findings of the assay are
still relevant. Antigen is present from day 1 of the clinical illness, and is recoverable
using a relatively simple assay system. This in itself should prompt the search for better
antibody combinations and detector systems.
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APPENDICES
APPENDIX 1: Biuret method for total protein estimation [1]
4.5 g of potassium sodium tartrate is dissolved in 40 ml 0.2 M NaOH. 1.5 g copper
sulphate is added, with continual stirring until completely dissolved, followed by 0.5 g
potassium iodide, and the whole made up to 100 ml with 0.2 M NaOH. For use, the
solution is diluted 1:5 with 0.2 M NaOH containing 5 g/1 potassium iodide.
50 ul of the test protein is mixed with 2.5 ml of the working strength biuret reagent to
produce an instant change in blue colour. The reaction is allowed to go to completion by
leaving for 15 min at RT. The reaction mix is then read at 555 nm in a
spectrophotometer, using biuret solution alone as the blank. The calibrant protein is
treated identically to produce a standard curve.
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APPENDIX 2 : Purification of IgG by Rivanol extraction [104]
500 ul of the antiserum to be purified is mixed with 345 ul distilled water, then
continually agitated whilst 325 ul of 3% Rivanol (pH 7.5) is added slowly. An
orange/yellow precipitate forms, which is discarded after centrifugation - this contains
all proteins except transferrin and immunoglobulins. To the supernatant is added solid
NaCl with continual mixing until the mixture becomes a creamy 'lemon curd'- this
removes rivanol. After centrifugation the precipitate is discarded. An equal volume of
saturated (NH4)2S04 is added to the supernatant with mixing, and after centrifugation the
supernatant, containing transferrin which does not precipitate, is discarded. The
precipitated immunoglobulin is washed by adding 1 volume 50% (NH4)2S04,
centrifuging and discarding the supernatant. The pellet is then resuspended back to the
original volume in 0.15 M NaCl, and then dialysed in visking tubing for 18 hr at RT
against 2 litres 0.15 M NaCl. The purified immunoglobulin is stored at 4°C. Purification
is checked by standard agarose electrophoresis on ultrathin gel of pre- and
post-purification serum and staining with Coomassie blue.
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APPENDIX 3 : Clinical details of patients with HSVE
1) NK, 68yrs, Female, CSF day 1.
An acute confusional state, pyrexia, hemiparesis. CSF contained 8 WBC, 0 RBC. EEG
demonstrated a focal temporal lobe abnormality. Paired serum and CSF showed > 4-fold
rise in titres with local synthesis in the CSF. Acyclovir administration led to complete
recovery, but relapsed 2 weeks after completion of therapy, and responded to a second
course.
2) SP, 26yrs, Female, CSF day 17.
Two week history of focal fitting, with confusion and behavioural disturbance. EEG
showed a temporal lobe focus, CT was normal. Genital herpes was found, HSV1 was
cultured from the scrapings. CSF contained 16WBC, 4 RBC. Paired serum and CSF
showed no serum response, but a > 4-fold elevation in CSF titres. Acyclovir was
administered after the first LP, but the patient was left with psychiatric disturbance and
memory loss.
3) CH, 37yrs, Female, CSF days 3, 14.
Three day history of aphasia, hemiparesis and pyrexia. EEG showed a focal temporal
abnormality, the CT was normal. CSF contained 61 WBC (34 mononuclear, 27
polymorphs), 18 RBC. The first CSF and serum pair showed local synthesis of specific
antibody. Acyclovir treatment resulted in complete recovery.
4) TJ, 65yrs, Male, CSF day 13.
Thirteen day history of headache, malaise and 1 day collapse. EEG showed a temporal
lobe focus and focal periodic complexes, the CT showed a temporal lobe abnormality.
Paired CSF and serum showed local synthesis of specific antibody. Acyclovir therapy
resulted in an initial deterioration followed by recovery to normality.
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5) JM, 33yrs, Male, CSF day 4.
Four day history of malaise, headache, pyrexia and behavioural change. After admission
the patient developed temporal lobe epilepsy and autonomic failure. CSF contained 72
WBC (99% lymphocytes). First paired CSF and serum samples were negative for HSV1
antibody, the second set were positive with intrathecal synthesis. The CT scan showed
an ill-defined abnormal temporal lobe area, the EEG a clear temporal lobe focus.
Following acyclovir therapy there was recovery, but the patient was left with a global
memory impairment.
6) ED, 32yrs, Male, CSF day 56.
Admitted to a hospital abroad with fever, headache, confusion, meningism and epilepsy,
but no focal neurological signs.The CT scan was normal, the EEG showed diffuse
abnormalities without focal features. CSF contained 880WBC (85% lymphocytes).
After treatment with cytarabine there was initial response, but six weeks later he
relapsed, with aggression, hyperphagia, hypersexuality (reminiscent of the Kluver-Bucy
syndrome), then progressing to coma. On transfer to the U.K. his EEG was still
generally abnormal, the CSF contained 13 WBC (97% lymphocytes), and there was local
synthesis of F1SV1 specific IgG. The MRI demonstrated bilateral temporal lobe
abnormalities. A repeat course of acyclovir resulted in an improvement in the conscious
state and the EEG, but the psychiatric problems persisted.
7) MH, 34yrs, Male, CSF day 4.
Four day history of malaise, drowsiness, dysphasia, arm weakness and sensory
disturbance with pyrexia. CSF showed an elevated total protein only. CSF showed
intrathecal synthesis of specific antibody. CT scan was normal, the EEG showed a
temporal lobe focus. Acyclovir administration was followed by an initial deterioration,
then recovery. Three weeks later the patient relapsed, a further course of acyclovir was
given with recovery, but the patient was left with mild behavioural abnormalities.
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8) PB, 48 yrs, Female, CSF days 47, 54.
A six week history of slowly deteriorating intellect and headache, followed by a sudden
5 day worsening with confusion. Both CSF samples showed local synthesis of specific
antibody. Following acyclovir treatment, there was complete recovery.
9) CL, 42 yrs, Female, CSF days 21, 28.
Following headache, malaise, fever, sore throat and nausea the patient presented with
three weeks of progressive tetraparesis and sensory loss, with brain stem and autonomic
dysfunction. Recent herpes labialis infection had occurred. CT brain was normal, but
brain stem was not specifically examined, and the EEG was also normal. CSF contained
28 then 35 WBC (95% lymphocytes), but there was no specific antibody response in
either of the CSF's available, although later CSF did show specific IgG. HSV1 was
isolated from the first CSF before therapy. Acyclovir was followed by clinical
improvement, but virus could not be isolated from subsequent CSF samples.
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